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Introduction 
Idiopathic non-infectious meningoencephalomyelitis (NIME) 
encompasses a group of idiopathic, non-infectious central nervous system 
(CNS) disorders (Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). 
This group includes several subtypes, including steroid responsive meningitis-
arteritis (SRMA), eosinophilic meningoencephalitis (EME), and 
meningoencephalomyelitis of unknown aetiology (MUA). As SRMA (which 
affects the meninges only) and EME have fairly distinct diagnostic findings, the 
term MUA is introduced to cover the three specific subtypes of NIME that can 
only be confirmed based on histopathology, being granulomatous 
meningoencephalomyelitis (GME) and necrotizing encephalitis (NE) (including 
necrotizing meningoencephalomyelitis (NME) and necrotizing leucoencephalitis 
(NLE)) (Granger et al., 2010; Talarico and Schatzberg, 2010; Coates and 
Jeffery, 2014) (Figure 1.1). 
 
 
Figure 1.1: Overview of the current classification of NIME. 
Overall, a clinical diagnosis of MUA can be achieved based on a 
combination of signalment, neurological examination results, magnetic 
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resonance imaging (MRI) findings and cerebrospinal fluid (CSF) analysis 
(Munana and Luttgen, 1998; Adamo et al., 2007; Granger et al., 2010; Talarico 
and Schatzberg, 2010; Coates and Jeffery, 2014), although these findings might 
vary substantially between patients (Wong et al., 2010).  
This group of diseases offers both a diagnostic and therapeutic 
challenge to owners and veterinarians. As the condition is considered fatal 
without initiation of appropriate treatment (Munana and Luttgen, 1998; Granger 
et al., 2010), recent studies have evaluated different treatment modalities and 
potential prognostic factors.   
Aetiology 
The exact aetiology and pathophysiology of MUA are currently 
unknown and the most current theories were covered and discussed in a recent 
literature review (Coates and Jeffery, 2014). Although MUA has most likely a 
multifactorial pathogenesis, the combination of a genetic predisposition and 
factors triggering an excessive immunologic response are considered the two 
most important factors in the development of this disorder (Kipar et al., 1998; 
Talarico and Schatzberg, 2010; Flegel et al., 2011; Coates and Jeffery, 2014). 
Suspected triggering factors include environmental factors or infectious 
antigenic triggers that might activate autoreactive cells in the CNS, although no 
such agent has yet been identified (Schatzberg et al., 2005; Barbet et al., 2010; 
Greer et al., 2010; Barber et al., 2012). Combination of this information with the 
generally positive response to immunosuppressive treatment suggests that 
conditions comprising MUA are immune-mediated diseases (Wong et al., 2010), 
and the cornerstone of medical treatment is therefore considered 
immunosuppressive therapy (Kipar et al., 1998; Talarico and Schatzberg, 2010; 
Coates and Jeffery, 2014).  
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Clinical presentation 
Middle-aged toy and terrier breeds are considered predisposed for 
GME (Munana and Luttgen, 1998; Adamo et al., 2007; Talarico and 
Schatzberg, 2010) whilst NE predominantly affects younger toy and small breed 
dogs including Pug, Yorkshire Terrier, Maltese, Chihuahua, Pekingese, 
Papillon, Shih Tzu, Coton de Tulear and Brussels Griffon (Talarico and 
Schatzberg, 2010; Cooper and others, 2014). However, it is stated that dogs of 
any breed and age can be affected (Granger et al., 2010; Coates and Jeffery, 
2014).  
Statistical analysis on 173 GME cases, 53 MUA cases and 69 NE 
cases revealed a significant difference in age distribution between dogs affected 
with GME and NE; dogs affected with NE were predominantly under 4 years old 
whereas the peak age for GME was 4-8 years (Granger et al., 2010). 
Historically, NME was described in Pug dogs with ages ranging from 6 months 
to 7 years (Cordy and Holliday, 1989), whilst dogs with a histopathological 
diagnosis of GME had ages ranging from 6 months to 12 years (Munana and 
Luttgen, 1998). In a series of 60 Pugs with NE (Levine et al., 2008), the median 
age was 18 months. In Pugs, fawn females were significantly more often 
diagnosed with NME compared to black males (Greer et al., 2009). Although 
female predominance is a widely held belief in GME (Cordy, 1979; Russo, 
1979; Braund, 1985; Bailey, 1986; Sorjonen, 1990; Munana and Luttgen, 1998), 
no statistical difference in female:male ratio could be found in more recent 
studies (Talarico and Schatzberg, 2010; Granger et al., 2010).  
Extraneural signs are rare, but pyrexia can occasionally accompany 
CNS inflammation (Talarico and Schatzberg, 2010). Common laboratory tests 
(complete blood count, biochemistry profile, urinalysis) are often within normal 
limits, however, results consistent with both inflammation and stress have been 
reported in dogs with GME (Thomas and Eger, 1989; Sorjonen, 1990; Tipold, 
1995). Concurrent myocardial necrosis has been reported in two Pug dogs with 
NME, which was thought to be due to catecholamine release by the 
sympathetic nervous system (Bradley, 1991; Kobayashi et al., 1994).  
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On neurological examination, disease localisation was categorized as 
a) mainly forebrain, brainstem or multifocal for GME, b) focal (forebrain, 
brainstem) or multifocal in MUA, and c) mainly forebrain in NE (Granger et al., 
2010; Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). Eight percent 
of dogs diagnosed with GME were presented with neurological deficits 
suggestive of a myelopathy (Granger et al., 2010), that could be located 
anywhere along the spinal cord with clinical signs ranging from general 
proprioceptive ataxia to paresis or plegia, with spinal hyperesthesia as a 
common finding (Griffin et al., 2008; Wong et al., 2010). 
Diagnostic findings 
As previously stated, MUA is a clinical diagnosis that can be achieved 
based on a combination of signalment, neurological examination results, cross-
sectional intracranial imaging findings and CSF analysis (Munana and Luttgen, 
1998; Adamo et al., 2007; Talarico and Schatzberg, 2010; Coates and Jeffery, 
2014). The study of Granger et al. (2010) systematically reviewed 457 
published cases with NIME (including MUA, GME and NE) and formulated 
guidelines to recruit cases diagnosed with MUA in the absence of a 
histopathological diagnosis. The 4 following inclusion criteria have been 
formulated: 1) dogs older than 6 months of age, 2) multiple, single or diffuse 
intra-axial hyperintense lesions on T2-weighted (T2W) magnetic resonance 
images (MRI), 3) pleocytosis on CSF analysis with >50% of 
monocytes/lymphocytes, 4) ruling out infectious diseases commonly occurring 
in the specific geographic area (Granger et al., 2010). As stated previously, a 
definitive diagnosis can only be obtained by histopathological examination. The 
authors refer to a recently published review article on pathological and 
immunological features of GME and NME in dogs for further details (Uchida et 
al., 2016). The most important findings are summarized in table 1.1. 
Both stereotactic computed tomography (CT) - guided brain biopsy 
procedures (Koblik et al., 1999) and free-hand biopsies through a mini-burr hole 
(Flegel et al., 2012) have been described in dogs with inflammatory CNS 
disease. Diagnostic accuracy ranged from 82% (n=17) (Flegel et al., 2012) to 
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100% (n=3) (Koblik et al., 1999) though results should be interpreted with 
caution due to the relative small sample sizes. Complications occurred in 12-
29% of dogs, with associated signs being: transient epistaxis, transient 
exacerbation of neurological signs, obtundation progressing to coma, medically 
uncontrollable seizures, tetraparesis, hemiparesis, ataxia and loss of conscious 
proprioception (Koblik et al., 1999; Flegel et al., 2012). Although most of these 
signs resolved within 3-14 days, an indirect fatality rate of 6% was noted (Flegel 
et al., 2012).  
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Table 1.1. Summary of pathological and immunological features of NME, NLE and GME (adapted from Coates and Jeffery, 2014; 
Uchida et al., 2016).  
Disease Pathological features Immunological features 
NME Acute NME (Pug with acute onset of seizures): absence of 
necrotic changes; diffuse leptomeningeal infiltration of 
lymphocytes, swelling of vascular endothelial cells in the 
superficial cerebral cortex 
Subacute or “typical” NME: multifocal, asymmetrical necrosis 
in the deep cerebral cortex consisting of perivascular 
infiltration of lymphocytes and macrophages, proliferation of 
reactive microglia around areas of necrosis 
Chronic NME: extensive (malacia) in cerebral cortex, nuclei of 
the thalamus, mesencephalon and cerebellum; moderate 
astrogliosis with proliferation of gemistocytic astrocytes 
(unique change in subacute and chronic NME). 
GFAP1 astrocytes distributed widely over cerebrum; CD31 
lymphocytes scattered in meninges, perivascular cuffs, and brain 
lesions but less compared with GME; MAC-3871 cells limited in 
NME but mainly in meninges and perivascular cuffs; lysozyme1 
cells faint compared with GME; expression of IFN-g and CXCR3 
highest in NME compared with NLE and GME. CD163 
macrophages localized in active inflammatory lesions 
perivascular cuffs and brain parenchyma. 
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Disease Pathological features Immunological features 
NLE Malacic lesions in the cerebral white matter and thalamus; 
minimal lesions are occasionally found in the mesencephalon, 
cerebellum and brainstem; extensive necrosis with mild 
infiltration of myelin-laden macrophages in the white matter of 
the cerebrum and thalamus; mild to moderate mononuclear 
cell infiltration in meninges and perivascular areas of cerebral 
white matter.  
Intralesional GFAP expression, CD3+ T cells dominate in 
perivascular cuffing and in diffuse histiocytic and lymphocytic 
infiltrates; rare B cells; MAC-387+ histiocytic cells were detected 
in lesions of Yorkshire terrier but few in French Bulldog; IgG 
deposits in white matter associated with inflammation; faint 
labeling IgM and IgA; CD163+ cells diffusely infiltrated the 
cerebral white matter.   
GME Cerebral white matter, cerebellum and brainstem are 
predominantly involved; perivascular cuffing of mononuclear 
cells (lymphocytes and macrophages). 
CD3 lymphocytes in perivascular cuffs, parenchymal 
granulomas, and leptomeninges; CD43 and CD45R1 expression 
were low; expressions for B cells and plasma cells were low; 
strong MHC class II antigen expression observed in resting and 
activated T and B lymphocytes; MAC-3871 common; CD163 
macrophages, epithelioid cells more frequent in perivascular 
cuffs than NME and NLE and in parenchymal lesions; CCR2 and 
highest in GME compared with NME and NLE; lysozyme1 
histiocytes 
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Cross-sectional imaging 
MRI has been reported to be 94.4% sensitive and 95.5% specific for 
detecting a brain lesion with similarly high performance for classifying neoplastic 
and inflammatory disease. On the contrary, MRI has been only 38.9% sensitive 
for classifying cerebrovascular disease. In general, high specificity but no 
sensitivity was retained for MR diagnosis of specific brain diseases (Wolff et al., 
2012). 
MR imaging is considered the most sensitive imaging modality for 
detecting intracranial lesions, but up to 7% (2/25 dogs, one diagnosed with 
GME and one with MUA) of scans showed no lesion on T2W images (T2WI) 
(Talarico and Schatzberg, 2010; Granger et al., 2010). Up to 14% (5/36 dogs, 
specific diagnosis not specified) of CT scans revealed no lesion (Granger et al., 
2010). Overall, the sensitivity of imaging in identifying all inflammatory lesions 
suspected from the neurological examination remains quite low (<60%) 
(Granger et al, 2010). Additionally, MRI abnormalities were only seen in 76% of 
cases with inflammatory CSF findings in 1 study (Lamb et al, 2005). Although 
the use of cross-sectional imaging might aid in differentiating between the 
different types of idiopathic meningoencephalitides (Talarico and Schatzberg, 
2010), no study is currently available looking into the use of MRI to differentiate 
between histopathologically confirmed cases of GME, NME and NLE.  
In the literature, one study specifically focuses on the MRI findings in 
11 dogs with histopathologically confirmed GME (Cherubini et al., 2006). The 
focal, multifocal or diffuse lesions were located in the forebrain, brainstem or 
cerebellum, and were hyperintense on T2W and fluid attenuating inversion 
recovery (FLAIR) images (Figure 1.2). Lesions were scattered throughout grey 
and white matter, showed variable intensities on T1-weighted images (T1WI) 
and variable degrees of contrast enhancement. Vasogenic oedema in the white 
matter was commonly present on T2-weighted images (T2WI), where 
meningeal enhancement was not commonly apparent and minimal if present 
(Cherubini et al., 2006; Talarico and Schatzberg, 2010; Coates and Jeffery, 
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2014). The lesion distribution (grey/white matter) was consistent with the 
histopathological findings (Cherubini et al., 2006). 
The most common MRI abnormalities in dogs with NME include 
bilateral but asymmetrical, multifocal forebrain lesions (more severe lesions in 
parietal and occipital lobes have been described), hyperintense on T2W and 
FLAIR images, typically affecting the cortical grey and subcortical white matter 
with loss of grey/white matter demarcation and variable degrees of contrast 
enhancement of the parenchymal lesions on T1-weighted (T1W) post-contrast 
images (Flegel et al., 2008; Young et al., 2009; Talarico and Schatzberg, 2010) 
(Figure 1.3). However, cerebellar and brainstem lesions were additionally 
detected in 4/18 and 3/18 cases in one study, respectively (Young et al., 2009). 
Meningeal enhancement could be present, accompanied by mass effect and 
varying degrees of ventriculomegaly (Coates and Jeffery, 2014).  
In NLE, multiple, bilateral but asymmetrical cerebral white matter and 
brainstem lesions have been detected (von Praun et al., 2006). These lesions 
were typically hyperintense on T2W and FLAIR images and often included 
multiple cystic areas of necrosis. Contrast enhancement of parenchymal lesions 
was minimal (Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). There 
was lack of meningeal enhancement and mass effect, with varying degrees of 
ventriculomegaly (Coates and Jeffery, 2014) (Figure 1.4).  
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Figure 1.2: Mid sagittal (A) and transverse (B) T2W and transverse FLAIR 
image (C) at the level of the interthalamic adhesion in a 6-year-old female entire 
Golden Retriever with a histopathological diagnosis of GME. Note the diffuse 
hyperintensities on the T2W and FLAIR images affecting grey (both cortical and 
deep grey matter) and white matter involving forebrain (temporal lobe) and 
brainstem (Images courtesy of The Royal Veterinary College, University of 
London). 
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Figure 1.3: Mid sagittal (A) and transverse (B) T2W and transverse FLAIR 
image (C) at the level of the interthalamic adhesion in a 2-year-old female entire 
Maltese Terrier with a histopathological diagnosis of NME. Note the diffuse 
forebrain lesion affecting the cortical grey and subcortical white matter on the 
T2W and FLAIR images, involving the frontal, temporal and parietal lobes. Mass 
effect causing loss of cerebral sulci and occlusion of the right lateral ventricle 
can be observed. The deep cerebral grey matter, brainstem and cerebellum 
seem unaffected in the presented case (Images courtesy of The Royal 
Veterinary College, University of London).  
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Figure 1.4: Mid sagittal (A) and transverse (B) T2W and transverse FLAIR 
image (C) at the level of the interthalamic adhesion in a 4-year-old male 
neutered Labrador Retriever with a histopathological diagnosis of NLE. Note the 
multiple lesions mainly affecting the cerebral white matter and the brainstem. 
Cystic areas were present throughout the forebrain white matter (Images 
courtesy of The Royal Veterinary College, University of London). 
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Thirty-three dogs with MUA only involving the spinal cord have been 
reported, including 3 dogs with GME (Cherubini et al., 2006; Griffin et al., 2008; 
Wong et al., 2010). Imaging findings were available for 15 of these 33 cases, 
using different types of imaging modalities. Twelve dogs underwent 
myelography alone or CT-myelography, revealing no abnormalities in 11 dogs 
and a ventral extradural spinal cord compression in 1 dog (Wong et al., 2010). 
MRI was performed in 3 dogs, revealing no abnormalities in 1 dog, and 
multifocal poorly demarcated intramedullary T2W hyperintensities with variable 
contrast enhancement in 2 dogs (Cherubini et al., 2006; Wong et al., 2010). 
Other imaging modalities, including positron emission tomography 
(PET) in NME, fluorodeoxyglucose PET (FDG-PET) and single voxel proton 
magnetic resonance spectroscopy (1H MRS) in MUA, and transcranial 
sonographic findings in GME were investigated as diagnostic modalities (Eom 
et al., 2008; Kang et al., 2009; Carvalho et al., 2012; Carrera et al., 2016).  
FDG-PET is a new imaging technique evaluating in-vivo tissue 
metabolism with the use of a metabolic tracer that acts as a glucose molecule. 
By this means, the tracer is transported into the tissue and trapped, which can 
afterwards be visualized. In both studies, a total of 5 dogs with NME, 1 dog with 
GME and 1 dog with MUA have been studied (Eom et al., 2008; Kang et al., 
2009). Interestingly, all dogs with NME showed glucose hypometabolism (most 
likely attributed to the presence of malacia and necrosis), whereas glucose 
hypermetabolism was seen in GME (most likely due to strong granulomatous 
inflammatory reaction). In conclusion, the authors stated that further studies 
with larger sample sizes are necessary to confirm the associations (Eom et al., 
2008; Kang et al., 2009). 
1H MRS is a non-invasive imaging diagnostic technique that provides 
specific biochemical information on numerous intracellular metabolites by 
measuring the signal that is emitted by proton nuclei because of their high 
magnetic sensitivity and presence in all tissues of the body. Long echo time 
sequences (typically >144 milliseconds) allow the determination of 
concentrations of N-acetyl aspartate (NAA), choline, creatinine and lactate, 
where short echo time sequences (typically <35 milliseconds) permit evaluation 
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of more metabolites, including myoinositol, glutamine, glutamate and lipids. This 
study has investigated 14 dogs with intracranial neoplasia and 15 dogs with 
MUA, and revealed that concentrations of NAA, creatinine and the glutamine-
glutamate complex were reduced in the brains of dogs with neoplasia and MUA, 
whereas choline concentration was increased. Additionally, concentrations were 
significantly lower in dogs with neoplasia compared to MUA. A high 
concentration of taurine was also identified in the brains of 10/15 dogs with 
MUA (Carrera et al., 2016).  
Transcranial B-mode Doppler sonography findings, performed through 
an intact skull, have been described in 11 dogs with GME (Carvalho et al., 
2012). Diffusely decreased brain parenchyma echogenicity and hyperechoic 
focal lesions were observed in those dogs, and these findings were 
histopathologically comparable to congestion and inflammatory changes in the 
brain tissue and oval-shaped granulomas, respectively.  Additionally, the 
restrictive index (RI), represented as peak systolic velocity (PSV) – (end 
diastolic velocity/PSV), was measured in 6 cerebral arteries (rostral, middle and 
caudal cerebral arteries of both left and right hemispheres). The RI was normal 
to high in all dogs, which can – according to the authors – be explained by 
intracranial pressure, which is normal to high in GME patients (Carvalho et al., 
2012).  
Cerebrospinal fluid analysis 
Cerebrospinal fluid pleocytosis, defined as an increase in white blood 
cell (WBC) count (reference <5 WBC/mm3), is one of the proposed diagnostic 
criteria for MUA (Granger et al., 2010). However, CSF analysis can be normal in 
3-57% of dogs with MUA (Menaut et al., 2009; Granger et al., 2010), which is 
comparable to the results of a study in dogs with GME and NE, where CSF 
analysis revealed a normal cell count in 16% of dogs with GME and in 12.5% of 
dogs with NE (Granger et al., 2010). Albuminocytological dissociation has been 
found in cases with a normal cell count. Increased total protein (TP) 
concentration is a nonspecific indicator of CNS disease, typically caused by 
either blood-brain-barrier disruption or intrathecal immunoglobulin production 
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(Cordy, 1979; Tipold, 1995; Granger et al., 2010). Lymphocytes were the 
predominant cell type in 42% of GME cases and 71% of MUA cases, whereas 
monocytes and lymphocytes were found equally in NE; neutrophils were the 
predominant cell type in <10% of cases in each group (Granger et al., 2010). 
Reported total nucleated cell counts (TNCC) ranged from 50-900 WBC/mm3 up 
to 11840 WBC/mm3 in GME (Adamo et al., 2007; Granger et al., 2010) and from 
0-6860 WBC/mm3 in MUA (Granger et al., 2010). Reported CSF TP 
concentrations ranged from 40-400mg/dl (Adamo et al., 2007; Granger et al., 
2010). In summary, most cases have a CSF mononuclear pleocytosis and as 
such a pleocytosis with >50% mononuclear cells is proposed as a diagnostic 
criterion for dogs with MUA (Granger et al., 2010; Coates and Jeffery, 2014).  
Of the 33 reported dogs with meningomyelitis of unknown aetiology, 
CSF findings were only available for 1 dog (Cherubini et al., 2006). This 
revealed a pleocytosis, with a TNCC of 420 WBC/mm3, and a TP concentration 
of 0.42g/l. The site of CSF collection was not mentioned (Cherubini et al., 
2006).  
Infectious disease testing 
The exact aetiology of MUA remains unknown, but infectious antigenic 
triggers together with environmental factors have been described as potentials 
activators of autoreactive cells in the CNS, although nu such agent has yet 
been identified (Schatzberg et al., 2005; Barber et al., 2010; Greer et al., 2010; 
Barber et al., 2012). Schatzberg et al. (2005) investigated the presence of 
Anaplasma Phagocytophylum, Ehrlichia canis, Toxoplasma gondii (T. gondii), 
Neospora caninum (N. caninum) and Cryptococcus neoformans by serology, 
and presence of canine herpesvirus, adenovirus and canine parvovirus by 
polymerase chain reaction (PCR) in the brains of dogs diagnosed with NME 
(n=12), NLE (n=3) or GME (n=7), but all investigations returned negative. Swab 
et al. (2007) retrospectively investigated the brains of 53 dogs with non-
suppurative meningoencephalitis for the presence of rabies virus, porcine 
herpesvirus, canine distempter virus (CDV), canine parvovirus, canine 
coronavirus, canine herpesvirus, canine adenovirus type I, Tick Borne 
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encephalitis, Borna disease virus, West Nile virus, canine parainfluenza virus, 
Encephalomyocarditis virus, prion proteins, Listeria monocytogenes, Chlamydia 
spp, Mycoplasma spp, and Escherichia coli. No infectious agent could be 
identified in 74% of cases, however, results should be interpreted with caution 
as obtaining a definitive diagnosis in those negative cases was not a specific 
aim of the study. 
It has generally been advised to exclude regional infectious diseases 
(Granger et al., 2010), and this mostly includes to perform serology for T. gondii 
and N. caninum in dogs, and to perform PCR analysis for CDV. However, ante 
mortem diagnosis of T. gondii and N. Caninum can be challenging. For T. 
gondii, 3 diagnostic options are available, including 1) visualization of 
bradyzoites or tachyzoites in tissues, effusions, bronchoalveolar lavage fluids or 
CSF, 2) detection of T. gondii specific antibodies (IgG and IgM) in serum and 3) 
DNA amplification bij PCR on CSF (Lapin, 2014). Unfortunately, some 
shortcomings are present in that visualization is very uncommon, a failure to 
demonstrate increased IgM titers (titer above 1:64) or a fourfold or greater 
increase in IgG titers does not rule out disease; and PCR can reveal false 
negative results. Currently, the combination of IgM detection in CSF and a 
positive PCR analysis is the most accurate way to diagnose CNS toxoplasmosis 
(Lapin, 2014). Similar diagnostic criteria account for N. caninum: 1) visualization 
in tissue or CSF is very uncommon, 2) IgG antibody titers of > 1:800 are 
typically associated with clinical disease, whereas titers between 1:200 and 
1:800 are considered undefined, and 3) DNA amplification by PCR analysis 
which returned positive in 4/5 dogs in one study, indicating that false negative 
results are possible (Lapin, 2014; Parzefall et al., 2014). Only sparse literature 
is available regarding prevalence of T. gondii and N. caninum in Belgium. On 
study stated that none of 2324 fecal samples examined (both dogs and cats) for 
T. gondii were positive (Vanparijs et al., 1991), and another study revealed that 
approximately 10% of Flemish dogs was seropositive for N. caninum (Barber et 
al., 1997). Currenlty, no studies are available on prevalence of CDV in Belgian 
dogs.  
Although T. gondii is known to occasionally cause meningoencephalitis 
in dogs (Dewey, 2016), currently no MRI reports describing those findings are 
  
 
General Introduction 
 
  
31 
available. On the contrary, some literature is available for cats, describing the 
presence of an intracranial granuloma that might resolve after appropriate 
treatment, consisting of surgical removal and/or antibiotic therapy (Pfohl and 
Dewey, 2005; Falzoni et al., 2008). N. caninum has previously been associated 
with necrotizing cerebellitis and cerebellar atrophy (Garosi et al., 2010) as well 
as with spinal cord changes, mesencephalic and metencephalic lesions, and 
with multifocal brain lesions on MR imaging in dogs (Parzefall et al., 2014). 
Three forms of CDV encephalitis are currently described, including acute CDV 
infection, CDV infection in mature dogs and “old dog encephalitis” (Dewey, 
2016). Dogs with acute CDV infection are mostly very young (<1 year) and 
mainly present with forebrain signs, where histopathology reveals a 
polioencephalopathy. Mature dogs (>1 year) with CDV infection tend to develop 
inflammatory demyelinating white matter disease primarily affecting the 
brainstem, cerebellum and spinal cord (leucoencephalomyelopathy), whereas 
“old dog encephalitis” mainly affects older dogs (>5 years) and presents with 
signs of forebrain dysfunction (visual deficits, behavioral changes) (Dewey, 
2016). Currently, MRI findings are only described in a cohort of 5 puppies, 
revealing hyperintense lesions and loss of contrast between grey and white 
matter on T2-weighted images in the cerebellum and/or brainstem. The majority 
of lesions were located in the temporal lobe of the cerebrum, so results should 
be interpreted with caution as all 5 dogs were presented with seizures (Bathen-
Noethen et al., 2008).  
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Treatment  
Although the criterion-referenced standard for a clinical trial is a 
randomized, placebo-controlled, double-blinded, prospective study, it is 
generally accepted that use of a placebo control treatment group is unethical 
because dogs with MUA have a poor outcome without treatment (Coates et al., 
2007; Smith et al., 2009; Coates and Jeffery, 2014). Historically, different 
inclusion criteria have been used, and because in some studies 
immunomodulary medication was only initiated later, e.g. after results for 
infectious disease testing returned negative, treatment results and outcomes 
are difficult to compare (Adamo et al., 2007; Coates et al., 2007; Wong et al., 
2010).  
As previously stated, the exact aetiology and pathophysiology of MUA 
remains unknown, but the cornerstone of medical treatment is 
immunosuppressive therapy. Several treatment protocols using different 
immunomodulating drugs, resulting in different long-term survival times have 
been reported (Sisson et al. 1989; Gregory et al., 1998; Munana and Luttgen, 
1998; Adamo and O’Brien, 2004; Gnirs, 2006; Zarfoss et al., 2006; Adamo et 
al., 2007; Coates et al., 2007; de Stefani et al., 2007; Feliu-Pascual et al., 2007; 
Uriarte et al., 2007; Jung et al., 2007; Menaut et al., 2008; Pakozdy et al., 2009; 
Smith et al., 2009; Granger et al., 2010; Kang et al., 2009; Wong et al., 2010; 
Flegel et al., 2011; Jung et al., 2012; Jung et al., 2013; Lowrie et al., 2013; 
Beckmann et al., 2015; Mercier and Barnes Heller, 2015; Barnoon et al., 2015; 
Lowrie et al., 2016). A comprehensive overview of all immunomodulatory 
therapies for MUA can be found in table 1.2. 
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Table 1.2. Summary of immunomodulatory drug therapies for MUA, including 
the reported number of dogs and the initial drug dosages. Abbreviations: PO = 
per os; IV = intravenous. (Adapted from: Coates and Jeffery, 2014). 
Drug Number 
of dogs 
Initial dosages References 
Azathioprine + 
prednisolone 
40 2mg/kg PO q24h for 2 weeks, 
then decrease to 2mg/kg q48h 
for azathioprine 
Wong et al., 2010 
Ciclosporine 5 6-30mg/kg PO q24h Adamo and O’Brien, 2004; 
Adamo et al., 2007 
Ciclosporine + 
ketoconazole 
3 5-12mg/kg PO q24h 
ciclosporine + 8mg/kg PO 
ketoconazole 
Adamo et al., 2007 
Ciclosporine + 
prednisolone 
23 6-30mg/kg PO q24h 
ciclosporine 
Adamo and O’Brien, 2004; 
Gnirs, 2006; Adamo et al., 
2007; Jung et al., 2007; 
Pakozdy et al., 2009; Kang 
et al., 2009; Jung et al., 
2012; Jung et al., 2013 
Cyclophosphamide 
and vincristine + 
prednisolone 
10 Cyclophosphamide: 50mg/m2 
PO q48h for 8 weeks, then 
every other week 
Vincristine: 0.5mg/m2 IV, every 
7 days for 8 weeks, then every 
14 days 
Smith et al., 2009 
Cytosine 
arabinoside + 
prednisolone 
158 50mg/m2 SC, q12h for 2 
consecutive days, then repeat 
every 3 weeks for  4 cycles  
IV infusion: 200 mg/m2 over 8 
hours 
Zarfoss et al., 2006; de 
Stefani et al., 2007; 
Menaut et al., 2008; Smith 
et al., 2009; Lowrie et al., 
2013; Lowrie et al., 2016 
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Drug Number 
of dogs 
Initial dosages References 
Leflunomide + 
prednisolone 
5 1.5-4mg/kg PO q24h Gregory et al., 1998 
Lomustine + 
prednisolone 
32 60mg/m2 PO every 6 weeks Uriarte et al., 2007; Flegel 
et al., 2011 
Mycophenolate 
mofetil + 
prednisolone 
30 10-20mg/kg PO q12h, reduce 
after 1 month to 5-10mg/kg 
q12h 
Feliu-Pascual et al., 2007; 
Barnoon et al., 2015 
Procarbazine + 
prednisolone 
31 25-50mg/m2 PO q24h Coates et al., 2007 
Prednisolone 78 1 to 2mg/kg PO q12h for 3–4 
weeks; 0.5–1mg/kg q12h for 6 
weeks; then 0.25–0.5mg/kg 
q12h for 3 weeks; then 0.25–
0.5mg/kg q24h for 3 weeks; 
then 0.25–0.5mg/kg q48h 
indefinitely 
Coates et al., 2007; 
Pakozdy et al., 2009; 
Granger et al., 2010; 
Flegel et al., 2011; Mercier 
and Barnes Heller, 2015 
 
Overall, treatment effect is monitored by clinical response and 
resolution of neurologic deficits, and occasionally by repeated CSF analysis and 
MR imaging (Coates and Jeffrey 2014). In a small cohort of dogs, Lowrie et al. 
(2013) suggested that a combination of MR imaging and CSF analysis provided 
greater sensitivity for prediction of relapse than one modality alone. The authors 
therefore suggested that treatment should only be tapered once MR imaging 
and CSF analysis (including TP concentration) returned to normal (Lowrie et al., 
2013). 
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Glucocorticosteroids 
Treatment with glucocorticosteroids (mostly prednisolone) only is 
generally associated with shorter survival times (ST) compared to combination 
therapy with other immunosuppressive agents (Munana and Luttgen, 1998; 
Jung et al., 2007; Pakozdy et al., 2009; Granger et al., 2010; Flegel et al., 2011; 
Mercier and Barnes Heller, 2015). However, in a clinical setting, adding more 
expensive immunosuppressive therapies to the glucocorticoid protocol might be 
financially prohibitive.  
Glucocorticosteroids bind to a cytosolic glucocorticosteroid receptor, 
which then moves to the nucleus, binds to DNA, and influences gene 
transcription. Cellular effects include stabilization of cell membranes, inhibition 
of phospholipase A2 with resultant inhibition of the cyclooxygenase and 
lipoxygenase pathways, decreased release of cytokines interleukin (IL) -1 and 
IL-6, and downregulation of Fc receptor expression on macrophages. The early 
effects of corticosteroids are believed to predominantly result from a rapid 
decrease in phagocytic activity of splenic and hepatic macrophages, whereas 
the long-term effects result primarily from suppression of cell-mediated 
immunity (suppression of T-helper cells) (Nelson and Couto, 2014). Most 
common adverse effects include polyuria, polydipsia, panting, muscle 
weakness, dermatological changes, predisposition to infections, and muscle 
atrophy. Glucocorticosteroids might cause insulin resistance, hyperglycaemia, 
vacuolar hepatopathy, and hypercoagulability (Nelson and Couto, 2014). 
Glucocorticosteroids are typically initiated at immunosuppressive doses, 
followed by tapering to a minimal effective dose while maintaining fair (or better) 
quality of life (Zarfoss et al., 2006).  
In the literature, 78 dogs diagnosed with MUA and receiving sole 
prednisolone therapy have been reported, and survival data were available for 
all dogs (Coates et al., 2007; Pakozdy et al., 2009; Granger et al., 2010; Flegel 
et al., 2011; Mercier and Barnes Heller, 2015). Median survival times (MSTs) 
ranged from 28 – 357 days (43/78) (Granger et al., 2010), 91 - 329 days (19/78) 
(Flegel et al., 2011) and 602 days (16/78) (Mercier and Barnes Heller, 2015) in 
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dogs receiving dosages ranging from 0.5 – 30 mg/kg/day (Coates et al., 2007; 
Pakozdy et al., 2009; Granger et al., 2010; Flegel et al., 2011; Mercier and 
Barnes Heller, 2015). 
Cytosine arabinoside 
Six studies evaluated treatment with cytosine arabinoside as an 
adjunctive treatment option to prednisolone in dogs diagnosed with MUA, 
covering a total of 158 cases. Cytosine arabinoside can be administered either 
as a continuous rate infusion (CRI) (doses ranging from 100-300 mg/m2 over 8-
24 hours) or as 4 subcutaneous (SC) injections of 50 mg/m2 in 48 hours (200 
mg/m2 in 48h) (Zarfoss et al., 2006; de Stefani et al., 2007; Menaut et al., 2008; 
Smith et al., 2009; Lowrie et al., 2013; Lowrie et al., 2016). Crook et al. (2013) 
showed that CRI administration of cytosine arabinoside provided a steady state 
concentration over the time it was administered compared to a rapid absorption 
and elimination when administered subcutaneously. A recent clinical study 
revealed a significantly better 3-month-survival in dogs initially receiving a CRI 
of cytosine arabinoside compared to the SC route (Lowrie et al., 2016). 
Cytosine arabinoside is a synthetic nucleoside analogue, which 
crosses the blood-brain-barrier, undergoes enzymatic activation, competes for 
incorporation into nucleic acids and then competitively inhibits DNA polymerase 
in mitotically active cells. Additionally, it causes topoisomerase dysfunction and 
prevents DNA repair; inhibits ribonucleotide reductase; inhibits membrane 
glycoprotein synthesis; and promotes leukemic cell differentiation in culture. All 
the effects are dependent on both cell cycle (S-phase) and rate of DNA 
synthesis (Zarfoss et al., 2006; Coates and Jeffery, 2014).  
Side effects in dogs were dose dependent and mainly included 
myelosuppression and gastro-intestinal upset (Zarfoss et al., 2006). However, 
no dose-limiting toxicities were mentioned in most cases (Lowrie et al., Menaut 
et al., 2009; Smith et al., 2009). Transient post-treatment lethargy, dysphagia or 
limb tremors (3/10); mild coat and skin changes (increased shedding or 
alopecia, mild localised dermatitis) (4/10); and transient to intermittent pelvic 
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limb weakness (3/10) was noticed in one study (Zarfoss et al., 2006). Three 
case reports described three additional side effects of cytosine arabinoside 
therapy. One dog developed infiltrative lung disease 24h after the 4th cytosine 
arabinoside infusion (300mg/m2), where after the dog was euthanized (Hart and 
Waddell, 2016). The second dog developed anterior uveitis three weeks after 
the 5th cytosine arabinoside treatment (50mg/m2 q12h for 48h), which resolved 
after treatment with topical antibiotics, non-steroidal anti-inflammatory drugs, 
artificial tears and local atropine (Bianchi and Dodi, 2007). At last, development 
of severe calcinosis cutis and deep pyoderma at the cytosine arabinoside 
injection site was described in three dogs (Volk et al., 2012).  
Reported MSTs with additional cytosine arabinoside ranged from 26 to 
1063 days (n=69) (Zarfoss et al., 2006; de Stefani et al., 2007; Menaut et al., 
2008; Smith et al., 2009; Lowrie et al., 2013; Lowrie et al., 2016).  
Ciclosporine 
Ciclosporine therapy has been described as sole treatment for MUA 
(n=5) (Adamo and O’Brien, 2004; Adamo et al., 2007), or as combination 
therapy with prednisolone (n=23) (Adamo and O’Brien, 2004; Gnirs, 2006; 
Adamo et al., 2007; Jung et al., 2007; Pakozdy et al., 2009; Kang et al., 2009; 
Jung et al., 2012; Jung et al., 2013), ketoconazole (n=3) (Adamo et al, 2007), or 
cytosine arabinoside and prednisolone (n=1) (Behr et al., 2009). Overall, 32 
dogs have been reported receiving initial doses ranging from 3 – 15 mg/kg PO 
every 12 hours, resulting in MSTs ranging from 236 to 930 days (Adamo and 
O’Brien, 2004; Gnirs, 2006; Adamo et al., 2007; Jung et al., 2007; Pakozdy et 
al., 2009; Kang et al., 2009; Jung et al., 2013). One dog receiving combination 
therapy survived for 1096 days (Jung et al., 2012).  
Ciclosporine is a fungal polypeptide that interferes with macrophage 
and monocyte activation by inhibiting the transcription of alfa-interferon. It 
suppresses T-cell mediated immune responses through inhibition of synthesis 
of IL-2 and other cytokines. Although ciclosporine is lipophilic, it has poor blood-
brain-barrier permeability (Adamo and O’Brien, 2004; Gnirs, 2006; Adamo et al., 
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2007). Because the blood-brain-barrier might be disrupted during inflammation 
in MUA, therapeutic ciclosporine concentrations may be present in affected 
areas of the CNS (Adamo et al., 2007). Commercial ciclosporine is available in 
2 very different types of oral formulations. A vegetable-oil based preparation 
that caused marked intraindividual and interindividual variations in blood drug 
concentrations, and a microemulsified form that results in a more consistent and 
predictable absorption. Oral bioavailability of the microemulsion has improved 
by up to 50% compared with the oil-based formulation (Archer et al., 2014). 
Reported side effects include mild hypertrichosis and transient 
lymphopenia (Adamo and O’Brien, 2004), vomiting during first 2 weeks of 
treatment (5/10) (Gnirs et al., 2006; Pakozdy et al., 2009) and severe gastro-
intestinal adverse effects with life-threatening anaemia (1/7) (Pakozdy et al., 
2009). A range of side effects has also been described in dogs receiving 
5mg/kg q24h (the approved atopy dosage), additionally including anorexia, 
urinary tract infections, persistent otitis externa, gingival hyperplasia and 
lymphadenopathy (Archer et al., 2014). 
Other immunosuppressive agents 
Other immunosuppressive agents have been described in combination 
with prednisolone for treatment of MUA, including azathioprine (n=40) (Wong et 
al., 2010), procarbazine (n=31) (Coates et al., 2007), lomustine (n=32) (Uriarte 
et al., 2007; Flegel et al., 2011), vincristine and cyclophosphamide (n=10) 
(Smith et al., 2009), leflunomide (n=5) (Gregory et al., 1998), and 
mycophenolate mofetil (n=30) (Feliu-Pascual et al., 2007; Barnoon et al., 2015).  
Following side effects were described in those studies: 
myelosuppression (19%) and haemorrhagic enteritis (15%) with procarbazine 
(Coates et al., 2007); leucopenia, severe thrombocytopenia and haemorrhagic 
gastro-enteritis with lomustine (Flegel et al., 2011); myelosuppression, 
haemorrhagic cystitis and pyometra with vincristine and cyclophosphamide 
(Smith et al., 2009); and haemorrhagic diarrhoea within the first 2 weeks of 
treatment with mycophenolate mofetil (Feliu-Pascual et al., 2007; Barnoon et 
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al., 2015). The side effects encountered with the combination of vincristine and 
cyclophosphamide were unacceptable to the author, excluding this protocol for 
further investigation (Smith et al., 2009). On treatment with azathioprine (n=40), 
major adverse events were infrequent and included poor coat or thin skin 
(13/40), urinary tract infection (3/40), vomiting (3/40), corneal ulcers (2/40), 
diabetes mellitus (2/40), renal failure, keratoconjunctivitis sicca, cruciate 
ligament rupture, hepatic mass, mammary gland adenoma, lymphoma, 
demodectic mange and septic arthritis of a single joint. However, many of the 
adverse effects, such as weight gain, poor coat, hypertriglyceridemia, 
thrombocytosis, and elevated liver enzyme activities, could have been 
associated with concurrent administration of corticosteroids (Wong et al., 2010).  
MSTs were available for some studies, being 425 days for 
procarbazine (Coates et al., 2007), 150-740 days for lomustine (Uriarte et al., 
2007; Flegel et al., 2011), 198 days for vincristine and cyclophosphamide 
(Smith et al., 2009), 250 days for mycophenolate mofetil (Barnoon et al., 2015), 
and 1834 days for azathioprine (Wong et al., 2010).  
Radiation therapy 
Three studies comprising 17 dogs examined the additional effect of 
radiation therapy (Sisson et al., 1989; Munana and Luttgen, 1998; Beckmann et 
al., 2015). This resulted in MSTs of 404-476 days, without occurrence of early 
or late radiotherapy reactions (Munana and Luttgen, 1998; Beckmann et al., 
2015).  
Prognostic factors 
As MUA is generally considered a fatal disease (Munana and Luttgen, 
1998), multiple studies attempted to identify prognostic factors for dogs 
diagnosed with MUA. Unfortunately, different studies revealed conflicting 
results, making the majority of findings inapplicable in a clinical setting.  
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Younger age at time of diagnosis was significantly associated with 
improved survival in dogs with MUA (Oliphant et al., 2016). Munana and 
Luttgen (1998) found significant longer survival times with focal versus 
multifocal neurological signs in dogs with GME. Additionally, dogs with focal 
forebrain signs had a significantly longer survival time compared to dogs with 
focal signs related to other areas of the CNS. Dogs with focal forebrain signs 
that underwent radiation therapy had a significantly longer survival time 
compared to dogs with focal forebrain signs that did not undergo radiation 
therapy (Munana and Luttgen, 1998). The finding of increased survival for dogs 
with focal neurological signs was, however, not repeated in more recent studies 
in dogs with MUA (Coates et al., 2007; Lowrie et al., 2013). Dogs presenting 
specifically with seizures or altered mentation had significantly shorter survival 
times (Bateman and Parent, 1999; Coates et al., 2007; Granger et al., 2010). 
Also, a significantly longer MST was recorded in dogs that were presented 
within 7 days of onset of clinical signs, compared to those presented after more 
than 7 days, suggesting that early diagnosis and treatment might influence 
survival time (Barnoon et al., 2015).  
One study identified a lower CSF TNCC to be significantly associated 
with improved survival in dogs with MUA (Oliphant et al., 2016), whilst others 
found that neither CSF TNCC nor protein concentration had an effect on 
survival time in dogs with MUA (Coates et al., 2007). One study suggested that 
serial monitoring of CSF TNCC and protein concentrations is a sensitive 
indicator of successful treatment of inflammatory disease; however, clinical 
relapse was not evaluated statistically (Cizinauskas et al., 2000). The study of 
Lowrie et al. (2013) failed to demonstrate an association between normal CSF 
analysis and improved outcome, but did find an association between abnormal 
CSF analysis at three months and relapse or poor outcome in dogs with MUA 
(Lowrie et al., 2013). In the study of Mercier and Barnes Heller (2015) CSF 
analysis was repeated 1 month after diagnosis, and their results suggested that 
serial CSF analysis might be a valid tool for monitoring success or failure of 
treatment in dogs diagnosed with MUA and treated with glucocorticoid 
monotherapy. 
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Different findings on MR imaging were evaluated for their possible 
prognostic value, but so far midline brain shift (Oliphant et al., 2016) and 
contrast enhancement on T1WI and lesion burden (lesion volume compared to 
parenchymal volume) (Young et al., 2009) could not be associated with survival 
in dogs with MUA and Pug dogs with NME, respectively. On the contrary, mass 
effect, loss of cerebral sulci and foramen magnum herniation were all 
significantly associated with death in dogs with MUA, however the clinical 
prognostic power was low for those findings and none of them was predictive of 
long-term outcome (Lowrie et al., 2013; Lowrie et al., 2016). Resolution of MRI 
lesions three months after diagnosis was indicative of a good outcome (Lowrie 
et al., 2013). 
Outcome 
Approximately 15% of dogs with GME will die before being treated 
(Munana and Luttgen, 1998; Granger et al., 2010). Despite initiation of 
appropriate and aggressive immunosuppressive treatment, 56% of dogs in one 
study died or was euthanized because of MUA, and 33% of deceased dogs did 
so within 3 days after diagnosis (Lowrie et al., 2013). Levine et al. (2008) 
showed that dogs with NME that had received any form of treatment had a 
significantly longer mean ST than those that received no treatment. 
Nevertheless, most dogs with MUA or GME that die, do so within the first 3 
months after diagnosis (Thomas and Eger, 1989; Smith et al., 2009; Lowrie et 
al., 2013). Eighteen/nineteen dogs (95%) survived for one month in one study 
(Smith et al., 2009), and only 1 of those dogs failed to survive for 1 year. 
Additionally, dogs that survived for 1 year often lived for a relatively long period 
beyond this, suggesting that animals alive after 1 month might have a relatively 
good chance of living several more years (Smith et al., 2009).  
In one study, relapse was recorded in 65% of dogs with MUA within a 
median of 210 days following diagnosis (Lowrie et al., 2013). This study 
revealed that abnormal CSF analysis at three months was associated with 
higher risk of relapse, but the combination of MRI and CSF analysis provided a 
greater sensitivity for predicting relapse than one modality alone. Discontinuing 
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treatment before resolution of MRI lesions always resulted in relapse (Lowrie et 
al., 2013). 
Follow-up information was available for 29 out of 33 dogs described 
with spinal MUA (Griffin et al., 2008; Wong et al., 2010). Overall, 17/33 dogs 
died or were euthanized because of MUA, and 9 dogs were alive at time of data 
capture (Griffin et al., 2008; Wong et al., 2010). No significant difference in ST 
could be identified between dogs with neurological signs of a myelopathy or an 
encephalopathy (Wong et al., 2010).  
Conclusions 
In the absence of an immediate histopathological diagnosis, the 
clinician should rely on previously established clinical diagnostic criteria used for 
the diagnosis of MUA. MRI is considered the gold standard for diagnosing 
intracranial inflammatory lesions, but studies looking into differentiation between 
GME, NME and NLE are currently unavailable. Immunosuppressive drugs are 
considered the cornerstone of treatment. Several studies have been performed 
regarding long-term outcome in MUA, but no information is available about 
short-term survival in those dogs. Further studies are therefore necessary to 
explore the underlying aetiology and pathophysiology of MUA, with optimisation 
of clinical diagnosis and treatment protocols, and to identify clinically reliable 
prognostic indicators. 
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MUA is a complex neurological disorder that causes diagnostic, 
therapeutic and prognostic challenges to both clinical neurologists and 
investigators. Currently, there is controversy and discussion about possible 
aetiologies, diagnostic criteria, different therapeutic options, prognostic factors 
and outcome in dogs diagnosed with MUA.  
Therefore, the general aim of this thesis was to gain more insight in the 
diagnosis (including clinical presentation and cross-sectional imaging findings), 
treatment, possible prognostic factors and outcome of dogs with MUA.  
 
The specific aims of this study were: 
 
 To evaluate the clinical presentation, diagnostic findings and long-term 
outcome in large dogs diagnosed with MUA. 
 To evaluate the clinical presentation, diagnostic findings and long-term 
outcome in dogs diagnosed with MUA only affecting the spinal cord. 
 To compare the efficacy of three sole prednisolone treatment schedules 
in dogs with MUA, and to describe their associated long-term outcome. 
 To compare the efficacy of sole prednisolone therapy and combination 
therapy with ciclosporine in dogs with MUA. 
 To evaluate prognostic factors for short-term outcome in dogs diagnosed 
with MUA.
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Abstract 
Although several studies indicate that MUA might affect every dog breed at 
every age, little is known about clinical presentation, diagnostic findings and long-
term survival in large dogs. The aim of this study was therefore to compare the 
clinical presentation, diagnostic findings and long-term survival between large and 
small dogs diagnosed with MUA. One hundred and eleven dogs met the inclusion 
criteria. Twenty-eight (25%) dogs were considered large dogs, compared to 83 
(75%) small dogs. Large dogs presented significantly more often with a decreased 
mentation. Age, gender, duration of clinical signs prior to diagnosis, presence of 
seizures or cluster seizures, variables on complete blood count and cerebrospinal 
fluid analysis, and all variables on MRI were not significantly different between small 
and large dogs. Median survival time was 281 and 106 days for the large and small 
dogs respectively, with no significant difference in survival curves for both groups. 
Although considered not typically affected by MUA, 25% of dogs included in this 
study were considered large dogs. Therefore, MUA should be included in the 
differential diagnosis for large dogs presenting with intracranial neurological signs. If 
diagnosed with MUA, large dogs also carried a guarded prognosis.   
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Introduction  
As stated in the introduction of this thesis, middle-aged female toy and 
terrier breeds are considered predisposed to develop GME (Munana and Luttgen, 
1998; Adamo et al., 2007; Talarico and Schatzberg, 2010). Necrotising encephalitis 
(including NME and NLE) predominantly affects toy and small dogs including 
Yorkshire Terrier, Maltese Terrier, French Bulldog, Shih Tzu, Lhasa Apso, 
Chihuahua, Pug, Pekingese, Papillon, Coton de Tulear and Brussels Griffon 
(Talarico and Schatzberg, 2010; Cooper et al., 2014). Although it is stated that dogs 
of any breed and age can be affected by MUA (Coates and Jeffery, 2014), literature 
regarding differences in clinical presentation, diagnostic findings and long-term 
survival between small and large dogs is currently unavailable. It is unknown 
whether the non-infectious inflammatory encephalopathies diagnosed in large dogs 
are just a variation on a common etiologic theme or represent a truly different 
aetiology compared to the various almost breed-specific encephalitides regularly 
diagnosed in small dogs. The aims of this study where therefore to describe the 
clinical presentation, diagnostic findings and long-term survival in large dogs 
diagnosed with MUA compared to small dogs. We hypothesized that no differences 
would be detected in clinical presentation, diagnostic findings and long-term survival 
between small and large diagnosed with MUA. 
 
Materials and methods 
Case selection  
The electronic medical database of the Small Animal Referral Hospital, 
Royal Veterinary College, University of London, was searched between January 
2006 and April 2015 for dogs diagnosed with “ meningoencephalitis of unknown 
origin (MUO)”, “MUA”, “GME”, “NME”, “NLE”, “inflammatory CNS disease”, “non-
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infectious meningoencephalitis” and the fully written versions of the above-
mentioned abbreviations. Dogs were included based on the criteria used by Granger 
et al. (2010), if they had (1) complete medical records available, (2) a complete 
neurological examination performed leading to a focal or multifocal intracranial 
neuroanatomical localisation, (3) inflammatory CSF analysis, (4) MR imaging of the 
brain demonstrating single, multiple or diffuse intra-axial hyperintense lesions on 
T2WI, and (5) outcome data available through revision of medical records or 
contacting the referring veterinarian by email or telephone. Dogs were excluded if 
(1) the clinical records or imaging studies were incomplete or not available for 
review, (2) dogs were diagnosed with meningomyelitis without clinical signs of 
intracranial involvement, (3) no pleocytosis was found on CSF analysis with the 
exception of dogs with signs of raised intracranial pressure (ICP) on imaging 
studies, in which case CSF collection was not performed, and if (4) outcome data 
were unavailable. Dogs with histopathological confirmation of the disease only 
needed to fulfil inclusion criteria (1) and (5).  
Dogs were divided in two groups based on their body weight: dogs <15kg, 
in this paper referred to as small dogs; and dogs >15kg, in this paper referred to as 
large dogs. For dogs with a body weight around 15kg, mean body weight for male 
and female dogs as reported on the Kennel Club website 
(http://www.thekennelclub.org.uk/services/public/breed/standard-find.aspx) were 
used to consider them small or large dogs. Information retrieved from the medical 
records included breed, age at diagnosis, gender, body weight, results of general 
physical and neurological examination and neuroanatomical localisation, duration of 
clinical signs prior to diagnosis, results of CBC and biochemistry profile, results of 
CSF analysis, and lactate concentration on venous blood gas analysis. Duration of 
clinical signs prior to diagnosis was classified as peracute (<2 days), acute (2–7 
days) or chronic (>7 days). For dogs that had CSF analysis performed, site of 
collection (cisternal or lumbar), TNCC, TP concentration and nucleated cell 
differential count were recorded. Total nucleated cell count was considered normal if 
<5 WBC/mm3. Total protein concentration was considered normal for a cisternal 
collection if <0.25g/l and for a lumbar collection if <0.4g/l. Possible neuroanatomical 
localisations included forebrain, brainstem or cerebellum. Dogs with vestibular signs 
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attributable to an intracranial lesion were diagnosed with central vestibular signs. If 
more than 2 of the above mentioned regions appeared to be affected on the 
neurological examination, dogs were given a multifocal neuroanatomical localisation, 
where dogs with only one region affected were given a focal neuroanatomical 
localisation. Magnetic resonance imaging was performed under general anaesthesia 
with a permanent 1.5T magnet (Intera, Philips Medical Systems, Eindhoven, the 
Netherlands) and all images were reviewed by a board certified neurologist (SDD) 
using Osirix DICOM viewer (Osirix Foundation, V.5.5.2 Geneva, Switzerland). The 
reviewer was blinded for signalment, results of the neurological examination and 
necropsy findings if available. Sequences could vary, but studies included a 
minimum of T2WI (TR (ms) / ET (ms), 3000/120), T1WI (TR/TE, 400/8) and FLAIR 
images of the entire brain in a sagittal, transverse and dorsal plane. The T1WI were 
acquired before and after IV administration of paramagnetic contrast medium 
(0.1mg/kg, gadoterate meglumine, Dotarem, Guerbet, Milton Keynes, UK). Variables 
recorded were lesion localisation and distribution, presence of parenchymal or 
meningeal contrast enhancement and presence of mass effect (brain herniation, 
midline shift, flattening of gyri/sulci).  
Statistical analysis 
Data analysis was performed with the aid of a standard statistical software 
package (Prism, Graphpad Software Inc, La Jolla, California, USA). A Mann-
Whitney U test was used to compare age, duration of clinical signs prior to 
diagnosis, venous blood lactate levels, white blood cell (total, neutrophil and 
lymphocyte) count on complete blood count (CBC), TNCC and TP concentration in 
CSF between small and large dogs. A fisher’s exact test was used to compare 
differences in gender, presence of seizures and cluster seizures, neuroanatomical 
localisation (mentation, forebrain, brainstem, central vestibular) and imaging findings 
(lesion localisation, meningeal or parenchymal contrast enhancement, mass effect, 
brain herniation, flattening gyri/sulci, rostral or caudal transtentorial herniation, 
foramen magnum herniation) between small and large dogs. Numeric variables were 
expressed as median and IQR. A false discovery rate (FDR) as used by Benjamini 
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et al. (2001) was applied to control for the increased risk of falsely significant results 
in the multiple comparisons. Values of P<0.05 were considered significant. Survival 
analysis was performed using both a Log-rank (Mantel-Cox) and Gehan-Breslow-
Wilcoxin test, resulting in MST calculation and Kaplan-Meier survival curves 
comparing survival percentage in small and large dogs. Survival was defined as time 
from diagnosis to death or euthanasia, including whether this happened because of 
disease progression or due to unrelated causes, or time from diagnosis to data 
collection for dogs that were alive at time of data capture. Dogs that died because of 
unrelated causes and dogs that were still alive at time of data capture were 
censored for calculations.  
Results 
Signalment 
Database research revealed 549 results. Dogs were excluded if they did 
not match the inclusion criteria, or if the combination of signalment, clinical 
presentation and imaging findings was more suggestive for another intracranial 
disorder (neoplasia, vascular lesion). Finally, 111 dogs were included in this study. 
These included 28 (25%) large and 83 (75%) small dogs. Large dogs represented 
were English Springer Spaniel (n=6), cross breed (n=5), Labrador Retriever (n=4), 
Golden Retriever (n=2), Akita (n=2), and one each of the following breeds: Border 
Collie, Boxer, Bernese Mountain dog, Curly-Coated Retriever, German Wirehaired 
pointer, Great Dane, Shar-Pei, Siberian Husky, Welsh Springer Spaniel. Compared 
to the general hospital population admitted between January 2006 and April 2015, 
English Springer Spaniels were not significantly overrepresented (P=0.196). Small 
dogs included West Highland White terrier (n=22), Chihuahua (n=8), Maltese terrier 
(n=8), Pug (n=8), French Bulldog (n=7), Cavalier King Charles Spaniel (n=6), 
crossbreed (n=6), Yorkshire terrier (n=5), Border terrier (n=2), Boston terrier (n=2), 
Pomeranian (n=2), Poodle (n=2) and one each of the following breeds: Bichon Frise, 
Welsh Corgi Cardigan, Lhasa Apso, Papillon and Sheltie.  
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Clinical presentation and diagnostic findings  
Large dogs had a significant shorter duration of clinical signs prior to 
diagnosis (P=0.012), more often presented with decreased mentation (<0.0001) and 
less often with cranial nerve deficits (P=0.027), and were more often diagnosed with 
a brainstem lesion on MRI (P=0.039) compared to small dogs. However, when a 
FDR of 10% was applied, only decreased mentation was found to be significantly 
different between both groups. Gender, age at presentation, neuroanatomical 
localisation, presence of seizures and cluster seizures, lactate concentration on 
venous blood gas analysis, TNCC and TP concentration on CSF analysis and the 
remaining MRI findings (meningeal or parenchymal contrast enhancement, mass 
effect, brain herniation, flattening gyri/sulci, rostral or caudal transtentorial herniation, 
foramen magnum herniation) were not different between small and large dogs. All 
statistical results can be consulted in table 2.1, and a clinical summery regarding the 
large dogs can be consulted in table 2.2. 
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Table 2.1: Investigated variables in small and large dogs diagnosed with MUA. 
Values are numbers with their percentage, or a median with interquartile range 
between brackets. * = P-value below the FDR threshold and thus considered to 
be significant. 
Variable 
Small dogs 
(n=83) 
Large dogs 
(n=28) 
P value/FDR 
Signalment 
   
   Age (months) 52 (6 – 146) 60 (10 – 120) 0.7373/0.0678 
   Male 44 (53%) 17 (61%) 0.0653/0.0143 
   Female 39 (47%) 11 (39%) 0.0653/0.0178 
Duration of clinical signs 
prior to diagnosis (days) 
8 (1-180) 5 (1 – 60) 0.0116/0.0071 
Clinical signs 
   
   Seizures 19 (23%) 10 (36%) 0.2164/0.0286 
   Cluster seizures 13 (16%) 7 (25%) 1.0000/0.0929 
Neuroanatomical 
localisation 
   
   Forebrain 58 (70%) 22 (79%) 0.4875/0.0464 
   Brainstem 53 (64%) 18 (64%) 1.0000/0.0964 
   Central vestibular 27 (33%) 4 (14%) 0.0904/0.0214 
   Abnormal mentation 26 (31%) 25 (89%) <0.0001/0.0036* 
Blood work 
   
   White blood cells (.109/l) 
10.6 (3.52 – 
32.8) 
9.8 (4.66 – 25.1) 0.5888/0.05 
   Neutrophils (.109/l) 7.5 (2.4 – 28.3) 7.1 (3.2 – 22.3) 0.4420/0.0429 
   Lymphocytes (.109/l) 1.3 (0.1 – 3.6) 1.2 (0.3 – 2.7) 0.3434/0.0393 
Venous blood gas 
   
   Lactate (mmol/l) 1.5 (0.6 – 3.6) 1.6 (0.4 – 10.4) 0.8711/0.0786 
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Variable 
Small dogs 
(n=83) 
Large dogs 
(n=28) 
P value/FDR 
CSF analysis 
   
   TNCC (WBC/mm3) 97 (1 – 2560) 48 (1 – 2220) 0.3360/0.03572 
   Total protein (mg/dl) 
0.54 (0.11 – 
3.51) 
0.43 (0.1 – 8.47) 0.7872/0.0714 
MRI findings 
   
   Focal lesion 24 (29%) 7 (25%) 0.7163/0.0607 
   Multifocal lesion 57 (69%) 20 (71%) 0.7335/0.0643 
   Diffuse lesion 6 (7%) 2 (7%) 1.0000/0.1 
   Forebrain localisation 66 (80%) 23 (82%) 0.7035/0.0571 
   Brainstem localisation 41 (49%) 20 (71%) 0.0414/0.0107 
   Cerebellar localisation 16 (19%) 5 (18%) 0.8893/0.0821 
   Mass effect 53 (64%) 13 (46%) 0.1297/0.025 
      Brain herniation 34 (41%) 10 (36%) 0.6586/0.0536 
      Caudal transtentorial 
herniation 
29 (35%) 10 (36%) 0.9097/0.0857 
      Foramen magnum   
herniation 
23 (28%) 7 (25%) 0.8066/0.075 
      Midline shift 31 (37%) 7 (25%) 0.2534/0.321 
      Flattening gyri/sulci 38 (46%) 13 (46%) 0.9140/0.0893 
 
 
  
 
Chapter 1: Large Dogs 
 
  
60 
Table 2.2: Overview of breed, age, TNCC in CSF, TP concentration in CSF, MRI findings, ST and post mortem (PM) necropsy findings 
for the large dogs included in this study. NP: not performed.  
Case Breed 
Age 
(months) 
TNCC 
(WBC/mm3) 
TP 
(g/l) 
MRI findings (lesion localisation) 
ST 
(days) 
PM 
diagnosis 
1 Akita 36 2220 4.65 Multifocal lesions brainstem and spinal cord 2 NP 
2 Bernese Mountain 
Dog 
45 12 0.38 Multifocal lesions forebrain and brainstem 120 NP 
3 Border Collie 70 300 2.47 Multifocal lesions forebrain and cerebellum 92 ALIVE 
4 Boxer 68 NP NP Multifocal lesions forebrain, brainstem and cerebellum 1 GME 
5 Cross Breed 85 23 0.26 Focal lesion forebrain 1580 ALIVE 
6 Cross Breed 64 1255 1.31 Multifocal lesions forebrain, brainstem and spinal cord 5 NP 
7 Cross Breed 23 555 1.92 Focal lesion brainstem 1 GME 
8 Cross Breed 26 1090 8.47 Focal lesion brainstem 1095 ALIVE 
9 Cross Breed 12 90 0.62 Multifocal lesions forebrain, brainstem and cerebellum 2708 ALIVE 
10 Curly-Coated 
Retriever 
63 80 0.78 Multifocal lesions forebrain, brainstem and cerebellum 2190 ALIVE 
  
 
Chapter 1: Large Dogs 
 
  
61 
Case Breed 
Age 
(months) 
TNCC 
(WBC/mm3) 
TP 
(g/l) 
MRI findings (lesion localisation) 
ST 
(days) 
PM 
diagnosis 
11 English Springer 
Spaniel 
61 62 0.6 Multifocal lesions forebrain and brainstem 2950 ALIVE 
12 English Springer 
Spaniel 
60 17 0.75 Diffuse lesions forebrain 1 NP 
13 English Springer 
Spaniel 
47 12 0.16 Multifocal lesions brainstem 72 ALIVE 
14 English Springer 
Spaniel 
61 29 0.23 Multifocal lesions forebrain and brainstem 2039 ALIVE 
15 English Springer 
Spaniel 
39 173 0.68 Focal lesion brainstem 1187 ALIVE 
16 English Springer 
Spaniel 
78 NP NP Multifocal lesions forebrain, brainstem and cerebellum 700 ALIVE 
17 German 
Wirehaired Pointer 
10 12 0.23 Multifocal lesions forebrain and brainstem 975 ALIVE 
18 Golden Retriever 75 1 0.21 Multifocal lesions forebrain and brainstem 1 GME 
19 Golden Retriever 60 22 0.46 Multifocal lesions forebrain and brainstem 1856 ALIVE 
20 Great Dane 60 40 0.1 Multifocal lesions forebrain 1 NP 
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Case Breed 
Age 
(months) 
TNCC 
(WBC/mm3) 
TP 
(g/l) 
MRI findings (lesion localisation) 
ST 
(days) 
PM 
diagnosis 
21 Japanese Akita 20 51 0.41 Multifocal lesions forebrain and brainstem 1 NP 
22 Labrador Retriever 120 8 0.1 Focal lesion forebrain 3 NME 
23 Labrador Retriever 47 3 0.24 Multifocal lesions forebrain and brainstem 1 NLE 
24 Labrador Retriever 27 NP NP Diffuse lesions forebrain 184 ALIVE 
25 Labrador Retriever 94 30 0.43 Multifocal lesions forebrain and brainstem 730 ALIVE 
26 Shar-Pei 36 NP NP Multifocal lesions forebrain 2129 ALIVE 
27 Siberian Husky 30 68 0.35 Focal lesion forebrain 18 NP 
28 Welsh Springer 
Spaniel 
89 675 5.56 Multifocal lesions forebrain and brainstem 3 GME 
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Infectious disease testing was performed in 78 dogs, including 
serology for Toxoplasma gondii and Neospora caninum in 58 dogs (16 large 
dogs and 42 small dogs), and/or and PCR analysis for Toxoplasma gondii, 
Neospora caninum and Canine Distemper Virus in 73 dogs (13 large dogs and 
41 small dogs). Overall, infectious disease testing was lacking in 9 large dogs 
from which 1 dog had complete necropsy performed and 4 dogs were still alive 
at time of data capture with survival times ranging from 184 – 2039 days. These 
4 dogs were all treated with an immunosuppressive treatment protocol. The 4 
remaining large dogs died within 20 days after diagnosis and breeds included 
English Springer Spaniel, crossbreed, Siberian Husky and Akita.  
Post-mortem examination was performed in 14 dogs, 8 small and 6 
large dogs. Results included GME (5 small dogs, 4 large dogs), NME (3 small 
dogs, 1 large dog) and NLE (1 large dog). 
Outcome 
All 111 dogs were initiated on immunosuppressive doses of 
glucocorticosteroids at time of diagnosis, combined with cytosine arabinoside in 
66 (80%) small dogs and 18 (64%) large dogs. Most dogs on cytosine 
arabinoside therapy had regular (3-4 weekly) re-examinations at a dedicated 
cytosine arabinoside clinic. Overall, dogs that were alive at time of data capture, 
were dogs that received sole prednisolone therapy or combined prednisolone 
and cytosine arabinoside treatment.  
At time of data capture, 11 (39%) large dogs and 27 (33%) small dogs 
were alive. Conversely, 17 (61%) large and 56 (67%) small dogs had died. Of 
the deceased dogs, 15 (88%) large dogs and 47 (84%) small dogs died or were 
euthanized because of disease progression, compared to 2 (12%) large dogs 
and 9 (16%) small dogs that died or were euthanized for unrelated causes. 
Overall, 54% of the large dogs and 57% of the small dogs died or were 
euthanized because of disease progression. The MST was 281 days and 106 
days for the small and large dogs respectively. There was no significant 
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difference in survival curves between small and large dogs (P=0.664) (Figure 
2.1). 
 
Figure 2.1: Kaplan-Meier survival curve comparing the percentage of survival in 
small (full black line) and large (dotted line) dogs. Results were censored for 
dogs that were still alive at time of data capture (single little blocks). 
Discussion  
This study evaluated the differences in clinical presentation, diagnostic 
findings and long-term survival between small and large dogs diagnosed with 
MUA. Large dogs were found to present significantly more often with a 
decreased mentation. No significant difference was seen in survival curves 
between small and large dogs. To the best of our knowledge, this is the first 
study describing clinical, diagnostic and outcome data in large dogs with MUA. 
Meningoencephalitis of unknown aetiology is generally considered a syndrome 
affecting small, toy and terrier breed dogs aged between approximately 3 and 7 
years (Munana and Luttgen, 1998; Adamo et al., 2007; Talarico and 
Schatzberg, 2010; Coates and Jeffery, 2014). However, a total of 45 large dogs 
are present in the literature from 1998 to 2015 (Gregory et al., 1998; Munana 
and Luttgen, 1998; Cherubini et al., 2006; Fliegner et al., 2006; Zarfoss et al., 
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2006; Coates et al., 2007; Pakozdy et al., 2009; Smith et al., 2009; Wong et al., 
2010; Flegel et al., 2011; Lowrie et al., 2013; Estey et al., 2014; Barnoon et al., 
2015; Beckmann et al., 2015; Mercier and Barnes Heller 2015). The distribution 
of the breeds in our study appears to be similar. Although the English Springer 
Spaniel was the most common large dog breed in our study, it was not 
significantly overrepresented compared to the general hospital population. The 
higher number of this breed in our study therefore likely reflects its popularity in 
the United Kingdom. MUA occurred, as expected, more often in small dogs, but 
still a quarter of dogs in the presented study were large dogs. Ignoring this 
population of dogs would underestimate the prevalence of MUA in the overall 
canine population. Therefore, MUA should be considered as a differential 
diagnosis in dogs other than small or toy breeds that have signs suggestive of 
inflammatory brain disease.  
Large dogs were more likely to present with a decreased mentation 
compared to their small counterparts. Abnormal mentation in dogs can be 
caused by lesions in the forebrain (telencephalon and diencephalon) and/or 
brainstem (mesencephalon, metencephalon, myelencephalon) (Garosi, 2013). 
A lesion in the brainstem is considered a typical MRI finding in cases of GME 
and NLE, but is considered an uncommon finding in dogs with NME (Coates 
and Jeffery, 2014) although histopathological lesions have been identified in the 
brainstem of Chihuahua and Pug dogs with NME (Higgins et al., 2008; Park et 
al., 2012). In the presented study, both small and large dogs were 
histopathologically diagnosed with GME and NME, and 1 large dog was 
diagnosed with NLE, which has not yet been previously described. In literature, 
NLE is mainly affecting Yorkshire terriers and a French Bulldog (Schatzberg, 
2005; Higginbotham et al., 2007; Timmann et al., 2007; Spitzbarth et al., 2010), 
which are all considered small dogs in this study. Necrotising 
meningoencephalitis has previously only been once described in a large dog; a 
26kg Staffordshire Bull Terrier mix (Estey et al., 2014).  
A limitation of the current study is the lack of histopathological 
confirmation in the majority of cases, which makes inclusion of other diseases 
than MUA possible (mainly cerebrovascular or neoplastic disease). Based on 
intracranial MRI, seven imaging abnormalities have been associated with 
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neoplastic brain disease in one study (Cherubini et al., 2005). These included 
the presence of a single lesion, regular lesion shape, presence of mass effect, 
dural contact, dural tail sign, lesions affecting adjacent bone and contrast 
enhancement (Cherubini et al., 2005). Another study demonstrated MRI to be 
94.4% sensitive and 95.5% specific for detection of a brain lesion and for 
classifying neoplastic and inflammatory disease correctly, but was only 38.9% 
sensitive for classifying cerebrovascular disease (Wolff et al., 2012). For the 
presented study, 6 large dogs had a focal lesion on MRI of the brain, where 
inflammatory lesions are more typically associated with multifocal or diffuse 
lesions on intracranial imaging (Cherubini et al., 2006). Two of those lesions 
were histopathologically confirmed as GME or NME. Of the 4 remaining dogs, 
one dog (Siberian husky) had a focal lesion in the frontal lobe that showed 
presence of mass effect, parenchymal contrast enhancement and dural contact.  
Although abnormalities on CSF analysis do not exclude neoplastic or 
vascular disease (Bohn et al., 2006), this dog had an increased TNCC (35 
WBC/mm3) and TP concentration (0.35g/l) on cisternal CSF analysis. The dog 
was only 30 months old, and died acutely at home 18 days after diagnosis after 
initial improvement on immunosuppressive therapy. The second, third and 
fourth dog (2 cross breeds and an English Springer Spaniel) were 26 – 85 
months old at time of diagnosis and had a focal lesion in the piriform lobe 
(crossbreed) or brainstem (cross breed and English Springer Spaniel). All three 
dogs had increased TNCC and TP concentrations on cisternal CSF analysis, 
and all were alive 1095 – 1580 days after diagnosis. All dogs had an acute 
onset of neurological signs, which might still be compatible with cerebrovascular 
disease, which might be supported by the long survival without treatment of 
those dogs. However, in cerebrovascular disease, contrast enhancement 
should only be visible after 7-10 days in dogs with ischaemic infarcts, and after 
6 days to 6 weeks in dogs with haemorrhagic infarcts (Garosi, 2012). All dogs 
with a focal lesion had intracranial imaging within 5 days after onset of 
neurological signs, and all lesions showed parenchymal contrast enhancement, 
which was considered less typical for cerebrovascular disease. Neoplastic 
disease can however not be excluded in those cases, although all 4 dogs were 
still young at time of diagnosis (2-5y of age) where brain tumours are typically 
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affecting middle-aged to older (over 5 years) dogs and cats, with the majority 
being older than 9 years of age (Dickinson, 2014; Snyder et al., 2006). 
Infectious disease testing was lacking in approximately 30% of both 
small and large dogs. The 9 large dogs that were not tested had focal (n=2), 
multifocal (n=5) or diffuse forebrain (n=2) lesions on MR imaging. Necrotising 
cerebellitis and cerebellar atrophy (Garosi et al., 2010) as well as multifocal 
brain involvement (Parzefall et al., 2014) have been described in association 
with Neospora caninum infection in dogs. In the study of Parzefall et al., (2014), 
mild cerebellar atrophy was additionally seen in 3 of 4 dogs. In the presented 
study, 11 large dogs died within 20 days after diagnosis and after 
immunosuppressive treatment. Necropsy confirming GME, NLE or NME was 
performed in 6/11 dogs. Of the 5 remaining dogs, all but 1 (Siberian Husky) had 
multifocal or diffuse forebrain lesions without cerebellar involvement, and 
showed no signs of perilesional edema on FLAIR images as described by 
Parzefall et al., (2014). Magnetic resonance imaging features of Toxoplasma 
gondii encephalitis have not yet been described for dogs, but it is known to 
cause focal granuloma formation both in the forebrain (Pfohl et al., 2005; 
Falzone et al., 2008) and the spinal cord (Alves et al., 2011) of cats. The 4 dogs 
with multifocal or diffuse brain lesions all had an increased TNCC with a 
mononuclear pleocytosis but without signs of presence of lymphoblastic cells. 
No further diagnostic investigations for lymphoma were performed. Gliomatosis 
cerebri is a central nervous system neoplasia that is mainly affecting 
brachycephalic breeds (Boxer, Boston Terrier, English Bulldog, Bull Mastiff) and 
MRI mainly reveals single lesions in thalamus and/or brainstem, although the 
cerebrum can be involved and sometimes no lesions are visible (Bentley et al., 
2014). This differential diagnosis seems less likely in these 4 dogs because of 
their breeds and the presence of multifocal or diffuse lesions, but necropsy 
confirmation is lacking in those cases. Overall, pitfalls of this study are its 
retrospective character, the lack of histopathological confirmation and infectious 
disease testing in a number of cases. In contrary, MUA is considered a clinical 
and imaging diagnosis in cases were definitive brain histology is lacking. 
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Conclusions 
Twenty-five per cent of dogs diagnosed with MUA in this study were 
considered large dogs. Ignoring this population of dogs would underestimate 
the prevalence of MUA in the overall canine population. Large dogs presented 
significantly more often with a decreased mentation compared to small dogs. 
The MST was not significantly different between small and large dogs, 281 and 
106 days respectively, leading to a guarded prognosis for all dogs diagnosed 
with MUA and receiving immunosuppressive treatment. In conclusion, MUA 
should be considered as a differential diagnosis in dogs other than small or toy 
breeds that have signs suggestive of inflammatory brain disease. 
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Abstract  
Although difficult to clinically diagnose, spinal-only 
meningoencephalomyelitis of unknown aetiology (SO-MUA) is an important 
differential diagnosis for dogs presenting with signs of spinal cord dysfunction. 
The aim of this study was to evaluate clinical presentation, diagnostic findings 
and long-term outcome for dogs clinically diagnosed with SO-MUA. 
Twenty-one dogs were included in the study. The majority of dogs 
presented with an acute (43%) or chronic (52%) onset of neurological signs. 
Ambulatory paresis was the most common neurological presentation (67%). 
Neurological examination most commonly revealed a T3-L3 myelopathy, and 
spinal hyperaesthesia was a common finding (71%). A spinal cord lesion was 
visible in 90% of cases on MR imaging. Lesions were typically extensive, ill-
defined, hyperintense on T2WI and isointense on T1W images (T1WI). 
Eighteen lesions (86%) showed parenchymal contrast enhancement and 17 
lesions (81%) showed contrast enhancement of overlying meninges. All dogs 
were treated with immunosuppressive doses of glucocorticosteroids, sometimes 
combined with cytosine arabinoside. At time of data capture, 10/21 dogs (48%) 
had died or been euthanized because of SO-MUA. Overall median survival time 
was 669 days.  
SO-MUA should be considered in the differential diagnosis of dogs 
presenting with an acute or chronic, progressive, and potentially painful 
myelopathy. MRI features can possible help to distinguish presumptive SO-
MUA from other more common spinal diseases. Overall, long-term survival is 
guarded as approximately 50% of dogs will die or be euthanized because of 
SO-MUA regardless of immunosuppressive treatment.  
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Introduction  
Pure myelitis (inflammation of spinal cord parenchyma) or 
meningomyelitis (inflammation of spinal cord parenchyma and surrounding 
meninges) are rare diseases in small animals and occur commonly in 
combination with inflammatory brain disease (Tipold and Stein, 2010). Viruses 
(canine distemper virus, feline coronavirus), bacteria (Staphylococcus spp., 
Streptococcus spp., Pasteurella, coliforms, Actinomyces, Nocardia spp.), fungi 
(Cryptococcus, Coccidioides spp., Blastomyces, Histoplasma), rickettsiae 
(Ehrlichia, Rickettsia, Rocky Mountain spotted fever), protozoa (Toxoplasma 
gondii, Neospora caninum), parasites (Dirofilaria immitis, Cuterebra, 
Angiostrongylus vasorum) and algae (Prototheca wickerhamii, Prototheca 
zopfii) are known causes of meningomyelitis in dogs and cats, with or without 
concurrent intracranial signs (Dewey and Da Costa, 2016; Csebi et al., 2010; 
Parry et al., 2009; Griffin et al., 2008). Apart from infectious causes, non-
infectious meningomyelitis including GME, pyogranulomatous 
meningoencephalomyelitis and SRMA are described (Dewey 2016; Parry et al. 
2009; Griffin et al. 2008; Meric 1988). In agreement with the terminology for 
MUA, dogs clinically diagnosed with non-infectious inflammatory myelitis that 
did not have positive infectious disease testing, that were not classified as 
SRMA or eosinophilic meningomyelitis, and that were not histopathologically 
confirmed, were named SO-MUA. A clinical diagnosis of SO-MUA is typically 
made by a combination of clinical presentation, imaging of the vertebral column, 
and results of CSF analysis (Griffin et al., 2008).  
Currently, only one previous study has focused specifically on the 
clinical presentation, diagnostic findings, and outcome in dogs with 
meningomyelitis caused by a variety of underlying aetiologies (Griffin et al., 
2008). Twenty-eight cases were included, of which 15 dogs were diagnosed 
with SO-MUA. Clinical signs reflected the affected spinal cord segments, and 
younger dogs, toy breeds, and hound breeds were suggested to be 
predisposed for meningomyelitis. Although results of myelography, CT, and CT-
myelography have been reported, little is known about MRI findings in dogs with 
SO-MUA. The aims of this study were therefore to describe the signalment, 
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clinical presentation, diagnostic findings, including results of MRI, and long-term 
survival in dogs diagnosed with presumptive SO-MUA without concurrent 
clinical signs of intracranial involvement. 
Materials and methods 
Case selection  
The electronic medical database of the Small Animal Referral Hospital, 
Royal Veterinary College, University of London, was searched between March 
2006 and February 2015 for dogs diagnosed with “MUA”, “MUO”, “GME”, 
“myelitis”, and “inflammatory spinal cord disease”. Dogs were included based 
on the criteria used by Granger et al. (2010), if they had (1) complete medical 
records available, (2) a complete neurological examination performed leading to 
a spinal cord localisation, (3) inflammatory CSF analysis, (4) MRI of the spinal 
cord, and if (5) long-term follow-up information was available through revision of 
medical records or through contacting the referring veterinarian by telephone. 
Dogs were excluded if (1) the clinical records or imaging studies were 
incomplete or not available for review, (2) dogs showed clinical or neurological 
signs of intracranial involvement at time of presentation, (3) they had a peracute 
onset of clinical signs that were not progressive after 12-24 hours, (4) they had 
signs of extradural or intradural/extramedullary spinal cord compression on MRI 
and if (5) they had positive infectious disease titres or if clinical presentation, 
CSF analysis or necropsy findings were suggestive of SRMA or eosinophilic 
meningoencephalomyelitis (>10% eosinophils in CSF) (Dewey and Da Costa, 
2016). Typical clinical presentation for SRMA was considered to be a dog less 
than 2 years of age of a typical dog breed (Boxer, Beagle, Bernese Mountain 
dog, Nova Scotia Duck Tolling Retriever, Golden Retriever, German 
Shorthaired Pointed) presenting with pyrexia and cervical hyperesthesia. CSF 
analysis in SRMA is typically revealing a predominantly neutrophilic pleocytosis 
(Dewey and Da Costa, 2016). Dogs with histopathological confirmation of the 
disease (GME or NME) only needed to fulfil inclusion criteria (1) and (5). 
Information retrieved from the medical records included breed, gender, age at 
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diagnosis, body weight, results of neurological examination including 
neuroanatomical localisation, duration of clinical signs prior to diagnosis, results 
of CBC and biochemistry profile, results of CSF analysis, treatment received, 
and outcome. For dogs that had CSF analysis performed, site of collection 
(cisternal or lumbar), TNCC, TP and cytological differentiation were recorded. 
Total nucleated cell count was considered normal if <5 cells/mm3. Total protein 
concentration was considered normal for a cisternal collection if < 0.25g/l and 
for a lumbar collection if <0.4g/l. Duration of clinical signs prior to diagnosis 
(days) was classified as peracute (<2 days), acute (2–7 days) or chronic (>7 
days).  
Neurological assessment 
The neurological status was classified from 0 to 5 according to the 
clinical examination (adapted from Scott et al., 1997): grade 0 = neurologically 
normal; grade 1 = spinal hyperesthesia without neurological deficits; grade 2 = 
ataxia, ambulatory para- or tetraparesis; grade 3 = non- ambulatory para- or 
tetraparesis; grade 4 = para- or tetraplegia with or with- out bladder control, and 
intact deep pain sensation; grade 5 = para- or tetraplegia, urine retention or 
overflow, and deep pain sensation loss.  
Possible neuroanatomical localisations included C1-C5, C6-T2, T3-L3 
or L4-S3 spinal cord segments. Dogs were diagnosed with a focal lesion if only 
one spinal cord segment was affected, and with a multifocal lesion if more than 
one spinal cord segment appeared to be affected on the neurological 
examination.  
Magnetic resonance imaging 
Magnetic resonance imaging was performed under general 
anaesthesia with a permanent 1.5T magnet (Intera, Philips Medical Systems, 
Eindhoven, the Netherlands) and all images were reviewed by the same author 
(IC) using Osirix Dicom viewer (Osirix Foundation, V.5.5.2 Geneva, 
Switzerland). Sequences could vary, but studies included a minimum of T2W 
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(repetition time (ms) (TR)/echo time (ms) (TE), 3000/120) and T1W (TR/TE, 
400/8) images of the affected spinal cord region in a sagittal and transverse 
plane. The T1W images were acquired before and after IV administration of 
paramagnetic contrast medium (0.1mg/kg, gadoterate meglumine, Dotarem, 
Guerbet). If MR images of the brain were present, they were reviewed 
concurrently. Variables recorded were lesion intensity on T2WI and T1WI, 
lesion localisation and distribution, lesion length and presence of parenchymal 
and/or meningeal contrast enhancement. Lesion length was measured using 
Osirix Dicom viewer, and performed on sagittal T2WI for dogs that had focal 
lesions. Lesion length was measured twice, and the mean value between both 
was used. To compensate for differences in body size, values were corrected 
towards length of vertebral body of C6 (for cervical lesions) or L2 (for 
thoracolumbar lesions). Vertebral body length was measured on T1W sagittal 
images.  
Treatment and follow-up 
For all dogs, the specific treatment protocol was recorded. During 
hospitalisation, all dogs underwent daily at least one general physical and 
complete neurological examination by a board-certified neurologist or neurology 
resident. The results of the neurological examination as well as response to 
treatment (improvement, deterioration or static status) were systematically 
recorded on the kennel sheets. Follow-up information during hospitalisation was 
collected from the medical records, and afterwards through medical records of 
re-examination visits or telephone contact with the referring veterinarian. A 
successful outcome was defined as the dog being ambulatory, faecal and 
urinary continent and, according to the owners, without signs of overt spinal 
hyperaesthesia. An unsuccessful outcome was defined as (1) deterioration in 
neurological status by one or more grades after diagnosis and treatment, or (2) 
if the dog was not independently ambulatory, possibly with previously non-
existing or worsening faecal and/or urinary incontinence, or was experiencing 
spinal hyperaesthesia as defined by the owner. 
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Statistical analysis 
Data analysis was performed with the aid of a standard statistical 
software package (Prism, Graphpad Software Inc). Regarding outcome, a 
Mann-Whitney U test was used to evaluate the effect of relative lesion length on 
long-term outcome. A fisher’s exact test was used to evaluate the effect of pain, 
presence of lymphopenia and additional administration of cytosine arabinoside 
on outcome. Numeric variables were expressed as median and interquartile 
ranges (IQR). Values of P<0.05 were considered significant. Survival analysis 
was performed using both a Log-rank (Mantel-Cox) and Gehan-Breslow-
Wilcoxin test, resulting in MST calculation and a Kaplan-Meier survival curve. 
Survival was defined as time from diagnosis to death or euthanasia, including 
whether this happened because of disease progression or due to unrelated 
causes, or time from diagnosis to data collection for dogs that were alive at time 
of data capture. Dogs that died because of unrelated causes and dogs that 
were still alive at time of data capture were censored for survival analysis.  
Results 
Signalment 
Twenty-one dogs were included in the study. Represented breeds 
included French Bulldog (n=2), Jack Russell Terrier (n=2), Lhasa Apso (n=2) 
and one each of Akita, Bearded Collie, Boxer, Bull Mastiff, Chihuahua, cross 
breed, English Springer Spaniel, Giant Schnauzer, Labrador Retriever, Maltese 
Terrier, Rhodesian Ridgeback, Rottweiler, Shih Tzu, West Highland White 
Terrier and Yorkshire Terrier. Overall, median age at presentation was 56 
months (10 – 128 months). Thirteen dogs (62%) were male and 8 dogs (38%) 
were female. Compared to the general hospital population between March 2006 
and February 2015, there was no significant difference in sex distribution in the 
group of dogs with SO-MUA (P=0.075). Median duration of clinical signs prior to 
diagnosis was 8 days (ranging from 1-90 days). One dog (5%) presented with 
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peracute, 9 dogs (43%) with acute and 11 dogs (52%) with a chronic onset of 
neurological signs.  
Neurological examination 
Thirteen (62%) and 8 (38%) dogs were diagnosed with a focal and 
multifocal spinal lesion on neurological examination, respectively. Regarding 
dogs with focal spinal lesions (n=13), 3 dogs were diagnosed with a lesion 
affecting the C1-C5 spinal cord segments, 2 dogs with a lesion affecting the C6-
T2 spinal cord segments, 6 dogs with a lesion affecting the T3-L3 spinal cord 
segments and 2 dogs with a lesion affecting the L4-S3 spinal cord segments. At 
time of diagnosis, no dogs presented as grade 0; 2 dogs (10%) were grade 1; 
14 dogs (67%) grade 2; and 5 dogs (24%) grade 3. No dogs were found to have 
paraplegia or tetraplegia at time of presentation. Pain on direct spinal palpation 
was present in 15 (71%) dogs. Urinary retention was seen in 2 dogs (10%), and 
a combination of urinary and faecal incontinence was noticed in 2 dogs (10%). 
One dog (5%) developed seizures 669 days after diagnosis of SO-MUA. An 
overview of the clinical and diagnostic findings of the 21 included dogs can be 
consulted in table 3.1.  
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Table 3.1: Clinical details of the 21 dogs diagnosed with SO-MUA. Dogs marked with * had additional intracranial abnormalities 
detected on MR imaging. FE = female entire, FN = female neutered, ME = male entire, MN = male neutered. 
Case Breed Gender 
Age 
(months) 
Clinical 
presentation 
Neuroanatomical 
localisation 
Spinal 
hyperaesthesia 
CSF 
TNCC 
(WBC/mm3) 
MRI lesion 
1 Akita FE 36 
Non ambulatory 
paraparesis 
Multifocal Yes 1740 Focal 
2 Rottweiler ME 123 Ataxia T3-L3 No 209 Focal 
3 Bull Mastiff ME 42 
Ambulatory 
paraparesis 
T3-L3 Yes 6 
No lesion 
visible 
4 
Labrador 
Retriever 
MN 105 
Ambulatory 
paraparesis 
L4-S3 Yes 123 Focal 
5 JRT MN 89 
Ambulatory 
paraparesis 
T3-L3 No 200 Focal 
6 Lhasa Apso FE 48 
Ambulatory 
tetraparesis 
C1-C5 Yes 900 Focal 
7 Shih Tzu MN 50 
Ambulatory 
tetraparesis 
C6-T2 Yes 5 Focal 
8 Giant Schnauzer ME 32 
Non ambulatory 
paraparesis 
Multifocal No 1345 Focal 
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Case Breed Gender 
Age 
(months) 
Clinical 
presentation 
Neuroanatomical 
localisation 
Spinal 
hyperaesthesia 
CSF 
TNCC 
(WBC/mm3) 
MRI lesion 
9 Yorkshire Terrier FN 36 
Ambulatory 
tetraparesis 
C1-C5 Yes 7 Focal 
10 
English Springer 
Spaniel 
ME 85 Ataxia Multifocal No 455 Focal 
11 
Rhodesian 
Ridgeback 
FE 123 Normal gait C1-C5 Yes 89 Focal* 
12 Bearded Collie MN 136 
Ambulatory 
paraparesis 
Multifocal Yes 162 
No lesion 
visible 
13 Boxer ME 26 Normal gait Multifocal Yes 6000 Focal 
14 Lhasa Apso MN 128 
Ambulatory 
paraparesis 
L4-S3 Yes 1540 Multifocal 
15 Chihuahua ME 19 Ataxia T3-L3 Yes 9 Multifocal 
16 Cross Breed FN 83 
Ambulatory 
paraparesis 
Multifocal No 1230 Multifocal 
17 French Bulldog ME 13 
Ambulatory 
paraparesis 
T3-L3 No 250 Multifocal 
18 Maltese Terrier FN 104 Ataxia Multifocal Yes 95 Focal 
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Case Breed Gender 
Age 
(months) 
Clinical 
presentation 
Neuroanatomical 
localisation 
Spinal 
hyperaesthesia 
CSF 
TNCC 
(WBC/mm3) 
MRI lesion 
19 
Jack Russell 
Terrier 
FN 56 
Non ambulatory 
tetraparesis 
C6-T2 Yes 2690 Focal* 
20 French Bulldog ME 10 
Non ambulatory 
paraparesis 
T3-L3 Yes 43 Focal 
21 
West Highland 
White Terrier 
FE 103 
Non ambulatory 
tetraparesis 
Multifocal Yes 1980 Multifocal 
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Diagnostic findings 
As required by the inclusion criteria, CSF collection revealed a 
pleocytosis in all cases. Overall, median TNCC was 209 WBC/mm3 (ranging 
from 6 – 6000 WBC/mm3). Total protein measurement was performed in all but 
3 CSF samples, and was above reference values in 17/18 dogs (94%). The 
median TP concentration was 1.67g/l (ranging from 0.21-16.3g/l). Complete 
blood count and serum biochemistry results were available in 16 dogs (76%). 
Leucocytosis was only present in 2 dogs (10%) and lymphopenia was present 
in 6 dogs (29%). Infectious disease testing based on serology and/or PCR on 
CSF for Canine Distemper Virus, Toxoplasma gondii, and Neospora caninum 
was not performed in 2 (10%) dogs and was negative in the remaining 19 (90%) 
dogs. In the 2 dogs with lacking infectious disease testing, full necropsy was 
performed, revealing GME.  
Magnetic resonance imaging of the spinal cord was available in all 
cases, revealing a focal lesion in 15 dogs (71%), a multifocal lesion in 4 dogs 
(19%) and no lesion was visible on sagittal T2WI or T1WI in 2 dogs (10%). 
Lesion length was measured in the focal cases only. Median lesion/vertebral 
body ratio was 4.8 (ranging from 0.6 – 10.9). All visible lesions were ill-defined, 
intramedullary, hyperintense on T2W images and isointense on T1WI (Figures 
3.1 and 3.2). Lesions showed parenchymal contrast enhancement in 18 dogs 
(86%), and contrast enhancement of overlying meninges in 17 dogs (81%) 
(Figures 3.3 and 3.4). In dogs presenting with spinal hyperaesthesia (n=15), 
there was no significant association with the presence of meningeal contrast 
enhancement on MRI (P=0.24). In the 2 cases where no lesion was visible on 
sagittal T2WI and T1WI, no parenchymal contrast enhancement was seen, but 
1 of those 2 dogs showed meningeal contrast enhancement. In 2 dogs (10%) 
intracranial images were present within the field of view of the cervical spinal 
cord images (T2W transverse and sagittal images), revealing multiple T2W 
hyperintensities in the forebrain and/or brainstem. Neither of those dogs had 
clinical or neurological signs of intracranial involvement at time of diagnosis. 
The first dog, a 56-month-old Jack Russell Terrier, never recovered from 
general anaesthesia after diagnostic procedures, and full necropsy revealed 
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GME. The second dog, a 123-month-old Rhodesian Ridgeback, developed 
seizures 669 days after diagnosis and was euthanized without further 
investigations. 
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Figure 3.1: T2W transverse (left image) MR image of the vertebral column and spinal 
cord at the level of C3, and sagittal (right image) MR image of the cervical and cranial 
thoracic vertebral column and spinal cord of a 56-month-old Jack Russell terrier. There is 
presence of a large, ill-defined, intramedullary hyperintensity extending from cranial C2 
until cranial C6.  
 
Figure 3.2: T2W sagittal (top image) and transverse (bottom left image), and pre-contrast 
T1W transverse (bottom right image) of the vertebral column and associated spinal cord 
of a 13-month-old French Bulldog. There is presence of a large, ill-defined, intramedullary 
lesion that is hyperintense on T2W images and isointense on T1W images. the lesion is 
extending from mid T10 until caudal L1. 
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Figure 3.3: T2W (A), T1W pre-contrast (B) and T1W post-contrast (C) sagittal MR images of the lumbar spinal cord of a 105-month-
old Labrador Retriever. Note the diffuse meningeal enhancement without apparent parenchymal enhancement. 
 
Figure 3.4: T2W (A), T1W pre-contrast (B) and T1W post-contrast (C) sagittal MR images of the lumbar spinal cord of a 104-month-
old Maltese Terrier. Note the parenchymal enhancement with only minimal meningeal enhancement (mainly rostral to the lesion).
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Treatment and outcome  
As required by the inclusion criteria, outcome was available in all dogs. 
As described above, one dog never recovered from general anaesthesia for 
MRI of the spinal cord, and this dog was censored for survival analysis. Mean 
duration of hospitalisation was 5 days (ranging from 1 – 19 days), with 17 dogs 
(81%) showing improvement in neurological status within those days. One dog 
(5%) remained neurologically stable (no improvement nor deterioration), and 3 
dogs (14%) showed deterioration of their neurological status. All dogs, including 
the dog that never recovered from anaesthesia, were treated with 
immunosuppressive doses of glucocorticosteroids immediately after diagnosis. 
This consisted of IV dexamethasone (dose ranging from 0.3 – 0.5mg/kg/day) in 
9 dogs (43%), and oral prednisolone (dose ranging from 2 – 4mg/kg/day) in 12 
dogs (57%). Fourteen dogs (67%) received additional treatment with cytosine 
arabinoside as a CRI of 200mg/m2 over 8 hours in 1 dog (7%) and as 4 SC 
injections of 50mg/m2 every 12 hours for 2 consecutive days in 13 dogs (93%).  
Twenty dogs (95%) survived to discharge. Of these dogs, 9 dogs 
(45%) were still alive at time of data capture. Of these 9 dogs, 8 dogs were 
neurologically normal according to follow-up information, and 1 dog was still 
showing ataxia and ambulatory paraparesis. Of the 8 normal dogs, 2 dogs were 
still receiving ciclosporine 5mg/kg every 24 hours, 1 dog was receiving cytosine 
arabinoside 50mg/ m2 every 12 hours for 2 consecutive days every 9 weeks, 1 
dog was receiving prednisolone 0.2mg/kg every 24 hours, 1 dog was receiving 
prednisolone 1mg/kg every 24 hours and cytosine arabinoside 50mg/ m2 every 
12 hours for 2 consecutive days every 4 weeks, and 3 dogs were not receiving 
any treatment at time of data capture. The dog that was still showing 
neurological abnormalities was receiving 0.5mg/kg prednisolone every other 
day and cytosine arabinoside 50mg/ m2 every 12 hours for 2 consecutive days 
every 5 weeks. Regarding the 11/20 dogs (55%) that had deceased at time of 
data capture, 3 dogs died or were euthanized because of disease progression, 
6 dogs were euthanized because of acute neurological deterioration after initial 
neurological improvement, and 2 dogs were euthanized because of unrelated 
causes (complications after stifle surgery and development of aggression). 
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Dogs that showed acute neurological deterioration after initial improvement did 
so within a median of 171 days after diagnosis (ranging from 30-669 days). Of 
those 6 dogs, 1 dog showed acute deterioration after discontinuation of 
prednisolone treatment, and 5 dogs were still receiving treatment consisting of 
prednisolone 1mg/kg every 24 hours, prednisolone 0.5mg/kg every 24 hours, 
prednisolone 2mg/kg every 24 hours and azathioprine 2mg/kg every 24 hours, 
or cytosine arabinoside 50mg/m2 every 12 hours for 2 consecutive days every 7 
weeks. Overall, we can conclude that 10/21 dogs (48%) died or were 
euthanized because of SO-MUA.  
No difference was seen in long-term survival between dogs receiving 
sole prednisolone therapy or combination therapy with cytosine arabinoside 
(P=0.31). Overall, the MST was 669 days (ranging from 1-2250 days) (Figure 
3). No significant difference was seen in relative lesion length on MR imaging 
between dogs that are alive and dogs that died or were euthanized because of 
SO-MUA (P=0.91). Post mortem confirmation was available in 3 dogs, revealing 
GME in 2 dogs and necrotising meningomyelitis in 1 dog. An overview of the 
treatment schedules, follow-up, ST and necropsy information can be consulted 
in table 3.2. 
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Table 3.2: Treatment and outcome details of 21 dogs diagnosed with SO-MUA. SC = subcutaneous, CRI = constant rate infusion, PM 
= post mortem.  
Case Breed 
Initial 
treatment 
Cytosine 
arabinoside 
dose (mg/m2), 
SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up 
and treatment 
Death 
because 
of SO-
MUA 
ST 
(days) 
PM 
1 Akita Prednisolone 
2mg/kg /day 
50mg/m2 SC Improvement Euthanasia because of 
acute deterioration after 
discontinuation of 
prednisolone treatment 
Yes 380 NP 
2 Rottweiler Prednisolone 
2mg/kg /day 
50mg/m2 SC Deterioration Euthanasia because of 
disease progression 
Yes 20 NP 
3 Bull Mastiff Prednisolone 
2mg/kg /day 
No cytosine 
arabinoside 
Deterioration Euthanasia because of 
disease progression 
Yes 6 NP 
4 Labrador 
Retriever 
Dexamethaso
ne 
0.3mg/kg/day 
50mg/m2 SC Improvement Euthanasia because of 
acute deterioration, was 
still receiving 1mg/kg of 
prednisolone every day 
Yes 30 NP 
5 Jack 
Russell 
Terrier 
Prednisolone 
2mg/kg /day 
No cytosine 
arabinoside 
Improvement Normal dog, still 
receiving 0.2mg/kg/day 
prednisolone 
No 237 NA 
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Case Breed 
Initial 
treatment 
Cytosine 
arabinoside 
dose (mg/m2), 
SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up 
and treatment 
Death 
because 
of SO-
MUA 
ST 
(days) 
PM 
6 Lhasa Apso Prednisolone 
4mg/kg /day 
50mg/m2 SC Improvement Euthanasia because of 
acute deterioration, was 
still receiving 0.5mg/kg 
prednisolone per day 
Yes 171 GME 
7 Shih Tzu Prednisolone 
2mg/kg /day 
50mg/m2 SC Improvement Normal dog, receiving 
ciclosporine 5mg/kg/day 
No 2250 NA 
8 Giant 
Schnauzer 
Prednisolone 
2mg/kg /day 
50mg/m2 SC Improvement Euthanasia because of 
aggression, was only 
receiving cytosine 
arabinoside every 5 
weeks  
No 752 NP 
9 Yorkshire 
Terrier 
Prednisolone 
2mg/kg /day 
No cytosine 
arabinoside 
Improvement Euthanasia because of 
acute deterioration, was 
still receiving 1mg/kg of 
prednisolone per day 
Yes 202 NME 
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Case Breed 
Initial 
treatment 
Cytosine 
arabinoside 
dose (mg/m2), 
SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up 
and treatment 
Death 
because 
of SO-
MUA 
ST 
(days) 
PM 
10 English 
Springer 
Spaniel 
Prednisolone 
2mg/kg /day 
No cytosine 
arabinoside 
Improvement Euthanasia because of 
post-operative infection 
after stifle surgery, dog 
normal and on no 
medication 
No 304 NP 
11 Rhodesian 
Ridgeback 
Dexamethaso
ne 
0.3mg/kg/day 
50mg/m2 SC Improvement Euthanasia because 
development of seizures, 
was still receiving 
cytosine arabinoside 
50mg/m2 SC every 7 
weeks 
Yes 669 NP 
12 Bearded 
Collie 
Prednisolone 
2mg/kg /day 
50mg/m2 SC Improvement Normal dog, receiving no 
current treatment 
No 1100 NA 
13 Boxer Prednisolone 
2mg/kg /day 
50mg/m2 SC Improvement Normal dog, receiving 
cytosine arabinoside 
50mg/m2 SC every 9 
weeks 
No 1460 NA 
14 Lhasa Apso Prednisolone 
2mg/kg /day 
50mg/m2 SC Stable Euthanasia because of 
disease progression 
Yes 33 NP 
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Case Breed 
Initial 
treatment 
Cytosine 
arabinoside 
dose (mg/m2), 
SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up 
and treatment 
Death 
because 
of SO-
MUA 
ST 
(days) 
PM 
15 Chihuahua Dexamethaso
ne 
0.3mg/kg/day 
No cytosine 
arabinoside 
Improvement Normal dog, receiving no 
current treatment 
No 635 NA 
16 Cross 
Breed 
Dexamethaso
ne 
0.3mg/kg/day 
200mg/m2 CRI Improvement Euthanasia because of 
acute deterioration, was 
still receiving 2mg/kg of 
prednisolone every day, 
combined with 2mg/kg 
azathioprine 
Yes 93 NP 
17 French 
Bulldog 
Prednisolone 
2mg/kg/day 
No cytosine 
arabinoside 
Improvement Normal dog, receiving no 
current treatment 
No 791 NA 
18 Maltese 
Terrier 
Dexamethaso
ne 
0.3mg/kg/day 
50mg/m2 SC Improvement Normal dog, still 
receiving 1mg/kg of 
prednisolone per day, 
and cytosine arabinoside 
50mg/m2 SC every 4 
weeks 
No 577 NA 
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Case Breed 
Initial 
treatment 
Cytosine 
arabinoside 
dose (mg/m2), 
SC or CRI 
Initial 
response to 
treatment 
Long-term follow-up 
and treatment 
Death 
because 
of SO-
MUA 
ST 
(days) 
PM 
19 Jack 
Russell 
Terrier 
Dexamethaso
ne 
0.5mg/kg/day 
No cytosine 
arabinoside 
Dog never 
recovered 
from general 
anaesthesia 
for MRI 
Dog never recovered 
from general anaesthesia 
Yes 0 GME 
20 French 
Bulldog 
Dexamethaso
ne 
0.3mg/kg/day 
50mg/m2 SC Improvement Ataxia and ambulatory 
paraparesis, still 
receiving 0.5mg/kg of 
prednisolone every other 
day and cytosine 
arabinoside 50mg/m2 
every 5 weeks 
No 90 NP 
21 West 
Highland 
White 
Terrier 
Dexamethaso
ne 
0.3mg/kg/day 
50 mg/m2 SC Improvement Normal dog, receiving 
ciclosporine 5mg/kg/day 
No 210 NA 
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Discussion 
This study evaluated the clinical presentation, diagnostic findings and 
long-term survival in 21 dogs diagnosed with presumptive SO-MUA. Dogs had a 
median age of 5 years at time of diagnosis. A lesion affecting the T3-L3 spinal 
cord segments resulting in ambulatory paraparesis was considered the most 
common clinical presentation. Although the overall MST was 669 days, 48% of 
dogs diagnosed with SO-MUA died or were euthanized because of this disease, 
indicating a guarded long-term prognosis. 
To be included in the study, dogs were not allowed to have clinical 
signs or neurological examination abnormalities suggestive of intracranial 
involvement. Interestingly, additional MR images of the brain were included in 
the field of view of the cervical MRI in 2 dogs, showing additional lesions in both 
cases. One of those dogs, a 123-month-old Rhodesian Ridgeback, developed 
seizures 669 days after diagnosis despite on-going cytosine arabinoside 
treatment, and was therefore euthanized. No necropsy was performed, but 
because intracranial lesions were already present at time of diagnosis, 
development of MUA was assumed. The other dog, a 56-month-old Jack 
Russell Terrier, never recovered from general anaesthesia for MR imaging. 
Necropsy was performed, revealing the presence of GME. Because intracranial 
MR images were only available in 2 dogs, it is currently unclear (1) if these brain 
abnormalities represent a multifocal nature of the disease or cranial extension 
of the cervical inflammatory lesions, and (2) if inflammatory brain lesions are 
currently under diagnosed in dogs with SO-MUA and if SO-MUA could therefore 
be considered a more generalised inflammatory disease process, a 
meningoencephalomyelitis. 
Pain on direct spinal palpation was present in 71% of dogs. Spinal pain 
reflects the involvement of the meninges, and/or vertebrae (vertebral 
periosteum), and/or nerve roots or spinal nerves (Da Costa, 2012). In the 
present study, the lesions showed meningeal contrast enhancement in 18/21 
dogs, but there was no significant association between spinal hyperaesthesia 
and the presence of meningeal enhancement on MRI.   
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MRI of the spinal cord revealed no lesion on sagittal T2WI and T1WI in 
10% of dogs (n=2), which appears similar to the 7% described for the brain in 
dogs with MUA (Granger et al., 2010). In the retrospective study of Griffin et al. 
(2008), only 1 dog with meningomyelitis had MRI performed, revealing no 
abnormalities. Based on these findings, presence of SO-MUA cannot be ruled 
out based on unremarkable MRI findings. The first dog was a 42-month-old Bull 
Mastiff with a one-month history of slowly progressive T3-L3 spinal cord lesion. 
After diagnostic procedures, the dog was treated with oral prednisolone but 
continued to deteriorate and was euthanized after 6 days. No necropsy was 
performed. The second dog was a 136-month-old Bearded Collie with a one-
week history of a progressive multifocal spinal cord neuroanatomical 
localisation (T3-S3 spinal cord lesion). The dog showed improvement on 
treatment with prednisolone and cytosine arabinoside (see table 3.2) after 
diagnostic investigations, and was still alive without current treatment 1100 days 
after diagnosis. Both dogs had inflammatory CSF analysis (increased TNCC 
and TP concentration). For both dogs, the presence of vascular, degenerative 
and neoplastic spinal cord lesions cannot be excluded. As both dogs had a 
progressive disease course, a vascular (ischaemic) lesion seemed less likely. A 
neoplastic lesion cannot be excluded, although this seems rather unlikely in the 
Bull Mastiff considering his young age. The second dog had a lymphocytic 
pleocytosis on CFS analysis, but no signs of lymphoma were seen on 
microscopical examination, however no specific test to look for clonality was 
performed.  
If a lesion was visible on MRI, all lesions were extensive, ill-defined, 
intramedullary, hyperintense on T2WI and isointense on T1WI. Other spinal 
conditions, including acute non-compressive nucleus pulposus extrusion 
(ANNPE) and ischaemic myelopathy (IM), are also associated with 
intraparenchymal hyperintensities on MRI. These conditions are however 
associated with other clinical and MRI characteristics, which could potentially 
aid in differentiating between these conditions (Cardy et al., 2015; Fenn et al., 
2016). Looking into a recent study (Cardy et al., 2015), the clinical presentation 
of dogs with spinal cord dysfunction, IM (most commonly fibrocartilagenous 
embolic myelopathy (FCEM)) and ANNPE are typically characterised by a 
peracute onset of non-progressive clinical signs and affected dogs do not 
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commonly demonstrate overt spinal hyperaesthesia at time of admission. This 
is in contrast with the clinical presentation of dogs with SO-MUA, which was 
characterised by an acute onset of progressive and mainly symmetrical 
neurological deficits, with pain on spinal palpation or manipulation in 86% of 
dogs (Cardy et al., 2015), which is comparable with the 71% of dogs presenting 
with spinal hyperaesthesia in the presented study. Although CSF analysis in 
dogs with IM is most often within normal limits, affected dogs can demonstrate 
an increased TP concentration and mild neutrophilic or mixed cell pleocytosis 
with a median TNCC of 12 WBC/mm3 (De Risio et al., 2007). A marked 
pleocytosis with a median TNCC of 209 WBC/mm3 was seen in the presented 
study, although results should be interpreted with caution as presence of a CSF 
pleocytosis was considered one of the inclusion criteria. To conclude, the 
presentation of a dog with an acute or chronic onset of a progressive and 
painful T3-L3 myelopathy in combination with an extensive, ill defined, 
intramedullary lesion with presence of parenchymal and/or meningeal contrast 
enhancement on MRI, and presence of a marked pleocytosis on CSF analysis, 
can be presumptively diagnosed with SO-MUA. The importance of 
differentiating between these conditions is highlighted by the differences in 
treatment and prognosis between dogs with presumptive SO-MUA and dogs 
with ANNPE or IM. 
A previous study demonstrated that short tau inversion recovery 
(STIR) hyperintensities in the cervical epaxial musculature of dogs with 
meningoencephalomyelitis had a sensitivity of 78% and a specificity of 92% in 
predicting inflammatory CSF results (Eminaga et al., 2013). In the presented 
study, STIR images were unfortunately only available in 3/21 cases. Adding this 
sequence to the protocol in dogs with presence of a focal or multifocal, ill-
defined T2W intramedullary hyperintensity might be considered in the future.  
Several studies have evaluated survival times of dogs diagnosed with 
MUA (Granger et al., 2010, Coates and Jeffery, 2014). Overall, dogs with MUA 
appear to have a guarded prognosis. A large systematic review of dogs with 
MUA revealed an overall reported MST of 240-590 days in 96 dogs treated with 
corticosteroids plus any other immunosuppressive protocol, compared to a MST 
of 28-357 days for 43 dogs receiving corticosteroids alone (Granger et al., 
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2010). In the presented study, dogs with presumptive SO-MUA had a MST of 
669 days (2 years), but ultimately, 48% of dogs died or were euthanized 
because of SO-MUA, indicating a more guarded long-term prognosis.  
Limitations of this study are the relative small sample size and 
retrospective character, which limited standardisation of patient assessment 
and treatment. Although dogs were all treated with glucocorticosteroids, it 
cannot be excluded that specific differences in treatment have influenced our 
results. Despite including cases over a relative large period and from a busy 
referral hospital, only 21 dogs could be included. This could indicate that SO-
MUA should be considered a rare disorder. 
Conclusions 
SO-MUA can be diagnosed in every dog breed of every age that is 
presented with signs of a mainly acute or chronic, possibly painful, myelopathy. 
Although clinical signs can vary, affected animals most typically present with 
ambulatory paraparesis and ataxia, localizing to T3-L3 spinal cord segments. 
MRI typically reveals an extensive, ill-defined and intramedullary lesion that 
appears hyperintense on T2WI and isointense on T1WI. Most lesions showed 
parenchymal contrast enhancement and/or enhancement of the overlying 
meninges on post-contrast T1WI which can possibly differentiate dogs with SO-
MUA from other more common spinal diseases. In 10% of cases, no lesion was 
visible on sagittal T2WI and T1WI. Almost 50% of dogs died or were euthanized 
because of SO-MUA, with a MST of 669 days for all dogs. Future studies 
should be performed looking into intracranial imaging in dogs diagnosed with 
presumptive SO-MUA and its prognostic value, extensive infectious disease 
testing in all cases and outcome using a standard treatment protocol to give 
more information about this condition. 
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Abstract  
MUA is a frequently diagnosed and often fatal disease in veterinary 
neurology. The aim of this retrospective study was to assess the efficacy of 3 
different sole prednisolone treatment schedules in dogs diagnosed with MUA. Dogs 
were diagnosed clinically with MUA based on previously described inclusion criteria, 
and treated with a 3, 8 or 18-week tapering prednisolone schedule. Thirty-eight dogs 
were included in the study, and 17, 15 and 6 dogs received the 3, 8 and 18-week 
tapering schedule, respectively. Overall, 37% of dogs died or were euthanized 
because of MUA, and a significant difference in survival time was seen between the 
three treatment schedules. Surprisingly, the highest number of dogs that died 
because of MUA was seen in the 8-week treatment schedule (56%), followed by the 
3-week (26%) and 18-week (0%) treatment schedule. Based on the results of this 
study, no definitive conclusions can be drawn regarding the ideal prednisolone 
dosing protocol for dogs diagnosed with MUA, but a more aggressive and 
immunosuppressive treatment protocol might lead to a better outcome.  
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Introduction 
MUA is a group of non-infectious central nervous system diseases, with a 
likely multifactorial pathogenesis (Coates et al., 2014). Making a definitive diagnosis 
requires histopathological examination of central nervous tissue, but a presumptive 
ante-mortem clinical diagnosis can be achieved based on a combination of 
neurological examination results, MRI findings and CSF abnormalities (Coates et al., 
2014). The exact aetiology and pathophysiology of MUA are currently unknown, but 
the cornerstone of medical treatment is considered to be immunosuppressive drugs. 
Several treatment protocols with different associated long-term survival times have 
been reported, whereby treatment with glucocorticosteroids only is generally 
associated with shorter survival times (Munana and Luttgen, 1998; Jung et al., 2007; 
Granger et al., 2010; Flegel et al., 2011; Mercier and Barnes Heller, 2015) compared 
to combination therapy with other immunosuppressive therapies, including cytosine 
arabinoside, ciclosporine, leflunomide, lomustine, azathioprine, procarbazine, 
mycophenolate mofetil, vincristine and cyclophosphamide or radiation therapy 
(Sisson et al. 1989; Gregory et al., 1998; Munana and Luttgen, 1998; Adamo and 
O’Brien, 2004; Gnirs, 2006; Zarfoss et al., 2006; Adamo et al., 2007; Coates et al., 
2007; de Stefani et al., 2007; Feliu-Pascual et al., 2007; Uriarte et al., 2007; Jung et 
al., 2007; Menaut et al., 2008; Pakozdy et al., 2009; Smith et al., 2009; Granger et 
al., 2010; Kang et al., 2009; Wong et al., 2010; Flegel et al., 2011; Jung et al., 2012;  
Jung et al., 2013; Lowrie et al., 2013; Beckmann et al., 2015; Mercier and Barnes 
Heller, 2015; Barnoon et al., 2015; Lowrie et al., 2016). However, in a clinical 
setting, adding more expensive immunosuppressive therapies to the glucocorticoid 
protocol might be financially impossible. A recently published prospective trial in 
dogs with MUA reported an overall median survival time of 602 days for dogs 
receiving immunosuppressive doses of glucocorticosteroids starting at a dose of 
1mg/kg twice daily, supporting the use of monotherapy with glucocorticosteroids in 
the treatment of MUA (Mercier and Barnes Heller, 2015). Therefore, the aims of this 
study were to retrospectively evaluate the efficacy of 3 different prednisolone 
treatment protocols that were historically used (3, 8 and 18 week tapering schedule) 
in dogs diagnosed with MUA. We hypothesized that a longer survival time would be 
achieved with a longer and more immunosuppressive treatment protocol.  
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Materials and methods 
The electronic medical database of Ghent University, Small Animal 
Department, was searched between March 2006 and September 2014, and owner 
contact was performed in October 2014. Adapted inclusion criteria were used 
(Granger et al., 2010), considering dogs suitable for inclusion if following data were 
available: (1) signalment, (2) localisation by neurological examination, (3) 
inflammatory CSF analysis, (4) intracranial MR and/or CT imaging results, (5) 
negative infectious disease testing, and (6) long-term follow-up through research of 
medical records or through telephone contact with the owner or referring 
veterinarian. Neurological status was recorded at time of admission, and further on a 
daily basis. Results were recorded daily in a computer program if the dog was 
hospitalized. Outcome was defined as successful if dogs were not showing the 
previously reported neurological signs or if improvement was seen according to the 
owner or referring veterinarian. Unsuccessful outcome was defined as death or 
euthanasia because of disease progression or if no change in neurological signs 
was seen. Relapse was defined as a sudden deterioration in neurological status 
after an initial improvement after diagnosis and initiation of treatment. All dogs were 
only receiving glucocorticosteroids as immunomodulating therapy, and a tapering 
prednisolone treatment schedule consisting of 3, 8 or 18 weeks was used (table 
4.1). 
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Table 4.1: Three different oral prednisolone treatment schedules  
3 weeks 8 weeks 18 weeks 
1 week 1mg/kg q24h 2 weeks 1mg/kg q12h 3 weeks 1.5mg/kg q12h 
1 week 0.5mg/kg q24h 2 weeks 0.5mg/kg q12h 6 weeks 1mg/kg q12h 
1 week 0.25mg/kg q24h 2 weeks 0.5mg/kg q24h 3 weeks 0.5mg/kg q12h 
 2 weeks 0.25mg/kg q24h 3 weeks 0.5mg/kg q24h 
  3 weeks 0.25mg/kg q24h 
 
Dogs treated with the 3-week schedule were diagnosed between March 
2006 and March 2010, dogs receiving the 8-week schedule between January 2009 
and August 2012, and dogs receiving the 18-week schedule between January 2010 
and September 2014. The 18-week treatment schedule started with an 
immunosuppressive dose of prednisolone, being 3mg/kg/day, compared to the 8-
week schedule that started at an immunosuppressive dose of 2mg/kg/day. The 3-
week tapering schedule started with an anti-inflammatory dose of 1mg/kg/day. It was 
recorded whether dogs survived their initial treatment protocol and whether a 
relapse in neurological signs (sudden deterioration after initial improvement) was 
seen during treatment and the associated changes made to the prednisolone 
schedule. ST was defined as time from diagnosis to death or euthanasia. A 
semiparametric Cox model (hazard analysis) was fitted to the data to detect 
differences in survival time between the three treatment groups. All statistical tests 
were performed using S-Plus. For all analyses, a value of P<0.05 was considered 
significant.  
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Results 
Thirty-eight dogs met the inclusion criteria. Breeds represented included 
Maltese terrier (n=10), Yorkshire terrier (n=3), Golden Retriever (n=3), Chihuahua 
(n=3), French bulldog (n=3), Pug  (n=2), Labrador retriever (n=2), West Highland 
White terrier (n=2), Shih Tzu (n=2), Boston terrier (n=2), American Staffordshire 
terrier (n=2) and 4 other individual breeds. Most common presenting neurologic 
signs were abnormal behaviour (n=19), altered mentation (n=18) and central 
vestibular signs (n=19). Brain imaging (CT and/or MRI) was available in all cases. 
Thirteen dogs (34%) only underwent CT imaging (Figure 4.1), 24 dogs (63%) only 
underwent MR imaging and 1 dog (3%) underwent both CT and MR imaging. No 
lesion was visible in 7 dogs (18%), based on CT (n=4) or MR (n=3) imaging. As 
required by the inclusion criteria, TNCC of the CSF was above reference limits (> 5 
WBC/mm3 after cisternal collection) in all cases with counts ranging from 9-1189 
WBC/mm3 (median: 55 WBC/mm3). An overview of the most important diagnostic 
findings can be consulted in table 4.2. 
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Figure 4.1. CT images at the level of the frontal lobe (A and B) and caudate nucleus 
(C and D) of an 8-month-old female entire French Bulldog. Images B and D are 
acquired after administration of IV gadolinium contrast. No lesions were visible on 
the pre-contrast CT images (A and C), but multiple hyperdense, rounded, intraaxial 
lesions were visible within the frontal (B) and parieto-temparal (D) cerebral cortex 
(arrows) of the dog.
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Table 4.2: Overview of the most important diagnostic findings in the included cases. Abbreviations: TNCC = total nucleated cell count, 
WBC = white blood cells, CT = computed tomography, MRI = magnetic resonance imaging, ST = survival time 
Case  Breed 
TNCC 
(WBC/ 
mm3) 
Imaging 
modality  
Description imaging 
findings 
Prednisolone 
schedule (weeks) 
ST (days) 
1 American Staffordshire Terrier 165 CT No lesion visible 3 2190 
2 American Staffordshire Terrier 52.25 MRI No lesion visible 3 1167 
3 Boston Terrier 24 MRI Diffuse 8 1460 
4 Boston Terrier 15 MRI Diffuse 8 30 
5 Chihuahua 30 MRI Focal forebrain 8 8 
6 Chihuahua 9 MRI Diffuse 18 730 
7 Chihuahua 16.5 MRI Focal cerebellum 18 70 
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Case  Breed 
TNCC 
(WBC/ 
mm3) 
Imaging 
modality  
Description imaging 
findings 
Prednisolone 
schedule (weeks) 
ST (days) 
8 German Shepherd 300 MRI Diffuse 8 10 
9 Miniature Schnauzer 30.25 MRI 
Focal forebrain / 
thalamus 
8 778 
10 French bulldog 22 CT Diffuse 3 61 
11 French bulldog 66 MRI Focal brainstem 8 1275 
12 French bulldog 25 MRI 
Multifocal brainstem 
and forebrain 
18 365 
13 Golden Retriever 118 CT No lesion visible 3 370 
14 Golden Retriever 20 MRI Focal brainstem 3 1095 
15 Golden Retriever 42.6 MRI Diffuse 18 120 
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Case  Breed 
TNCC 
(WBC/ 
mm3) 
Imaging 
modality  
Description imaging 
findings 
Prednisolone 
schedule (weeks) 
ST (days) 
16 Labrador Retriever 209 MRI Diffuse 3 1095 
17 Labrador Retriever 1189 MRI Diffuse 8 150 
18 Maltese terrier 74 CT No lesion visible 3 2190 
19 Maltese terrier 66 CT Diffuse 3 2310 
20 Maltese terrier 12.4 CT Diffuse 3 2035 
21 Maltese terrier 800 CT Diffuse 3 2 
22 Maltese terrier 21 MRI Diffuse 8 13 
23 Maltese terrier 64 MRI Diffuse 8 84 
24 Maltese terrier 96.25 MRI Diffuse 8 180 
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Case  Breed 
TNCC 
(WBC/ 
mm3) 
Imaging 
modality  
Description imaging 
findings 
Prednisolone 
schedule (weeks) 
ST (days) 
25 Maltese terrier 120 MRI Diffuse 8 1275 
26 Maltese terrier 15 MRI No lesion visible 18 730 
27 Maltese terrier 50 MRI 
Multifocal brainstem 
and forebrain 
18 365 
28 Pug 217 CT Diffuse 3 185 
29 Pug 52.25 CT Diffuse 3 1095 
30 Shih Tzu 82.5 MRI and CT Diffuse 3 1921 
31 Shih Tzu 55 MRI No lesion visible 8 72 
32 Tervueren Shepherd 27 MRI Diffuse 8 210 
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Case  Breed 
TNCC 
(WBC/ 
mm3) 
Imaging 
modality  
Description imaging 
findings 
Prednisolone 
schedule (weeks) 
ST (days) 
33 Weimaraner 110 MRI Diffuse 8 72 
34 West Highland White terrier 33 CT No lesion visible 3 730 
35 West Highland White terrier 500 MRI Diffuse 8 545 
36 Yorkshire terrier 33 CT Diffuse 3 2490 
37 Yorkshire terrier 143 CT Diffuse 3 2490 
38 Yorkshire terrier 500 CT Diffuse 3 6205 
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Seventeen (45%), 15 (39%), and 6 (16%) dogs received the 
3, 8, and 18-weeks prednisolone treatment schedule, respectively. In 8 dogs 
(21%) this therapy was combined with phenobarbital for treatment of seizures. 
There was a significant difference in ST between the three treatment groups 
(P=0.028) (Figure 4.2).  
 
Figure 4.2: Kaplan-Meier survival curve comparing survival times in the three 
treatment groups. Dogs that were still alive at time of data capture, or died 
because of unrelated causes, were censored for survival analysis.  
Overall, 24 dogs (63%) had a successful outcome, 22 of those dogs 
were alive at time of data capture. The remaining 2 dogs were euthanized 
because of other reasons 730 and 1167 days after their diagnosis, respectively, 
and both dogs were not receiving any immunomodulating medication at time of 
euthanasia. Fourteen dogs (37%) had an unsuccessful outcome, and died or 
were euthanized because of MUA. The MST could not be calculated for the 
group of dogs receiving the 3-week and 18-week tapering prednisolone 
schedule, as more than 50% of those dogs was alive at time of data capture. 
The MST for the dogs treated with the 8-week tapering schedule, was 180 days. 
Five dogs died or were euthanized (1 in the 3-week group en 4 in the 8-week 
group) during their treatment schedule and no changes were made to their 
schedule. Ten dogs (26%) showed a relapse in neurological signs, 4 of those 
dogs did so after terminating their 3-week tapering schedule, 3 dogs after 
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terminating their 8-week treatment schedule, 2 dogs during their 8-week 
schedule (after 3 and 6 weeks), and 1 dog after terminating the 18-week 
schedule. If the relapse was seen after termination of the treatment schedule, 
the same schedule was initiated again (n=7), and the dose was increased again 
to the starting dose if a relapse was seen before termination of the tapering 
schedule (n=3). There was no significant difference in relapse rates between 
the three treatment schedules (P=0.886). An overview of the results can be 
found in table 4.3. 
Table 4.3: Summary of survival, relapse and MST in dogs within the treatment 
groups. NR = not related (dog died for reason unrelated to MUA) 
         3 weeks         8 weeks       18 weeks 
Number of dogs 17 15 6 
    Dead            5 (2 NR) 9 0 
    Alive 10 6 6 
Deceased cases    
    During protocol 1 4 0 
    After protocol 4 5 0 
Relapsed cases 4 5 1 
    During protocol 0 2 1 
    After protocol 4 3 0 
MST -         180 days - 
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Discussion 
Thirty-eight dogs diagnosed with MUA received oral prednisolone 
therapy in 3 different tapering schedules. Overall, 37% of dogs were euthanized 
because of MUA, and survival curves for the three treatment schedules were 
significantly different. Surprisingly, the highest mortality rate was seen in the 8-
week (immunosuppressive) treatment group (56%), followed by the 3-week 
(anti-inflammatory) (28%) and the 18-week (immunosuppressive) treatment 
(0%) schedule. Possible explanations might be that (1) all dogs at the institution 
historically received the 3-weeks treatment protocol when a suspicion of non-
infectious encephalitis was made. However, as new literature became available 
on a possibly immune-mediated origin, dogs diagnosed with MUA admitted with 
severe neurological signs may have received a longer, more 
immunosuppressive (8-weeks) treatment schedule and (2) the 18-week tapering 
schedule was only introduced in the last 4 years of inclusion, so the recently 
included cases might still decease in the following weeks to months, now falsely 
(positively) influencing the results.  
In literature, the MST in dogs diagnosed with MUA and receiving sole 
prednisolone therapy ranges from 28-357 days (Granger et al., 2010), 91-329 
days (Flegel et al., 2011) and 602 days (Mercier and Barnes Heller, 2015). As 
more than 50% of the dogs was alive or censored for outcome calculations at 
time of data capture, no overall MST could be calculated in the presented study. 
However, the MST was 180 days in the 8-week treatment group, which appears 
to be the group with the highest percentage of deceased and relapsed dogs. 
Further prospective studies should be performed, including more dogs receiving 
the more immunosuppressive treatment schedules, although one can have 
ethical problems with comparing an immunosuppressive and anti-inflammatory 
treatment protocol for a presumed immune-mediated disease.  
Pitfalls of the current study are the lack of histopathological 
confirmation in all cases, the low number of cases and the relatively high 
percentage of dogs that was diagnosed using CT imaging (34%). However 18% 
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of dogs had no visible lesion on CT or MR imaging which is comparable to the 
7% for MRI and 14% for CT described previously (Granger et al., 2010). 
Prednisolone therapy is associated with common side effects, and to overcome 
these, other immunosuppressive drugs can be added to the protocol. Looking at 
the side effects of the prednisolone treatment was beyond the scope of this 
article, as not all side effects were systematically recorded and these are 
difficult to trace back through telephone contact with the owner or referring 
veterinarian.  
To conclude, overall prognosis for dogs diagnosed with MUA and 
treated with sole prednisolone therapy is guarded. Almost 40% of dogs will 
succumb due to the disease. A long and immunosuppressive treatment 
schedule is advised, but larger studies are needed to support this. 
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Abstract 
Although ciclosporine has previously been investigated as sole or add-
on treatment for dogs diagnosed with MUA, no specific treatment protocols 
have been defined. The aims of this study were 1) to compare sole 
prednisolone therapy with combination therapy with ciclosporine, 2) to describe 
two clinically useful treatment protocols, and 3) to evaluate previously 
investigated prognostic factors.  
A prospective, randomized clinical study including client-owned dogs 
was performed. Dogs were clinically diagnosed with MUA using previously 
described inclusion criteria. Dogs were re-admitted 2, 4 and 6 months after 
diagnosis for a complete neurological examination and analysis of cerebrospinal 
fluid. Four months after diagnosis, MR imaging was repeated. Twelve dogs met 
the inclusion criteria. Seven dogs were treated with a sole prednisolone 
treatment schedule, and 5 dogs with combination therapy of prednisolone and 
ciclosporine. A previously described 18-week tapering immunosuppressive 
prednisolone treatment protocol was compared with combination of the same 
protocol with ciclosporine. Treatment resulted in a MST of 87 and 567.5 days 
for dogs treated with sole prednisolone and combination therapy, respectively, 
but no difference in survival curves was found between both treatment groups. 
Previously established prognostic factors including duration of clinical signs 
prior to diagnosis, presentation within one week of onset of clinical signs, 
presence of seizures or abnormal mentation at time of diagnosis, presence of 
focal versus multifocal signs and presence of focal forebrain versus focal 
brainstem signs at time of diagnosis, results of CSF analysis, and MRI findings 
including mass effect, loss of cerebral sulci and foramen magnum herniation, 
were not associated with outcome in the presented study.  
Overall, 67% of dogs died because of MUA. Two clinically useful 
treatment protocols were described, but no significant difference in MST could 
be demonstrated comparing both protocols. Additionally, previously established 
prognostic factors could not be confirmed.   
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Introduction 
Meningoencephalomyelitis of unknown aetiology (MUA) encompasses 
a group of idiopathic, non-infectious CNS diseases that lack histopathological 
confirmation (Granger et al., 2010; Talarico and Schatzberg, 2010; Coates and 
Jeffery, 2014). A clinical diagnosis of MUA can be achieved based on a 
combination of signalment, neurological examination results, MRI findings and 
CSF analysis (Munana and Luttgen, 1998; Adamo et al., 2007; Granger et al., 
2010; Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). The condition 
is considered fatal without initiation of appropriate treatment (Munana and 
Luttgen, 1998; Granger et al., 2010). Conditions comprising MUA, including 
GME, NLE and NME, are considered immune-mediated diseases, and the 
cornerstone of medical treatment is immunosuppressive therapy (Sorjonen, 
1990; Vandevelde et al., 1981; Kipar et al; 1998; Wong et al., 2010). Several 
treatment protocols with different associated long-term survival times have been 
reported, whereby treatment with glucocorticosteroids only is generally 
associated with shorter survival times (Munana and Luttgen, 1998; Jung et al., 
2007; Pakozdy et al., 2009; Granger et al., 2010; Flegel et al., 2011; Mercier 
and Barnes Heller, 2015) compared to combination therapy with other 
immunosuppressive therapies.  
Ciclosporine therapy has been described as sole treatment for MUA 
(Adamo and O’Brien, 2004; Adamo et al., 2007), or as combination therapy with 
prednisolone (Adamo and O’Brien, 2004; Gnirs, 2006; Adamo et al., 2007; Jung 
et al., 2007; Pakozdy et al., 2009; Kang et al., 2009; Jung et al., 2012; Jung et 
al., 2013), ketoconazole (Adamo et al, 2007), or cytosine arabinoside and 
prednisolone (Behr et al., 2009). Only 2 prospective studies are currently 
available (Jung et al., 2007; Pakozdy et al., 2009) evaluating sole prednisolone 
therapy and combination therapy with ciclosporine. Jung et al. (2007) included 3 
dogs on sole prednisolone therapy and 4 dogs receiving combination therapy, 
and found a mean survival of 58.3 and 305.7 days for sole prednisolone and 
combination therapy, respectively. Pakozdy et al. (2009) included 7 dogs in 
each treatment group, resulting in significantly different MSTs, 28 days for sole 
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prednisolone therapy and 620 days for combination therapy. No clinically 
applicable treatment schedule has been described in both studies. 
Because MUA generally has a guarded prognosis, multiple studies 
attempted to identify prognostic factors, often resulting in conflicting results. 
Currently, the following established prognostic factors for dogs with MUA are 
available in the literature: 1) younger age at time of diagnosis was significantly 
associated with improved survival (Oliphant et al., 2016), 2) presence of 
seizures or altered mentation were significantly associated with shorter survival 
(Bateman and Parent, 1999; Coates et al., 2007; Granger et al., 2010); 3) 
presentation within 7 days of onset of clinical signs was significantly associated 
with longer survival (Barnoon et al., 2015); 4) abnormal serial CSF analysis was 
significantly associated with relapse and poor outcome (Lowrie et al., 2013); 
and 5) mass effect, loss of cerebral sulci and foramen magnum herniation on 
MRI were all significantly associated with death within 3 months (Lowrie et al., 
2013).  
The aims of this study were 1) to compare sole prednisolone therapy 
with combination therapy with ciclosporine, 2) to describe two clinically useful 
treatment protocols, and 3) to investigate possible prognostic factors including 
clinical factors and factors identified on serial MRI and CSF analysis. We 
hypothesized that combination therapy with ciclosporine, and 
resolution/improvement of MRI lesions and/or CSF abnormalities would lead to 
an improved survival and a decreased risk for relapse.  
Materials and methods 
Case selection 
A prospective recruitment of dogs diagnosed clinically with MUA was 
performed at Ghent University between January 2014 and September 2015. 
Dogs were included based on the criteria used by Granger et al. (2010), if they 
had (1) a complete neurological examination performed leading to a focal or 
multifocal intracranial neuroanatomical localisation, (2) MR imaging of the brain 
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demonstrating single, multiple or diffuse intra-axial hyperintense lesions on 
FLAIR and T2WI, (3) cisternal CSF examination results, and if (4) infectious 
disease testing returned negative. The study was approved by the Ethical 
Committee of Ghent University (EC 2013/103) and all owners signed an 
informed consent form before inclusion. Parameters recorded included 
signalment, duration of clinical signs prior to diagnosis, neurological 
examination findings, MRI of the brain, CSF analysis, treatment schedule used, 
presence of relapses and long-term outcome. Neurological examination on time 
of admission and 2, 4 and 6 months after diagnosis, was performed by a board 
certified neurologist or a neurology resident. On the neurological examination, 
mentation was divided into bright alert responsive (BAR), quiet alert responsive 
(QAR), obtundation, stupor and coma, representing decreasing mental status in 
this order. Possible neuroanatomical localisations included forebrain, brainstem 
or cerebellum. Dogs with vestibular signs attributable to a brainstem-associated 
lesion were diagnosed with central vestibular disease. If 2 or more of the above 
mentioned neuroanatomical regions appeared to be affected on the 
neurological examination, dogs were given a multifocal neuroanatomical 
localisation, where dogs with only one region affected were given a focal 
neuroanatomical localisation. Long-term outcome data were collected through 
revision of medical records or by contacting the owner or referring veterinarian 
by email or telephone in September 2016. 
Diagnostic investigations 
MRI was performed under general anaesthesia with a permanent 0.2T 
magnet (Airis Mate, Hitachi Ltd, Tokyo, Japan) and included a minimum of T2W 
and T1W images in a sagittal and transverse plane, and transverse FLAIR 
images of the entire brain. T1WI were acquired before and after administration 
of paramagnetic contrast (Dotarem, Guerbet, Brussels, Belgium). Variables 
recorded were presence of mass effect (brain herniation, midline shift, flattening 
of gyri/sulci). MR imaging was repeated 4 months after diagnosis following the 
same protocol, and images were reviewed for evolution of the previously visible 
lesion(s) (improved, static, or deteriorated). 
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Parameters analysed in the CSF included TNCC, WBC differentiation 
and TP concentration. TNCC was considered normal if the total WBC count 
revealed a number <5 WBC/mm3. TP concentration was considered normal if 
<0.25g/l in a cisternal tap and if <0.4g/l in a lumbar tap (Dewey and Da Costa, 
2016). TNCC was performed manually using a counting chamber. WBC 
differentiation was additionally performed manually on the CSF samples with a 
pleocytosis. For all dogs, PCR examination was performed on CSF for detection 
of Bartonella spp., Borrelia burgdorferi sensu latu, canine distemper virus, 
Cryptococcus neoformans, Cryptococcus gatii, Neospora spp. and Toxoplasma 
gondii.  
Treatment, follow-up and outcome 
After a presumptive diagnosis of MUA was made, dogs were randomly 
assigned to 1 of 2 treatment protocols in a 1-2-1-2 way. Protocol 1 consisted of 
a tapering prednisolone treatment schedule; protocol 2 consisted of the same 
prednisolone schedule with ciclosporine added to the protocol (table 5.1).  
Table 5.1: Description of two evaluated treatment protocols. 
Protocol 1: Sole prednisolone Protocol 2: Prednisolone + ciclosporine 
1.5mg/kg q12h for 3 weeks + 5mg/kg ciclosporine q24h 
1mg/kg q12h for 6 weeks + 5mg/kg ciclosporine q24h 
0.5mg/kg q12h for 3 weeks + 5mg/kg ciclosporine q24h 
0.5mg/kg q24h for 3 weeks + 5mg/kg ciclosporine q24h 
0.25mg/kg q24h for 3 weeks + 5mg/kg ciclosporine q48h 
0.25mg/kg q48h Only 5mg/kg ciclosporine q48h 
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Neurological examination and CSF analysis were repeated 2, 4 and 6 
months after diagnosis, MRI of the brain 4 months after diagnosis. A relapse 
was defined as a sudden deterioration after initial improvement, mainly 
consisting of recurrence of the initial or additional neurological signs. If a 
relapse was noted clinically, the prednisolone schedule was restarted as a 
rescue protocol. Follow-up information was retrieved from the clinical program 
or through telephone contact with the owner or referring veterinarian in 
September 2016.  
Statistical Analysis 
Data analysis was performed with the aid of a standard statistical 
software package (Prism, Graphpad Software Inc, La Jolla, California, USA). A 
Mann-Whitney U test was used to compare age, duration of clinical signs prior 
to diagnosis, TNCC and TP concentration in CSF with long-term outcome. A 
fisher’s exact test was used to compare differences in long-term outcome for 
presence of seizures and abnormal mentation, neuroanatomical localisation 
(focal versus multifocal, and focal forebrain versus focal brainstem) and imaging 
findings (mass effect, foramen magnum herniation and loss of cerebral sulci). 
Numeric variables were expressed as median and IQR. Values of P<0.05 were 
considered significant.  
Results 
Signalment and clinical presentation 
Fifteen dogs were included in the study. However, three dogs had to 
be excluded because of a necropsy diagnosis of intracranial lymphoma (n=2) or 
because of lack of owner compliance to the treatment plan (n=1). For the 
remaining 12 dogs, breeds included Chihuahua (n=4), Pug dog (n=3), Yorkshire 
Terrier (n=2), and 1 each of the following breeds: Lhasa Apso, Shih Tzu and 
Maltese terrier. Nine dogs (75%) were female (of which 3 were neutered) and 3 
dogs (25%) were entire males. Median weight at time of diagnosis was 4.45kg 
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(ranging from 1.75 tot 8.6kg). Median age at time of diagnosis was 28 months 
(ranging from 11 to 78 months). Median duration of clinical signs prior to 
diagnosis was 14 days (ranging from 1 to 30 days).  
Diagnostic investigations at time of diagnosis 
On neurological examination, 2 dogs (17%) were BAR, 3 dogs (25%) 
were QAR, 6 dogs (50%) were obtunded and 1 dog (8%) was stuporous. Four 
dogs (33%) had generalized tonic-clonic epileptic seizures of which 1 dog (25%) 
presented with cluster seizures. Nine dogs (75%) were diagnosed with a focal 
and 3 dogs (25%) with a multifocal neuroanatomical localisation. Of the dogs 
with the focal localisation, 4 dogs (44%) presented with a central vestibular 
lesion and 4 dogs (44%) with a focal forebrain lesion.  
As required by the inclusion criteria, MRI of the brain was available for 
all dogs, revealing multifocal or diffuse lesions affecting the forebrain, brainstem 
and/or cerebellum. Mass effect was noted in 11 dogs (92%), including loss of 
cerebral sulci in 7 dogs (64%) and foramen magnum herniation in 4 dogs (36%) 
(Figure 5.1). 
Cisternal CSF was obtained in all dogs at time of diagnosis, revealing 
a normal TNCC in one dog (8%), and an increased TNCC in the remaining 
eleven dogs (92%), with a median of 283 WBC/mm3 (ranging from 0-1413.5 
WBC/mm3). Blood contamination was present in two dogs (16%). Manual 
differentiation mainly revealed a mononuclear pleocytosis. Protein concentration 
was measured in all samples, and was elevated in all but 1 sample. The median 
TP concentration was 0.92g/l (ranging from 0.22-17.20g/l). As required by the 
inclusion criteria, infectious disease testing was negative in all CSF samples. An 
overview of the clinical and serial CSF findings can be consulted in table 5.2.  
Diagnostic investigation during treatment 
Seven dogs (58%) were alive at the 2-month re-examination, and 5 
dogs (42%) at the 4-month and 6-month re-examination.  
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In the 7 dogs that were alive at the 2-month re-examination, the 
neurological examination revealed no abnormalities in 4 dogs (57%), residual 
central vestibular signs in 2 dogs (29%) initially diagnosed with a multifocal 
lesion, and a mild residual head tilt in 1 dog (14%) initially diagnosed with a 
central vestibular lesion. 
In 5 dogs (42%), follow-up MRI 4 months after diagnosis was available. 
This revealed an improvement of the lesions in 4 dogs (80%), and resolution of 
all visible lesions in 1 dog (20%) (Figure 5.2). 
Follow-up CSF analysis was performed after 2 months in 7 dogs, and 
after 4 and 6 months in 5 dogs. Results of serial neurological examinations, 
CSF analysis and imaging findings can be consulted in table 5.2. 
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Figure 5.1: MRI images of a 17-month-old female entire Pug, presenting with 
seizures and abnormal mentation, histopathologically diagnosed with NME. 
Sagittal (A), transverse (B) T2WI and transverse FLAIR (C) images at the level 
of the interthalamic adhesion revealed presence of a diffuse hyperintense lesion 
affecting the frontal, parietal, temporal and occipital lobes (white arrows). Loss 
of cerebral sulci is visible in figures B and C.  
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Figure 5.2: MR images of a 32-month-old female neutered Pug dog presenting 
with cluster seizures. Sagittal (A and C) and transverse (B and D) T2WI at the 
level of the frontal lobe are presented, taken at time of diagnosis (A and B) and 
4 months into treatment (C and D). The lesions present in the frontal lobe (white 
arrows) improved on the follow-up images, as well as the loss of cerebral sulci 
(arrowheads) noticed on the initial images. 
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Treatment and outcome 
All dogs received a tapering prednisolone schedule starting with 
1.5mg/kg q12h at time of diagnosis. Seven dogs were receiving tapering 
prednisolone only, ciclosporine therapy was added to the schedule in 5 dogs 
(41%), and phenobarbital in 4 dogs (33%). 
Eight dogs improved on the initial therapy (4 dogs on monotherapy 
prednisolone, and 4 dogs receiving combination therapy with ciclosporine), 1 
dog remained neurologically stable, and 3 dogs deteriorated (2 dogs on 
monotherapy prednisolone, and 1 dog on combination therapy with 
ciclosporine). At time of data capture, 3 dogs (25%) were still alive with survival 
times ranging from 365 to 820 days. These dogs were clinically normal 
according to the owner, and currently not receiving any medication apart from 
phenobarbital therapy in 1 dog. Eight dogs (67%) died or were euthanized 
because of MUA (survival times ranging from 1-1020 days), 1 dog died in a 
road traffic accident 30 days after diagnosis and this dog was censored for 
survival analysis. Post mortem examination was only available in 2 of the 8 
deceased dogs, revealing NME (both pug dogs). No side effects were noted in 
any of the dogs treated with ciclosporine. Information regarding relapse and 
long-term survival time can be consulted in table 5.2.  
Relapses were observed in 5 dogs (41%), including one relapse in 3 
dogs (60%) and two relapses in the remaining 2 dogs (40%). Relapses were 
seen at a median of 95 days after diagnosis (ranging from 29-138 days). Two 
dogs were euthanized after diagnosis of the second relapse, the remaining 3 
dogs improved neurologically after initiation of the rescue protocol.  
The MST was 87 and 567.5 days for dogs treated with sole 
prednisolone and combination therapy, respectively. However, survival curves 
were not significantly different between both groups (P=0.49) (Figure 5.3). 
Duration of clinical signs prior to diagnosis (P=0.36), presentation within one 
week after onset of clinical signs (P=0.55), age at time of presentation (P=0.43), 
presence of seizures (P=0.21) or abnormal mentation (P=0.99) at time of 
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diagnosis, presence of focal versus multifocal neurological signs at time of 
diagnosis (P=0.67), presence of focal forebrain versus focal brainstem (central 
vestibular disease) at time of diagnosis (P=0.33), and TNCC (P=0.29) and TP 
concentration (P=0.99) on CSF analysis at time of diagnosis were all not 
associated with survival. Additionally, the presence of abnormal CSF TNCC at 
time of diagnosis or re-examination was not associated with relapse (P=0.99). 
Presence of mass effect (P=0.67), loss of cerebral sulci (P=0.99) or presence of 
foramen magnum herniation (P=0.67) on MRI were not associated with survival. 
 
Figure 5.3. Kaplan-Meier survival curve comparing the percentage of survival 
in dogs treated with sole prednisolone therapy (full line) and dogs that received 
combination therapy of prednisolone and ciclosporine (dotted line). Results 
were censored for dogs that were still alive at time of data capture (single little 
blocks). 
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Table 5.2: Overview of the diagnostic, therapeutic and outcome findings in 12 dogs with MUA. Values above reference limits are 
marked in bold; Time: 0m = time of diagnosis, 2m = 2 months after diagnosis, 4m = 4 months after diagnosis, 6m = 6 months after 
diagnosis; RTA = Road Traffic Accident.  
Case Breed Time 
Relapse 
(after # 
days) 
TNCC 
(WBC/ 
mm3) 
TP 
(g/l) 
Mass 
effect 
MRI 
Loss 
cere-
bral 
sulci 
MRI 
Foramen 
magnum 
herniation 
MRI 
Ciclo-
sporine 
Death 
because 
of MUA 
ST 
(days) 
1 
Yorkshire 
terrier 
0m 
 
0 0.345 Yes No Yes No Yes 1 
2 Chihuahua 0m 
 
1313 2.556 No No No No Yes 3 
3 Pug 0m 
 
46.57 0.98 Yes Yes No No Yes 207 
  
2m 
 
16 0.373 
      
   
93 
        
  
4m 
 
2.75 0.474 
      
   
138 
        
  
6m 
 
8.75 0.468 
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Case Breed Time 
Relapse 
(after # 
days) 
TNCC 
(WBC/ 
mm3) 
TP 
(g/l) 
Mass 
effect 
MRI 
Loss 
cere-
bral 
sulci 
MRI 
Foramen 
magnum 
herniation 
MRI 
Ciclo-
sporine 
Death 
because 
of MUA 
ST 
(days) 
4 Shih Tzu 0m 
 
957 0.369 Yes Yes No Yes Yes 1020 
  
2m 
 
38.5 0.209 
      
   
95 
        
  
4m 
 
59 2.434 
      
  
6m 
 
11 0.252 
      
5 Pug 0m 
 
224.13 1.3 Yes No No Yes Yes 115 
  
2m 
 
15.12 0.502 
      
   
81 
        
   
115 
        
6 Pug 0m 
 
316 1.11 Yes No No No Yes 87 
   
29 
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Case Breed Time 
Relapse 
(after # 
days) 
TNCC 
(WBC/ 
mm3) 
TP 
(g/l) 
Mass 
effect 
MRI 
Loss 
cere-
bral 
sulci 
MRI 
Foramen 
magnum 
herniation 
MRI 
Ciclo-
sporine 
Death 
because 
of MUA 
ST 
(days) 
  
2m 
 
16.5 0.284 
      
   
87 
        
7 
Maltese 
terrier 
0m 
 
49.5 0.413 Yes No No No No 820 
  
2m 
 
0 0.157 
      
  
4m 
 
0 0.413 
      
  
6m 
 
0 0.1 
      
8 
Lhasa 
Apso 
0m 
 
1413.5 
17.20
8 
Yes Yes Yes Yes Yes 2 
9 
Chihua-
hua 
0m 
 
756 1.828 Yes No Yes Yes No 730 
  
2m 
 
23 
       
  
4m 
 
190 
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Case Breed Time 
Relapse 
(after # 
days) 
TNCC 
(WBC/ 
mm3) 
TP 
(g/l) 
Mass 
effect 
MRI 
Loss 
cere-
bral 
sulci 
MRI 
Foramen 
magnum 
herniation 
MRI 
Ciclo-
sporine 
Death 
because 
of MUA 
ST 
(days) 
   
120 
        
  
6m 
 
0 0.177 
      
10 
Yorkshire 
terrier 
0m 
 
77 0.229 Yes Yes No No Yes 2 
11 Chihuahua 0m 
 
420 0.288 Yes Yes Yes Yes 
Not 
related 
(RTA) 
30 
12 Chihuahua 0m 
 
250 0.879 Yes Yes No No No 365 
  
2m 
 
0 0.364 
      
  
4m 
 
1551 2.127 
      
   
126 
        
  
6m 
 
26 0.323 
      
  
 
Chapter 4: Prednisolone and Ciclosporine 
 
  
130 
Discussion 
This study evaluated and provided two treatment regimens for dogs 
with MUA, and evaluated possible prognostic factors for survival. Although it 
was hypothesized that combination therapy would result in improved survival 
compared to sole prednisolone therapy, no significant difference in MST could 
be detected, most likely caused by the low case number. Additionally, 
previously established prognostic factors could not be confirmed in the present 
study.  
Ciclosporine therapy has previously been described as sole treatment 
for MUA (Adamo and O’Brien, 2004; Adamo et al., 2007), or as combination 
therapy with prednisolone (Adamo and O’Brien, 2004; Gnirs, 2006; Adamo et 
al., 2007; Jung et al., 2007; Pakozdy et al., 2009; Kang et al., 2009; Jung et al., 
2012; Jung et al., 2013), ketoconazole (Adamo et al, 2007), or cytosine 
arabinoside and prednisolone (Behr et al., 2009). Twenty-six dogs have been 
reported receiving prednisolone doses ranging from 2-30mg/kg/d combined with 
ciclosporine doses ranging from 6-30mg/kg/d (Adamo and O’Brien, 2004; Gnirs, 
2006; Adamo et al., 2007; Jung et al., 2007; Pakozdy et al., 2009; Kang et al., 
2009; Granger et al., 2010; Jung et al., 2012; Jung et al., 2013). In the 
presented study, a more immunosuppressive prednisolone schedule as 
previously described by Talarico and Schatzberg (2010) was used, combined 
with 5mg/kg/d of ciclosporine. This is the approved dose for atopic dermatitis in 
dogs (a common pruritic dermatologic problem affecting dogs, associated with 
IgE antibodies targeting environmental antigens). The same dose was advised 
in dogs with pemphigus foliaceus, an autoimmune skin disease. It was however 
anecdotally reported that dogs receiving this lower dosages of ciclosporine 
(≤5mg/kg q24h) can develop severe secondary infections (Archer et al., 2014). 
On the contrary, higher doses of ciclosporine (5-10mg/kg q12h) have been 
advised in dogs with acute and possibly life-threatening auto-immune diseases, 
including immune-mediated thrombocytopenia and immune-mediated 
haemolytic anaemia, to achieve clinically relevant depression of T-lymphocytes 
and as such immunosuppression (Archer et al., 2014). Therefore, we wanted to 
investigate whether this lower dose of ciclosporine combined with an 
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immunosuppressive schedule of prednisolone would be of additional value in 
dogs with MUA, which we could not prove in the presented study.  
The discrepancy in number of dogs included in both treatment groups 
(7 dogs were treated with sole prednisolone therapy and 5 dogs with 
combination therapy with ciclosporine) is mainly caused by the 3 cases that 
were initially included in the study and that were mainly addressed to the 
combination therapy group. After exclusion, there was no equal randomization 
between groups.  
None of the previously established prognostic factors for dogs with 
MUA, including age and presence of seizures or altered mentation at time of 
diagnosis, presentation within 7 days after onset of clinical signs, abnormal CSF 
analysis at time of diagnosis, and presence of mass effect, foramen magnum 
herniation or loss of cerebral sulci on MRI, could be confirmed in the presented 
study. Munana and Luttgen (1998) found significant longer survival times for 
dogs with focal neurological signs versus dogs with multifocal neurological 
signs. Additionally, dogs with focal forebrain signs had a significantly longer 
survival time compared to dogs with focal signs related to other areas of the 
CNS. This finding was not repeated in more recent studies (Coates et al., 2007; 
Lowrie et al., 2013) nor in the presented study. 
One study identified a lower CSF TNCC to be significantly associated 
with improved survival in dogs with MUA (Oliphant et al., 2016), whilst others 
found that neither CSF TNCC nor TP concentration had an effect on survival 
time in dogs with MUA (Coates et al., 2007). The study of Lowrie et al. (2013) 
failed to demonstrate an association between normal CSF analysis and 
improved outcome, but did find an association between abnormal CSF analysis 
at three months and relapse or poor outcome (Lowrie et al., 2013). In the study 
of Mercier and Barnes Heller (2015) CSF analysis was repeated 1 month after 
diagnosis, and their results suggested that serial CSF analysis might be a valid 
tool for monitoring success or failure of treatment in dogs diagnosed with MUA 
and treated with glucocorticoid monotherapy. In the presented study however, 
TNCC and TP of CSF were not predictive for outcome or relapse. 
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Overall, 26 dogs have been previously reported receiving initial doses 
of ciclosporine ranging from 3-15mg/kg PO every 12 hours, resulting in MSTs 
ranging from 236 to 930 days (Adamo and O’Brien, 2004; Gnirs, 2006; Adamo 
et al., 2007; Jung et al., 2007; Pakozdy et al., 2009; Kang et al., 2009; Jung et 
al., 2013). One dog receiving combination therapy survived for 1096 days (Jung 
et al., 2012). In the presented study, the MST was 87 and 567.5 days for dogs 
treated with sole prednisolone and combination therapy, respectively, however 
survival curves were not significantly different between both groups. Overall, 
only 2 previous studies revealed a mean ST of 305 days (Jung et al., 2007) or a 
MST of 602 days (Pakozdy et al., 2009) for dogs treated with ciclosporine and 
prednisolone, which is comparable to the MST of 567.5 days calculated in the 
presented study. It is however important to state that both studies are 
performed with a comparable small number of dogs, and a similar ciclosporine 
dose (6mg/kg/day for the study of Pakozdy et al. (2009) and 5mg/kg/d for the 
study of Jung et al. (2007)). On the contrary, the initial doses of steroids used in 
these studies differ from the initial dose used in the presented study (3mg/kg/d), 
being 5-30mg/kg/d and 2mg/kg/d, respectively. Survival times on combination 
therapy in the presented study ranged from 2 – 1020 days, which is comparable 
to the 2 – 1096 days reported in literature (Adamo et al., 2007; Kang et al., 
2009; Jung et al., 2012; Jung et al., 2013).  
Results of the presented study should however be interpreted with 
caution, mainly because of the small sample size and the limited number of 
dogs that was alive at time of data capture (1 of the 4 dogs alive was censored 
for survival analysis). Definitive histopathology is lacking in all but 2 cases, 
revealing NME. Interestingly, all dogs included in the study can be considered 
breeds that are predisposed to develop NE including Pug, Yorkshire Terrier, 
Maltese, Chihuahua, Pekingese, Papillon, Shih Tzu, Coton de Tulear and 
Brussels Griffon (Talarico and Schatzberg, 2010; Cooper and others, 2014). It is 
however stated that dogs of any breed and age can be affected by all subtypes 
of MUA (Granger et al., 2010; Coates and Jeffery, 2014). Additionally, one dog 
with a normal TNCC was included in the study. Normally, a pleocytosis (>5 
WBC/mm3) with monocytic predominancy is one of the inclusion criteria for 
MUA in dogs. On the contrary, it is previously stated that CSF examination can 
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be normal in 3-57% of dogs with MUA (Menaut et al., 2009; Granger et al., 
2010), in 16% of dogs with GME and in 12.5% of dogs with NE (Granger et al., 
2010). Albuminocytological dissociation has been found in cases with a normal 
cell count (Granger et al., 2010). The included dog was a 78-month-old male 
neutered Yorkshire terrier with multifocal lesions mainly affecting the subcortical 
white matter, and so a presumptive diagnosis of NLE was suspected and the 
dog was included in the study.  
A larger prospective, multi-centre study should be performed including 
more dogs to establish the previously published prognostic factors and the here 
described treatment protocol. 
 Conclusions 
In the presented study, 67% of dogs died because of MUA with no 
difference in outcome seen between dogs treated with sole prednisolone 
therapy and combination therapy with ciclosporine. Overall, initiation of 
treatment resulted in a MST of 115 days. Several described prognostic factors 
to select for optimal treatment candidates and to manage owner expectance, 
could not be confirmed. Further studies including more cases are warranted to 
evaluate the efficacy of the two described treatment protocols. 
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Abstract  
Although several studies have evaluated the long-term outcome of 
MUA in dogs, little is known about short-term survival and initial response to 
therapy. The aim of this study was therefore to evaluate possible prognostic 
factors for 7-day survival after diagnosis of MUA in dogs.  
Medical records were reviewed for dogs diagnosed with MUA between 
2006 and 2015. Previously described inclusion criteria were used, and for all 
dogs 7-day survival data needed to be available. A poor outcome was defined 
as death within 1 week. One hundred and sixteen dogs met the inclusion 
criteria. Thirty dogs (26%) died within 7 days after making a presumptive 
diagnosis of MUA. Assessed variables included age, sex, weight, duration of 
clinical signs and treatment prior to diagnosis, venous blood glucose and lactate 
levels, white blood cell count on complete blood count, total nucleated cell count 
/ total protein concentration / white blood cell differentiation on cerebrospinal 
fluid analysis, presence of seizures and cluster seizures, mentation at 
presentation, neuroanatomical localisation, imaging findings and treatment after 
diagnosis. Univariate statistical analysis was performed to identify variables to 
be included in a multivariate model. Multivariate analysis identified three 
variables significantly associated with poor outcome, including decreased 
mentation at presentation, presence of seizures, and increased percentage of 
neutrophils on cerebrospinal fluid analysis.  
Despite initiation of appropriate treatment, more than a quarter of dogs 
died within one week after making a presumptive diagnosis of MUA, 
emphasizing the need for evaluation of short-term prognostic factors. The 
information of this study can aid in the management of expectations of both 
clinical staff and owners with dogs diagnosed with MUA.   
  
Chapter 5: one week survival 
 
  
139 
Introduction 
MUA describes all clinically diagnosed cases of GME, NME and NLE 
that lack histopathological confirmation (Coates and Jeffery, 2014). A clinical 
diagnosis can be achieved based on a combination of neurological examination 
results, MRI findings and CSF abnormalities (Coates and Jeffery, 2014). The 
exact aetiology and pathophysiology of MUA are currently unknown, but the 
cornerstone of medical treatment is immunosuppressive therapy. Several 
treatment protocols using different immunomodulating drugs, resulting in 
different long-term survival times have been reported (Sisson et al. 1989; 
Gregory et al., 1998; Munana and Luttgen, 1998; Adamo and O’Brien, 2004; 
Gnirs, 2006; Zarfoss et al., 2006; Adamo et al., 2007; Coates et al., 2007; de 
Stefani et al., 2007; Feliu-Pascual et al., 2007; Uriarte et al., 2007; Jung et al., 
2007; Menaut et al., 2008; Pakozdy et al., 2009; Smith et al., 2009; Granger et 
al., 2010; Kang et al., 2009; Wong et al., 2010; Flegel et al., 2011; Jung et al., 
2012; Jung et al., 2013; Lowrie et al., 2013; Beckmann et al., 2015; Mercier and 
Barnes Heller, 2015; Barnoon et al., 2015; Lowrie et al., 2016).  
Although several studies have focused on long-term survival, little is 
known about early survival and initial response to therapy of dogs diagnosed 
with MUA. The primary aim of this study was therefore to evaluate early survival 
and initial response to immunosuppressive therapy in those dogs. The 
secondary aim of this study was to investigate possible prognostic factors for 7-
day survival after diagnosis of MUA. It was hypothesized that a substantial part 
of dogs with MUA would succumb in the first week after diagnosis despite 
appropriate treatment and monitoring. It was further hypothesized that specific 
characteristics of the clinical presentation, neurological examination, clinical 
pathology abnormalities, imaging findings and type of treatment would be 
associated with 7-day survival in dogs with a presumptive diagnosis of MUA. 
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Materials and methods 
Case selection  
The electronic medical database of the Small Animal Referral Hospital, 
Royal Veterinary College, University of London, was searched between January 
2006 and April 2015 for dogs diagnosed with MUA. Dogs were included based 
on the criteria used by Granger et al. (2010), if they had (1) complete medical 
records available, (2) a complete neurological examination performed leading to 
a focal or multifocal intracranial neuroanatomical localisation, (3) inflammatory 
CSF analysis, (4) MR imaging of the brain demonstrating single, multiple or 
diffuse intra-axial hyperintense lesions on T2W images, and if (5) 7-day follow-
up information was available. Dogs were excluded if (1) the clinical records or 
imaging studies were incomplete or not available for review, (2) dogs were 
diagnosed with meningomyelitis without clinical signs of intracranial 
involvement, (3) no pleocytosis was found on CSF analysis with the exception 
of dogs with signs of raised ICP on imaging studies, in which case CSF 
collection was not performed, and if (4) positive infectious diseases titres were 
found on serology or PCR examination for canine distemper virus, Toxoplasma 
gondii or Neospora caninum. Dogs with histopathological confirmation of the 
disease only needed to fulfil inclusion criteria (1) and (5). Information retrieved 
from the medical records included breed, gender, age at diagnosis, sex, body 
weight, results of neurological examination and neuroanatomical localisation, 
duration of clinical signs and treatment prior to diagnosis, presence of 
concurrent diseases, results of CBC and biochemistry profile, results of CSF 
analysis including TNCC, WBC differentiation and TP concentration, lactate and 
glucose concentration on venous blood gas analysis, treatment received and 7-
day survival time.  
Dogs were divided in two groups based on their body weight: dogs 
<15kg, in this paper referred to as small dogs; and dogs >15kg, in this paper 
referred to as large dogs. Mentation was divided into bright alert responsive 
(BAR), quiet alert responsive (QAR), obtundation, stupor and coma, 
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representing decreasing mental status in this order. Possible neuroanatomical 
localisations included forebrain, brainstem or cerebellum. Dogs with vestibular 
signs attributable to a brainstem-associated lesion were diagnosed with central 
vestibular signs. If 2 or more of the above mentioned regions appeared to be 
affected on the neurological examination, dogs were given a multifocal 
neuroanatomical localisation, where dogs with only 1 region affected were given 
a focal neuroanatomical localisation. MRI was performed under general 
anaesthesia with a permanent 1.5T magnet (Intera, Philips Medical Systems, 
Eindhoven, the Netherlands) and all images were reviewed by a board certified 
neurologist (SDD) using Osirix Dicom viewer (Osirix Foundation, V.5.5.2 
Geneva, Switzerland). The reviewer was blinded for the results of the 
neurological examination, outcome after 7 days and histopathological findings. 
Sequences could vary, but studies included a minimum of T2WI (TR/TE, 
3000/120), T1WI (TR/TE, 400/8) and FLAIR images of the entire brain in a 
sagittal, transverse and dorsal plane. The T1WI were acquired before and after 
IV administration of paramagnetic contrast medium (0.1mg/kg, gadoterate 
meglumine, Dotarem, Guerbet, Milton Keynes, UK). Variables recorded were 
lesion localisation and distribution, presence of parenchymal or meningeal 
contrast enhancement and presence of mass effect (brain herniation, midline 
shift, flattening of gyri/sulci). For dogs that had CSF analysis performed, site of 
collection (cisternal or lumbar), TNCC, TP and cytological differentiation were 
recorded. Total nucleated cell count was considered normal if the TNCC <5 
WBC/mm3. Total protein concentration was considered normal for a cisternal 
collection if <0.25g/l and for a lumbar collection if <0.4g/l (Dewey and Da Costa, 
2016).  
Treatment and follow-up 
For all dogs, the specific treatment protocol was recorded 
(corticosteroids with or without cytosine arabinoside). During hospitalisation, all 
dogs underwent daily at least one general physical and complete neurological 
examination by a board-certified neurologist or neurology resident. The results 
of the neurological examination as well as response to treatment (improvement, 
deterioration or static) were systematically recorded on the kennel sheets. 
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Follow-up information for the first 7 days after diagnosis was collected from the 
medical records. If dogs were discharged within the first seven days, medical 
records were searched for the presence of a re-examination or the presence of 
owner communication confirming the dog being alive. Dogs were excluded from 
the study if this information was not available. A successful outcome was 
defined as survival for at least 7 days after making a diagnosis of MUA, while an 
unsuccessful outcome was defined as death in the first 7 days after diagnosis. 
For dogs that died in the first week after diagnosis, it was recorded if dogs were 
euthanized at owner request after a diagnosis was made and without treatment, 
if dogs failed to recover from general anaesthesia after MRI, or if dogs died or 
were euthanized due to progression of disease after successful recovery from 
general anaesthesia. Dogs that did not survive general anaesthesia or were 
euthanized at owner request after a diagnosis was made without treatment 
were not included for further analysis. 
Statistical analysis 
Outcome was defined as death or alive 7 days after diagnosis. Data 
analysis was performed with the aid of a standard statistical software package 
(Prism, Graphpad Software Inc, La Jolla, California, USA). A Mann-Whitney U 
test was used to compare age, weight, duration of clinical signs prior to 
diagnosis, venous blood glucose and lactate levels, white blood cell (total, 
neutrophil and lymphocyte) count on CBC, TNCC/TP/neutrophil percentage in 
CSF, between dogs that were death or alive one week after diagnosis. A 
fisher’s exact test was used to compare differences in sex, treatment prior to 
diagnosis, presence of seizures and cluster seizures, mentation (BAR, QAR, 
obtundation, stupor, coma), neuroanatomical localisation (multifocal, forebrain, 
brainstem, central vestibular), treatment after diagnosis (steroids, cytosine 
arabinoside, mannitol) and imaging findings (lesion localisation, meningeal or 
parenchymal contrast enhancement, mass effect, brain herniation, flattening 
gyri/sulci, rostral or caudal transtentorial herniation, foramen magnum 
herniation) between dogs that were death and alive one week after diagnosis.  
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A binary response mixed model was carried out using SPSS 
(Statistical Package for the Social Sciences v. 21.0.1; SPSS Inc.). Whether the 
dog was dead or alive 7 days after diagnosis was the binary response variable. 
Factors found to be significant at the univariate level were taken forward for 
multivariate analysis. Body weight, duration of clinical signs, lactate 
concentration on venous blood gas analysis, TNCC on CSF analysis and 
percentage of neutrophils in CSF were modelled as continuous fixed effects. 
Mentation was modelled as a categorical fixed effect, and the presence of 
seizures, cluster seizures and cytosine arabinoside administration were 
modelled as binomial fixed effects. Breed was included as a random effect, with 
cross breeds coded plainly as ‘cross breed’ due to the unknown parentage of 
many of these dogs. This random effect took into account the genetic non-
independence of multiple members of the same breed in the study population, 
and possible demographic and environmental factors. Multicollinearity was 
checked for in all models, identified from inflated standard errors in the models, 
and thus avoided. Model fit was assessed using the deviance and Akaike's 
information criterion. Numeric variables were expressed as median and IQR. 
Values of P<0.05 were considered significant. Receiver operating characteristic 
(ROC) analysis was performed to examine the performance of the significant 
continuous variables on multivariate analysis as an indicator of prognosis, by 
determining the power of the test by measuring the area under the curve (AUC). 
A perfect test has an AUC value of 1.0, with an AUC of 0.5 means the test 
performs no better than chance. 
Results 
Signalment 
One hundred and sixteen dogs met the inclusion criteria and were 
included in the study. Eighty-seven small dogs (75%) and 29 large dogs (25%) 
were included in the study. Median age at time of presentation was 52.5 months 
(4 – 146 months) and median body weight was 9.2kg (1.65-94 kg). Fifty dogs 
(43%) were female, of which 30 were neutered, compared to 66 males (57%), 
  
Chapter 5: one week survival 
 
  
144 
of which 40 were neutered. Median duration of clinical signs prior to diagnosis 
was 7 days (range 1-180 days). Twenty dogs (17%) were treated with anti-
inflammatory doses of glucocorticosteroids (dose ranging from 0.5-1mg/kg 
every 12-24 hours) prior to diagnosis, with a median duration of 3.5 days 
(ranging from 1-90 days).  
Neurological examination 
Mentation was classified as BAR in 30 dogs (26%), QAR in 21 dogs 
(18%), obtundation in 59 dogs (51%) and stupor in 6 dogs (5%). No dogs 
presented comatose. Twenty-nine dogs (25%) presented with seizures, of 
which 20 dogs (69%) presented with cluster seizures and 2 dogs (31%) with 
status epilepticus. Sixty-six dogs (57%) presented with multifocal neurological 
signs, 50 dogs (43%) with focal neurological signs. Of those 50 dogs, 39 dogs 
(78%) presented with focal forebrain signs, 8 dogs (16%) with focal brainstem 
signs, 2 dogs (4%) with focal cerebellar signs, and 1 dog (2%) with central 
vestibular signs.  
Diagnostic findings 
Results of CBC and biochemistry profile were available in 97 dogs 
(84%). Leucocytosis was present in 13 dogs (13%) and lymphopenia in 32 dogs 
(33%). Serology and/or PCR analysis for Toxoplasma gondii, Neospora 
caninum and canine distemper virus were available and negative in 82 dogs 
(71%). Lactate and glucose concentrations on venous blood gas analysis were 
available in 49 dogs (42%), revealing an increased lactate and/or glucose 
concentration in 9 (18%) and 12 (24%) dogs, respectively. CSF analysis was 
not performed in 20 dogs (17%), revealed no abnormalities in 3 dogs (3%) and 
a pleocytosis in the remaining 93 dogs (80%). In the 3 dogs with a normal 
TNCC, complete necropsy revealed GME (n=1), NME (n=1) or NLE (n=1). For 
the dogs where a pleocytosis was found (n=93), median TNCC was 80 
WBC/mm3 (ranging from 6-2560 WBC/mm3). For the dogs that died in the first 
week after diagnosis, median percentage of lymphocytes, neutrophils and 
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monocytes/macrophages was 54%, 5% and 24%, respectively, compared to 
dogs that survived the first week after diagnosis where percentages were 66%, 
1% and 23%, respectively. Pre-treatment with glucocorticosteroids did not 
significantly influence the TNCC on CSF analysis (P=0.9116). 
Magnetic resonance imaging revealed a focal lesion in 31 dogs (27%), 
a multifocal lesion in 77 dogs (66%) and a diffuse lesion in 8 dogs (7%). Mass 
effect was seen in 66 dogs (57%), consisting of brain herniation (n=44), midline 
shift (n=38) and/or flattening of gyri or sulci (n=51).  
Treatment and outcome 
All but two dogs were alive after MR imaging. Spontaneous breathing 
did not return in one dog (1%) after anaesthesia, treatment was initiated with 
dexamethasone but the dog was euthanized after 1 hour at owners request. As 
only an attempt of 1 hour was made, this dog was excluded for further analysis.  
One dog (1%) was euthanized during general anaesthesia at owners request 
because of severe neurological signs, without an attempt for treatment. The 
remaining 114 dogs (98%) were treated with glucocorticosteroids. Detailed 
treatment data were only available in 104 cases, and treatment consisted 
mainly of an intravenous (IV) dose of dexamethasone within hours after 
reaching a diagnosis (dose ranging from 0.3-0.6mg/kg), followed by oral 
prednisolone (dose ranging from 1-2mg/kg every 12-24 hours) therapy (n=79), 
or of oral prednisolone therapy (dose ranging from 1-2mg/kg every 12-24 hours) 
that was initiated within hours after diagnosis (n=25). Eighty-eight of 114 dogs 
(85%) received additional treatment with cytosine arabinoside. This was given 
as subcutaneous (SC) injections (50mg/m2 SC every 12 hours for 2 consecutive 
days) in 69 dogs (78%) and as an IV constant rate infusion (CRI) (200mg/m2 
over 8 hours) in 19 dogs (22%). Twenty-seven dogs (23%) required mannitol 
(0.5-1g/kg IV over 15-20 minutes) administration during hospitalisation for 
clinical signs suggestive of raised ICP. This was administered immediately after 
intracranial MRI in 9 dogs (33%) and during hospitalisation in the remaining 18 
dogs (67%) at a median time after diagnosis of 1 hour (ranging from 1-48 
hours).   
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Of the 114 dogs in which treatment was initiated, 84 (74%) survived 
and, 30 dogs (26%) died or were euthanized during the first 7 days after making 
a presumptive diagnosis of MUA. These dogs died (n=10) or were euthanized 
(n=20) due to deteriorating neurological signs. A median survival time (MST) of 
1 day was calculated for all dogs that died within one week after diagnosis. 
Overall, histopathological confirmation (necropsy) was available in 14 dogs, 
revealing a diagnosis of GME (n=9), NME (n=4) or NLE (n=1). Dogs that 
demonstrated neurological improvement did so within a median time of 24 
hours after diagnosis (ranging from 12-72 hours) and clinical improvement 
within this time period was significantly associated with 7-day survival 
(P<0.0001). 
Factors associated with survival 
Univariate analysis revealed that higher body weight (P=0.027), shorter 
duration of clinical signs prior to diagnosis (P=0.042), decreased mentation at 
presentation (P=0.048), presence of seizures (P=0.0015) or cluster seizures 
(P=0.0050), increased lactate concentration on venous blood gas analysis 
(P=0.026), higher TNCC on CSF analysis (P=0.031), higher percentage of 
neutrophils in CSF (P=0.0224), administration of IV dexamethasone 
(P=0.0019), and no administration of cytosine arabinoside (P=0.012), all were 
associated with a poor outcome. Administration of a cytosine arabinoside CRI 
was significantly associated (P<0.0001) with a poor outcome compared to 
administration of subcutaneous (SC) cytosine arabinoside. None of the other 
evaluated clinical, clinical pathology, or imaging variables were significantly 
associated with outcome in this model (Table 6.1).  
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Table 6.1: Results after univariate analysis. Values are numbers with respective 
percentages or median values with respective interquartile ranges. Values differ 
significantly at P<0.05 (marked with bolt text and *). Dogs (n=2) that did not 
recover from the general anesthesia for MR imaging, were not included in the 
analysis considering treatment.  
Variable 
Death ≤7 days 
(n=32) 
Alive after 7 
days (n=82) 
P value * 
Signalment 
  
  
   Age (months) 55 (7 - 35) 50.5 (4 - 146) 0.987 
   Male 21 (66%) 45 (54%) 0.521 
   Female 11 (34%) 39 (46%) 0.521 
   Body weight (kg) 10.25 (3 – 94) 
8.9 (1.65 – 
54.9) 
0.027* 
Duration of clinical signs 
prior to diagnosis (days) 
6 (1 – 60) 8 (1 – 180) 0.042* 
Treatment with 
glucocorticosteroids prior to 
diagnosis (days) 
1.5 (1 – 9) 
(n=4) 
3 (1 – 48) 
(n=16) 
0.061 
Clinical signs     
   Seizures 15 (47%) 14 (17%) 0.0015* 
   Cluster seizures 11 (34%) 9 (11%) 0.0050* 
Neuroanatomical 
localisation 
    
   Forebrain 24 (75%) 56 (67%) 0.502 
   Brainstem 21 (66%) 50 (60%) 0.671 
   Central vestibular 8 (25%) 23 (27%) 1.000 
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Variable 
Death ≤7 days 
(n=32) 
Alive after 7 
days (n=82) 
P value * 
   Abnormal mentation 7 (22%) 23 (27%) 0.362 
   Stuporous 4 (13%) 2 (2%) 0.048* 
Complete blood count 27 (84%) 70 (85%)   
   White blood cells (.109/l) 
13.10 (3.54 – 
25.1) 
9.97 (4.6 – 
32.8) 
0.103 
   Neutrophils (.109/l) 10.16 (2.4 – 23.9) 7.2 (3 – 28.3) 0.267 
   Lymphocytes (.109/l) 1.1 (0.1 – 3.5) 1.3 (0.17 – 3.6) 0.177 
   Lymphopenia 11 (34%) 21 (25%) 0.217 
Venous blood gas 15 (47%) 34 (41%)   
   Lactate (mmol/l) 2.1 (0.5 – 5.5) 1.4 (0.4 – 5,6) 0.026* 
   Glucose (mmol/l) 6.3 (4 – 7.9) 
5.69 (3.2 – 
11.1) 
0.100 
CSF analysis 25 (78%) 69 (84%)   
   TNCC (WBC/mm3) 364 (1 – 2220) 66 (5 - 2560) 0.031* 
   Total protein (g/l) 0.79 (0.1 – 5.56) 
0.46 (0.11 – 
8.5) 
0.410 
   Not performed because 
signs of raised ICP 
7 (22%) 13 (15%) 0.289 
    Lymphocyte percentage 54 (2 – 97) 66 (1 – 98) 0.0874 
    Neutrophil percentage 5 (0 – 64) 1 (0 – 61) 0.0224* 
    Monocyte/macrophage 
percentage 
24 (3 – 87) 23 (0 – 92) 0.981 
MRI findings     
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Variable 
Death ≤7 days 
(n=32) 
Alive after 7 
days (n=82) 
P value * 
   Focal lesion 7 (22%) 24 (29%) 0.635 
   Multifocal lesion 22 (69%) 55 (65%) 0.635 
   Diffuse lesion 3 (9%) 5 (6%) 0.386 
   Forebrain localisation 26 (81%) 63 (75%) 0.327 
   Brainstem localisation 16 (50%) 45 (54%) 0.445 
   Cerebellum localisation 4 (13%) 17 (20%) 0.248 
   Mass effect 16 (50%) 50 (60%) 0.405 
      Brain herniation 8 (25%) 36 (43%) 0.058 
         Caudal transtentorial    7 (22%) 36 (43%) 0.053 
         Foramen magnum  8 (25%) 22 (26%) 0.549 
      Midline shift 11 (34%) 27 (32%) 0.492 
      Flattening gyri/sulci 15 (47%) 36 (43%) 0.427 
   Contrast enhancement      
      Meningeal  24 (75%) 54 (64%) 0.191 
      Parenchymal  20 (63%) 60 (71%) 0.239 
Treatment     
   Dexamethasone 27 (84%) 52 (62%) 0.0019* 
   Prednisolone 1 (6%) 24 (28%) 0.0019* 
   Cytosine arabinoside 19 (60%) 69 (82%) 0.012* 
        CRI 12 (20%) 7 (10%) < 0.0001* 
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Variable 
Death ≤7 days 
(n=32) 
Alive after 7 
days (n=82) 
P value * 
        SC 9 (47%) 60 (87%) < 0.0001* 
   Mannitol 8 (25%) 19 (23%) 0.806 
Improvement after 
treatment 
4 (13%) 82 (97%) <0.0001* 
   Time from diagnosis to 
treatment with 
corticosteroids (hours) 
2 (1 – 48) 2 (1 – 72) 0.153 
 
A binary response mixed model was carried out on factors found to be 
significant at the univariate level. Three variables were significantly associated 
with poor outcome in the final model: percentage of neutrophils in CSF, 
decreased mentation at presentation and a history of seizures (Table 6.2).  
Table 6.2: Results of binary response mixed model analysis (reference 
category: dead at 1 week). Values differ significantly at P<0.05 (marked with *). 
OR = odds ratio, CI = confidence interval, SE = standard error.  
Variable Sub 
category 
SE 
(coefficient) 
OR (95% 
CI OR) 
t p 
Neutrophils - 0.96 0.093-0.99 -2.21 0.030* 
Mentation 
BAR 18.33 1.39-
241.33 
2.24 0.027* 
QAR 4.77 0.41-55.00 1.27 0.208 
Obtundation 6.40 0.58-69.72 1.55 0.126 
Stupor Reference category 
Seizures 
No 4.20 1.08-16.37 2.10 0.039* 
Yes Reference category 
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Dogs with a higher % of neutrophils were at an increased risk of death 
at 1 week (mean ± SE dead: 14.88 ± 4.01; alive: 6.31 ± 1.40), with a negative 
association between increased % of neutrophils and likelihood of being alive at 
1 week. Dogs with a decreased mentation at presentation were at increased 
risk of death within 1 week (% dead at 1 week BAR: 20% versus stupor: 
66.7%), with dogs presented BAR had an 18.33 increased odds of being alive 
at 1 week compared to those presented in a stuporous state. Finally, dogs with 
a history of seizures were at an increased risk of death at 1 week (dead at 1 
week no seizures: 19.5% vs. seizures: 51.7%), with dogs without seizures had a 
4.20 increased odds of being alive at 1 week compared to those with seizures. 
ROC-analysis revealed that none of the significant continuous variables was 
able to reliably differentiate between good and poor short-term outcome in dogs 
with MUA (Figure 6.1).  
 
Figure 6.1: ROC curve for neutrophil percentage in CSF. The AUC was 0.63, 
indicating that this continuous variable has no clinical use in differentiating 
between good and poor outcome within 7 days after diagnosis. Consequently, 
no reliable threshold values with a combined high sensitivity and specificity 
could be identified to differentiate between both dogs with a good and poor 
outcome. 
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Discussion  
This study evaluated the prevalence and potential risk factors for 1-
week survival in dogs diagnosed with MUA. Although it was hypothesized that a 
proportion of dogs would not survive the first week after obtaining a diagnosis of 
MUA, a high proportion (26%) of dogs died within this specific time period 
despite initiation of appropriate treatment and close monitoring. Despite the lack 
of specific studies evaluating short-term survival in dogs with MUA, our findings 
indicate better outcomes compared with previous findings. It has been stated 
that approximately 15% of dogs diagnosed with GME died before being treated 
(Granger et al., 2010), compared to only 1/116 dogs (0.9%) in the presented 
study where the owner decided to euthanize the dog without attempting to treat. 
A recent study reported that 56% of dogs diagnosed with and treated for MUA 
died or were euthanized with a median survival time of 2 days (Lowrie et al., 
2013), which is almost double the percentage of the presented study. The 
results of our study demonstrated that 25% of dogs would die in the first week 
after diagnosis and initiating appropriate treatment for MUA. It seems therefore 
important to include this group of dogs when considering the overall prognosis 
of dogs with MUA. 
In a recent study by Sharma and Holowaychuk (2015), increased 
venous lactate concentrations were a risk factor for non-survival to hospital 
discharge in dogs with head trauma. Additionally, hyperglycaemia has been 
associated with severity of injury in cases of head trauma in dogs and cats, but 
not with outcome (Syring et al., 2001). In the presented study, blood glucose 
and lactate levels were measured on admission or before MR imaging on 
standard venous blood gas analysis. No significant difference was found in 
blood glucose levels between dogs that did or did not survive the first week after 
diagnosis. In the univariate analysis, lactate concentrations were significantly 
increased in dogs with a poor outcome, but this result was not confirmed in the 
multivariate analysis. As both measurements were only available for review in 
approximately 20% of the cases, further studies should be performed to draw 
further conclusions. 
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This study identified some potential risk factors for death in the first 7 
days after obtaining a presumptive diagnosis of MUA. In agreement with 
previous findings, dogs presenting with seizures and/or a decreased mentation 
were at increased risk of not surviving the first week after diagnosis (Bateman 
and Parent, 1999; Coates et al., 2007). Although it is possible these dogs 
represent a group of animals with a worse clinical phenotype, it cannot be 
excluded that the necessity of administering anti-epileptic drugs in these 
patients was associated with increased sedation and therefore contributed to a 
further decline of their neurological function. In contrast to results of a recent 
study (Lowrie et al., 2013), a higher neutrophil percentage on CSF analysis was 
significantly associated with an increased risk of death in the first week after a 
diagnosis of MUA. However, the constructed ROC-curve could not demonstrate 
a reliable threshold value with a combined high sensitivity and specificity to 
predict survival and so the exact neutrophil percentage should not be 
considered a useful tool for assessing prognosis in individual animals with MUA. 
In previous studies, it was stated that adding another 
immunosuppressive agent or radiation therapy to the standard treatment 
protocol with glucocorticosteroids improves survival of dogs with MUA (Munana 
and Luttgen, 1998; Jung et al., 2007; Coates et al., 2007; Granger et al., 2010; 
Flegel et al., 2011; Beckmann et al., 2015; Barnoon et al., 2015) but this could 
not be confirmed in the present study. Unexpectedly, treatment with SC 
injections of cytosine arabinoside and oral prednisolone therapy were both 
significantly associated with a better short-term outcome. Most likely, this is 
highly biased at the level of the clinician, who would possibly opt for IV 
dexamethasone and an additional CRI of cytosine arabinoside in dogs with 
more severe neurological signs. Additionally, a previous study (Crook et al., 
2013) indicated more favourable pharmacokinetic properties of intravenous 
continuous infusion of cytosine arabinoside compared to subcutaneous 
injections. Both findings could not be confirmed in the multivariate analysis 
performed in our study.  
This study is obviously limited by its retrospective character. Inclusion 
criteria were based on previously reported studies, but they are not restrictive. 
In the present study, dogs were excluded if TNCC on CSF analysis and/or 
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intracranial MRI were within normal limits, infectious disease testing was not 
required for inclusion and no standardisation of the treatment protocol was 
obtained. Medical management was also tailored to individual needs and 
therefore some dogs might have received additional medication, such as anti-
epileptic drugs and mannitol. Additionally, dogs did receive different treatment 
protocols prior to admission and diagnosis. Results might have been biased 
towards more severely affected dogs by only including dogs with a CSF 
pleocytosis, dogs with abnormal intracranial imaging and dogs with clinical 
signs of raised ICP when CSF analysis was not performed. Definitive post 
mortem diagnosis was available in almost half of the dogs (14/30) that died 
within 1 week after diagnosis in the hospital. This might also implicate a bias 
towards the more severely affected cases, as dogs that die or are euthanized 
within a hospital environment are more likely to have post-mortem examination 
performed.  
Conclusions 
Twenty-six percent of dogs diagnosed with MUA in this study died 
within one week after diagnosis, emphasizing the need for evaluation of short-
term prognostic factors. Presence of a decreased mentation at time of 
presentation, presence of seizures, and increased neutrophil percentage in the 
CSF were significantly associated with death within 7 days after diagnosis. The 
results of this study might be important when considering the overall prognosis 
of dogs with MUA and managing expectations of owners and hospital staff. 
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The main goal of this thesis was to gain more insight in the clinical 
presentation, diagnostic findings, treatment and prognosis of dogs diagnosed 
with MUA.  
The typical clinical presentation of dogs with MUA is well described but 
a substantial number of large dogs have been included in multiple studies. 
Specific data regarding clinical presentation, diagnostic findings and long-term 
outcome are currently lacking about this group of dogs.  
The same accounts for dogs diagnosed with MUA only affecting the 
spinal cord. As the disease is generally considered fatal if left untreated, 
multiple (prospective and retrospective) studies have been published, 
investigating different treatment protocols including one or multiple 
immunosuppressive drugs. These drugs however add a substantial cost to the 
treatment, which might be a limiting factor for some owners. Sole prednisolone 
therapy has generally been associated with poor outcome or very short 
(median) STs compared to combination therapy with other immunosuppressive 
agents. Two studies were conducted, a retrospective study to evaluate three 
historically used sole prednisolone treatment protocols, and a prospective study 
comparing one of the sole prednisolone treatment schedules with combination 
therapy with ciclosporine.  
As stated above, MUA is considered a fatal disease, so multiple 
studies have been performed investigating potential prognostic factors for dogs 
with MUA. Although these studies evaluated a large amount of clinical and 
imaging variables, only few clinically useful factors have been identified so far. 
Additionally, as a lot of studies focus on long-term survival, little is currently 
known about initial response to treatment and short-term (one week) survival in 
dogs diagnosed with MUA.  
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Clinical presentation and diagnostic findings 
Clinical presentation 
In a first study (Part I, Chapter 1) we evaluated the differences in 
clinical presentation, diagnostic findings and long-term survival between small 
(<15kg) and large (>15kg) dogs diagnosed with MUA. The study included 111 
dogs, including 28 (25%) large dogs and 83 (75%) small dogs. Large dogs were 
found to present significantly more often with a decreased mentation, but no 
other differences could be identified regarding clinical presentation, diagnostic 
findings and long-term survival between both groups.  
MUA is generally considered a syndrome affecting small, toy and 
terrier breed dogs (Munana and Luttgen, 1998; Adamo et al., 2007; Talarico 
and Schatzberg, 2010; Coates and Jeffery, 2014). Interestingly, a quarter of 
dogs in the presented study were large dogs, so ignoring this population of dogs 
would underestimate the prevalence of MUA in the canine population. Overall, a 
total of 45 large dogs have been reported between 1998 and 2015 (Gregory et 
al., 1998; Munana and Luttgen, 1998; Cherubini et al., 2006; Fliegner et al., 
2006; Zarfoss et al., 2006; Coates et al., 2007; Pakozdy et al., 2009; Smith et 
al., 2009; Wong et al., 2010; Flegel et al., 2011; Lowrie et al., 2013; Estey et al., 
2014; Barnoon et al., 2015; Beckmann et al., 2015; Mercier and Barnes Heller 
2015), with a similar breed distribution compared to our study. Adding the 28 
dogs of our study gives a total number of 73 large dogs described. The 
Labrador Retriever (13/73; 17%), the English Springer Spaniel (9/73; 12%) and 
the Golden Retriever (7/73; 10%) were the three most commonly affected 
breeds over all studies. It is however not clear whether this reflects the 
popularity of those breeds in the respective countries or a specific breed 
predisposition for MUA. Therefore, MUA should be considered a differential 
diagnosis in dogs other than small or toy breeds that have signs suggestive of 
inflammatory CNS disease.  
Although female predominance is a widely held belief in GME (Cordy, 
1979; Russo, 1979; Braund, 1985; Bailey, 1986; Sorjonen, 1990; Munana and 
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Luttgen, 1998), no statistical difference in female:male ratio could be found in 
more recent studies (Talarico and Schatzberg, 2010; Granger et al., 2010). A 
total of 194 dogs was investigated in this thesis, including 101 males (52%) and 
93 females (48%), revealing no difference in female:male ratio.  
As stated in the introduction, dogs affected with NE were 
predominantly under 4 years old whereas the peak age for GME was 4-8 years 
(Granger et al., 2010). Historically, NME was described in Pug dogs with ages 
ranging from 6 months to 7 years (Cordy and Holliday, 1989), whilst dogs with a 
histopathological diagnosis of GME had ages ranging from 6 months to 12 
years (Munana and Luttgen, 1998). In a series of 60 Pugs with NE (Levine et 
al., 2008), the median age was 18 months. In the presented studies in this 
thesis, median age at time of presentation was around 4 years in all studies (54 
months (Part I, Chapter 2), 48 months (Part II, Chapter 3), 52.5 months (Part 
III, Chapter 5)). On the contrary, median age at time of presentation was 28 
months in the prospective study (Part II, Chapter 4), which is remarkable 
younger. This can however be explained by the fact that all dogs in this study 
are breeds previously described to develop NE.  
As 8% of dogs diagnosed with GME presented with neurological 
deficits suggestive of a myelopathy (Granger et al., 2010), we performed a 
second study (Part I, Chapter 2) evaluating the clinical presentation, diagnostic 
findings and long-term survival in 21 dogs diagnosed with SO-MUA. In our 
study, an acute or chronic onset of a lesion affecting the T3-L3 spinal cord 
segments resulting in ambulatory paraparesis was considered the most 
common clinical presentation. Thirty-three dogs with MUA only involving the 
spinal cord were previously reported, including one dog with paraplegia 
(Cherubini et al., 2006; Griffin et al., 2008; Wong et al., 2010), whereas no dog 
with paraplegia was included in our study. Unfortunately, more specific details 
were lacking for the majority of the previously published dogs. As the clinical 
presentation and diagnostic findings are not specific for SO-MUA, this disorder 
should be included in the differential diagnosis for all dogs presenting with 
different degrees of spinal cord dysfunction.  
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Pain on spinal palpation was present in 71% of dogs with SO-MUA in 
our second study, which is comparable to the 86% stated in a recent study 
(Cardy et al., 2015). Paraspinal hyperesthesia (Sorjonen, 1990) and cervical 
hyperesthesia (Cordy and Holliday, 1989) were previously described in GME 
and NME, respectively. As spinal pain reflects the involvement of the meninges, 
and/or vertebrae (vertebral periosteum), and/or nerve roots or spinal nerves (Da 
Costa, 2012), this cannot be considered a typical finding for SO-MUA. However, 
it is important for the clinician to understand that MUA should be in the 
differential diagnosis for dogs presenting with any form of spinal hyperesthesia.  
Clinical diagnostic findings 
Although presence of leucocytosis on CBC has previously been 
reported in dogs with GME (Thomas and Eger, 1989; Sorjonen, 1990; Tipold, 
1995), nothing is currently known about prevalence and prognostic value. 
Throughout the different chapters, leucocytosis was present in approximately 
15% of cases where CBC was available for review (13% for Part I, Chapter 1 
and Part III, Chapter 5; 9.5% for Part I, Chapter 2; 14% for Part II, Chapter 3; 
and 17% for Part II, Chapter 4). In Part III, Chapter 5, statistical analysis was 
performed to investigate whether presence of leucocytosis was associated with 
survival after 7 days, but this did not reach significance (P=0.103). In the other 
chapters, no further statistical analysis was performed.  
MR imaging 
MR imaging is considered the most sensitive imaging modality for 
detecting intracranial lesions, but up to 7% of scans showed no lesion on T2WI 
in dogs with MUA (Talarico and Schatzberg, 2010; Granger et al., 2010). 
Overall, the sensitivity of imaging in identifying all inflammatory lesions 
suspected from the neurological examination remained quite low (<60%) 
(Granger et al., 2010). In our first study (Part I, Chapter 1), the presence of 
intracranial lesions on MRI was part of the inclusion criteria, but no differences 
in MRI findings could be detected between small and large dogs.  
  
General Discussion and Conclusions 
 
  
161 
Although studies looking into the use of MRI for differentiating between 
histopathologically confirmed cases of GME, NME or NLE are lacking, MRI 
findings in the different disease entities have been fairly well described 
previously (Cherubini et al., 2006; von Praun et al., 2006; Flegel et al., 2008; 
Young et al., 2009; Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). 
On the contrary, MRI findings have been only described for 4/33 dogs reported 
with SO-MUA, revealing no abnormalities in 1 dog, and multifocal poorly 
demarcated T2W hyperintensities with variable contrast enhancement in 2 dogs 
(Cherubini et al., 2006; Wong et al., 2010). Therefore, we performed a second 
study (Part I, Chapter 2) to describe the specific MRI findings in 21 dogs with 
SO-MUA. No lesions were visible on sagittal T2WI or T1WI in 10% of cases, 
comparable to the 7% reported for MUA (Talarico and Schatzberg, 2010; 
Granger et al., 2010). All visible MRI lesions in our study were extensive, ill-
defined, intramedullary, hyperintense on T2WI and isointense on T1WI. 
Parenchymal contrast enhancement was seen in 18 lesions (86%), and 17 
lesions (81%) showed contrast enhancement of the overlying meninges.  
Interestingly, although dogs were not allowed to have clinical signs or 
neurological examination results suggestive of intracranial involvement for 
inclusion in our second study (Part I, Chapter 2), additional MR images of the 
brain were included in the field of view of the cervical MRI in 2 dogs, showing 
additional lesions (suggestive of MUA) in both cases. As intracranial images 
were only available in 2 dogs, it is currently unclear (1) if these brain 
abnormalities represent a multifocal nature of the disease or cranial extension 
of the cervical inflammatory lesions, and (2) if inflammatory brain lesions are 
currently under diagnosed in dogs with SO-MUA and if SO-MUA could therefore 
be considered a more generalised inflammatory disease process, a 
meningoencephalomyelitis. 
CSF analysis 
Results on CSF analysis throughout the different chapters should be 
interpreted with caution as a CSF pleocytosis is considered an inclusion 
criterion for all studies. Overall, TNCC was normal in 2% of cases, including 3 
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dogs with histopathologically confirmed GME, NME or NLE in Part III, Chapter 
5; and 1 dog without necropsy in Part II, Chapter 4. TP concentration was not 
set as an inclusion criterion in all studies, and TP measurements were available 
in 157/194 cases, revealing normal values in 36/157 cases (23%). 
Although exclusion of regional infectious causes is a proposed 
diagnostic criterion for MUA (Granger et al., 2010), infectious disease testing 
was lacking in 52/187 cases (28%) in this thesis. All studies were performed in 
Belgium or the United Kingdom, but no prevalence studies for T. gondii, N 
caninum or CDV are available apart from two studies performed in the mid 90’s 
in Belgium (Vanparijs et al., 1991; Barber et al., 1998). These studies revealed 
that approximately 10% of dogs in Belgium was seropositive for N. caninum 
(Barbet et al., 1998) and that no T. gondii oocysts were detected on 
examination of 2324 faecal samples of dogs and cats (Vanparijs et al., 1991). 
However, infectious disease testing should still be encouraged in all dogs 
suspected of MUA to exclude possible infectious agents as much as possible.  
Treatment  
Aggressive immunosuppressive therapy was initiated at time of 
diagnosis in all dogs included in all chapters of this thesis. This is important as 
early and aggressive therapy might improve survival in dogs with MUA 
(Barnoon et al., 2015). In the literature, immunosuppressive therapy is 
sometimes only initiated after results of infectious disease testing returned 
negative, complicating comparison between different study designs.  
Treatment with sole prednisolone therapy 
The exact aetiology and pathophysiology of MUA remain unknown, but 
as one or several different factors are believed to trigger an excessive 
immunologic response resulting in inflammatory changes in the CNS (Flegel et 
al., 2011), immunosuppressive therapy is considered the cornerstone of 
medical treatment. Treatment with glucocorticosteroids (mostly prednisolone) 
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only is generally associated with shorter survival times compared to 
combination therapy with other immunosuppressive agents (Munana and 
Luttgen, 1998; Jung et al., 2007; Pakozdy et al., 2009; Granger et al., 2010; 
Flegel et al., 2011; Mercier and Barnes Heller, 2015). Therefore, several 
treatment protocols using different immunomodulating drugs have been 
reported (Sisson et al. 1989; Gregory et al., 1998; Munana and Luttgen, 1998; 
Adamo and O’Brien, 2004; Gnirs, 2006; Zarfoss et al., 2006; Adamo et al., 
2007; Coates et al., 2007; de Stefani et al., 2007; Feliu-Pascual et al., 2007; 
Uriarte et al., 2007; Jung et al., 2007; Menaut et al., 2008; Pakozdy et al., 2009; 
Smith et al., 2009; Granger et al., 2010; Kang et al., 2009; Wong et al., 2010; 
Flegel et al., 2011; Jung et al., 2012; Jung et al., 2013; Lowrie et al., 2013; 
Beckmann et al., 2015; Mercier and Barnes Heller, 2015; Barnoon et al., 2015; 
Lowrie et al., 2016).  
Although combination therapy might result in a better long-term 
outcome in MUA, adding more expensive immunosuppressive therapies to the 
glucocorticoid protocol might be financially impossible in a clinical setting. 
Additionally, at the institution where our third study (Part II, Chapter 3) was 
conducted, dogs with MUA were historically only treated with prednisolone and 
the personal perception of the authors was that dogs were doing considerable 
well on this therapy. In the literature, initial prednisolone doses ranged from 
0.34-30mg/kg/d (Munana and Luttgen, 1998; Jung et al., 2007; Pakozdy et al., 
2009; Flegel et al., 2011; Mercier and Barnes Heller, 2015), but only one study 
(Talarico and Schatzberg, 2010) was providing a clinically useful treatment 
schedule. Therefore, the first aim of our third study was to retrospectively 
evaluate the clinical use of three different treatment schedules, and to provide a 
clinically useful sole prednisolone treatment schedule.  
In this third study, we evaluated 38 dogs diagnosed with MUA that 
received oral prednisolone therapy in 3 different historically used tapering 
schedules (3, 8, and 18-week tapering prednisolone schedule). A significant 
difference was found between the three treatment schedules, with the highest 
number of deceased dogs in the 8-week treatment group (57%), followed by the 
3 (26%) and 18-week (0%) treatment groups. It is possible that dogs receiving a 
longer and more immunosuppressive protocol might have a better outcome, but 
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this result should be confirmed in future studies. This 18-week treatment 
schedule is the same schedule as proposed by Talarico and Schatzberg (2010), 
so the authors would advise further clinical use of this schedule. However, as 
the initial dose is 3mg/kg/d, side effects might be significant.  
Combination therapy with ciclosporine 
Although ciclosporine was previously investigated as sole and add-on 
treatment for dogs diagnosed with MUA, no specific treatment protocols have 
currently been described (Adamo and O’Brien, 2004; Gnirs, 2006; Adamo et al., 
2007; Jung et al., 2007; Pakozdy et al., 2009; Kang et al., 2009; Jung et al., 
2012; Jung et al., 2013). Therefore, we performed a fourth study (Part II, 
chapter IV) to describe a clinically useful treatment protocol and to compare 
sole prednisolone therapy with combination therapy with ciclosporine in 12 
dogs. The sole prednisolone protocol used in this fourth study was the same as 
the 18-week prednisolone schedule previously described in the third study. The 
described doses as add-on therapy for ciclosporine range from 6-30mg/kg/d 
(Adamo and O’Brien, 2004; Gnirs, 2006; Adamo et al., 2007; Jung et al., 2007; 
Pakozdy et al., 2009; Kang et al., 2009; Granger et al., 2010; Jung et al., 2012; 
Jung et al., 2013), but we decided to work with 5 mg/kg/d, as this dose is also 
known to cause some degree of immunosuppression (Archer et al., 2014). 
Although the difference in MST between both treatment groups seems clinically 
important (87 versus 567 days), no statistically significant results could be 
obtained. A power analysis was performed (non-parametric repeated sampling) 
revealing that 74 additional dogs were necessary in each treatment group to 
reach significantly different hazard ratios, which is quite a substantial number. 
Additionally, no previously established prognostic factors including clinical and 
diagnostic factors could be confirmed in this study.  
Combination therapy with cytosine arabinoside 
Investigation of the use and efficacy of cytosine arabinoside as an 
adjunctive therapy in canine MUA was not a primary goal of this thesis. 
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However, a total of 102 dogs treated with glucocorticosteroids plus cytosine 
arabinoside were recruited for the first (Part I, Chapter 1), second (Part I, 
Chapter 2) and fifth (Part III, Chapter 5) study. It should be noted that the 
same pool of dogs was used for the first and fifth study. Cytosine arabinoside 
can be administered either as a CRI (doses ranging from 100-300mg/m2 over 
8-24 hours) or as 4 SC injections of 50mg/m2 in 48 hours (200mg/m2 in 48h) 
(Zarfoss et al., 2006; de Stefani et al., 2007; Menaut et al., 2008; Smith et al., 
2009; Lowrie et al., 2013; Lowrie et al., 2016). Crook et al. (2013) showed that 
CRI administration of cytosine arabinoside provided a steady state 
concentration over the time it was administered compared to a rapid absorption 
and elimination when administered subcutaneously. A recent clinical study 
revealed a significantly better 3-month-survival in dogs initially receiving a CRI 
of cytosine arabinoside compared to the SC route (Lowrie et al., 2016). 
In a fifth study (Part III, Chapter 5), we evaluated short-term outcome 
and prognostic factors in 116 dogs diagnosed with MUA. Eighty-eight dogs 
(85%) received additional cytosine arabinoside therapy; 69 via the 
subcutaneous and 19 via the intravenous route. Administration of cytosine 
arabinoside was significantly associated with a better outcome, but 
administration of a CRI was associated with a poor outcome compared to SC 
administration. Most likely, this is highly biased at the level of the clinician, 
whom would possible opt for IV cytosine arabinoside in more severely affected 
dogs. In the second study (Part I, Chapter 2), no significant difference in 
survival could be found for dogs receiving additional cytosine arabinoside 
therapy. As only 1/14 dogs (7%) were receiving a CRI of cytosine arabinoside, 
no conclusions can be drawn from this study regarding the route of 
administration.  
Prognostic factors and outcome 
Prognostic factors 
As MUA is generally considered a fatal disease (Munana and Luttgen, 
1998), multiple studies attempted to identify prognostic factors. Unfortunately, 
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different studies revealed conflicting results, making the majority of findings 
inapplicable in a clinical setting. Currently, the following established prognostic 
factors for dogs with MUA are available in the literature: 1) younger age at time 
of diagnosis was significantly associated with improved survival (Oliphant et al., 
2016), 2) presence of seizures or altered mentation were significantly 
associated with shorter survival (Bateman and Parent, 1999; Coates et al., 
2007; Granger et al., 2010); 3) presentation within 7 days of onset of clinical 
signs was significantly associated with longer survival (Barnoon et al., 2015); 4) 
abnormal serial CSF analysis was significantly associated with relapse and poor 
outcome (Lowrie et al., 2013); and 5) mass effect, loss of cerebral sulci and 
foramen magnum herniation on MRI were all significantly associated with death 
in dogs with MUA, however the clinical prognostic power was low for those 
findings and none of them was predictive of long-term outcome (Lowrie et al., 
2013; Lowrie et al., 2016).  
 In our second study (Part I, Chapter 2), we investigated multiple 
possible prognostic factors in dogs with SO-MUA including clinical, diagnostic 
and treatment factors, but no association with long-term outcome could be 
made. On the contrary, our fifth study (Part III, Chapter 5), in agreement with 
previous studies, revealed that decreased mentation at presentation and 
presence of seizures were significantly associated with poor short-term 
outcome. Increased percentage of neutrophils on cerebrospinal fluid analysis 
also was significantly associated with poor short-term outcome, but no clinically 
useful cut-off values could be identified. None of the previously established 
prognostic factors could be confirmed in our fourth study (Part II, Chapter IV), 
although results should be interpreted with caution as only a limited number of 
dogs (n=12) was involved in this prospective randomized study.  
Outcome 
Although several studies have focused on long-term survival, little is 
known about short-term survival and initial response to therapy of dogs 
diagnosed with MUA. A recent study reported that 56% of dogs diagnosed with 
and treated for MUA died or were euthanized with a MST of 2 days (Lowrie et 
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al., 2013). In our fifth study (Part III, Chapter 5) we therefore evaluated the 
short-term survival in 114 dogs with MUA, revealing that 26% of dogs died 
within 7 days after diagnosis despite initiation of early and aggressive treatment. 
It seems therefore important to include this group of dogs when considering the 
overall prognosis of dogs with MUA. As more than 50% of the included dogs 
was alive after 7 days, no MST could be calculated in this study.  
On the contrary, several studies using different treatment protocols 
resulting in different long-term survival times have been reported, with resulting 
MST ranging from 2 – 1834 days (Sisson et al. 1989; Gregory et al., 1998; 
Munana and Luttgen, 1998; Adamo and O’Brien, 2004; Gnirs, 2006; Zarfoss et 
al., 2006; Adamo et al., 2007; Coates et al., 2007; de Stefani et al., 2007; Feliu-
Pascual et al., 2007; Uriarte et al., 2007; Jung et al., 2007; Menaut et al., 2008; 
Pakozdy et al., 2009; Smith et al., 2009; Granger et al., 2010; Kang et al., 2009; 
Wong et al., 2010; Flegel et al., 2011; Jung et al., 2012; Jung et al., 2013; 
Lowrie et al., 2013; Beckmann et al., 2015; Mercier and Barnes Heller, 2015; 
Barnoon et al., 2015; Lowrie et al., 2016). Our first study (Part I, Chapter 1) 
revealed an overall MST of 272 days. When separately evaluated for large and 
small dogs, the MST was 106 and 281 days, respectively, which is all-
comparable to the published literature for MUA. As no specific survival data 
were available for dogs with SO-MUA, we performed a second study (Part I, 
Chapter 2) specifically evaluating the long-term outcome in those dogs. The 
study revealed a MST of 669 days, and 48% of dogs had died or been 
euthanized because of the disease.  
In our third study (Part II, Chapter 3) we specifically evaluated the 
long-term survival in dogs with MUA receiving three different treatment 
protocols of sole prednisolone therapy. For this therapy, reported MSTs were 28 
– 357 days (Granger et al., 2010), 91 - 329 days (Flegel et al., 2011) and 602 
days (Mercier and Barnes Heller, 2015). As more than 50% of the dogs was 
alive or censored for outcome calculations at time of data capture in our study, 
no overall MST could be calculated. However, the MST was 180 days in the 8-
week treatment group, which appears to be the group with the highest 
percentage of deceased and relapsed dogs. Our fourth study (Part II, Chapter 
IV) revealed an overall MST of 115 days in a prospective study including 12 
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dogs with MUA that were treated with sole prednisolone or combination therapy 
of prednisolone with ciclosporine, although no difference in MST could be 
demonstrated between both treatment groups.  
Overall, long-term outcome data are available for 182 dogs in this 
thesis, revealing that 98/138 dogs (71%) died because of MUA, which is higher 
compared to the previously reported 56% (Lowrie et al., 2013). It has been 
previously mentioned that most dogs with MUA or GME that die, do so within 
the first three months after diagnosis (Thomas and Eger, 1989; Smith et al., 
2009; Lowrie et al., 2013). For the presented studies, 63/98 dogs (65%) died 
within 3 months after diagnosis. In both prospective studies (Part II, Chapter 3 
and 4) and the retrospective study regarding SO-MUA (Part I, Chapter 2), 7/34 
dogs (21%) died because of MUA within 7 days after diagnosis, which is 
comparable to the results of the fifth study (Part III, Chapter 5), where 26% of 
dogs with MUA died within one week after diagnosis.  
Limitations 
MUA is a clinical diagnosis that is based on a combination of 
signalment, neurological examination results and cross-sectional imaging 
findings in the absence of histopathological confirmation (Munana and Luttgen, 
1998; Adamo et al., 2007; Talarico and Schatzberg, 2010; Coates and Jeffery, 
2014). Specific diagnostic criteria are currently available, but this might bias 
studies towards more severely affected cases. To illustrate this, dogs with 
normal MRI findings (reported in 7-10% of dogs with MUA) or normal CSF 
analysis (reported in 3-57% of dogs with MUA) do not fit those inclusion criteria 
and will mostly not be included in prospective or retrospective studies, which 
also accounts for all studies in this thesis. Additionally, dogs were included in 
Part II, Chapter 3 based on CT imaging whereas MRI is generally considered 
the diagnostic imaging modality of choice for diagnosis of MUA. Four out of 5 
reported studies in this thesis are retrospective studies. These carry the pitfall 
that they only carry limited standardization of patient assessment (different 
people and institutions involved) and therapy (different institutions use different 
treatment protocols and have different follow-up practices). Additionally, there 
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might be debate about which infectious disease testing to perform or not to 
perform in dogs diagnosed with MUA. PCR testing is expensive for the pet 
owner and might therefore be declined, and carries the risk for false negative 
results. On the contrary, as long as histopathological confirmation is lacking, no 
certainty can be obtained about the underlying pathology (GME, NME or NLE) 
and so conclusions should be drawn with caution.  
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Future perspectives 
Large, prospective, multi-centre studies are needed to further 
investigate the findings of this thesis. The first study revealed that 25% of dogs 
affected with MUA are large dogs (>15kg), but it remains currently unclear 
whether this reflects a different disease entity, or just the same disease that is 
emerging in the whole canine population. A study to specifically look into 
clinical, clinicopathological, imaging and histopathological findings in large dogs 
with MUA is needed. The same accounts for dogs with SO-MUA, as currently 
only a small cohort of 21 dogs and the associated MRI findings were described. 
On-going research investigating clinical presentation, diagnosis and outcome in 
those dogs is warranted.  
Although the criterion-referenced standard for a clinical trial is a 
randomized, placebo-controlled, double-blinded, prospective study, it is 
generally accepted that use of a placebo control treatment group is unethical 
because dogs with MUA have a poor outcome without treatment. Large, multi-
centre studies are necessary to compare different treatment products and 
schedules in a larger patient population.  
Together with the investigation of additional clinical and outcome data, 
it is also important that the clinical diagnosis of MUA becomes more and more 
certain based on several inclusion criteria. As more and more institutions 
currently have high-field MRI available, evaluation of more criteria to 
differentiate between NME, NLE and GME can possibly aid the clinician in 
making a presumptive diagnosis. At the same time, authors should be 
motivated to use the same inclusion criteria to facilitate reliable comparison 
between studies.   
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Conclusions 
In conclusion, this thesis revealed novel information regarding clinical 
presentation, diagnosis, treatment and prognosis for dogs with MUA. Different 
breeds and different regions of the central nervous system can be affected by 
MUA. Typical MRI findings in dogs with MUA only affecting the spinal cord were 
provided, but further investigations regarding dogs with paraplegia and dogs 
with concurrent intracranial involvement are warranted. Overall, the prognosis of 
MUA is guarded. Twenty-six percent of dogs will die or be euthanized within 
one week after diagnosis despite treatment, and a large number of dogs will die 
or be euthanized because of MUA on the long-term. Further studies are 
warranted to provide more accurate and clinically useful diagnostic variables 
and prognostic factors. Large, prospective, randomized multi-centre studies 
should be performed to investigate different immunomodulating treatment 
protocols. 
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Meningoencephalomyelitis of unknown aetiology (MUA) in dogs is a 
complex and incompletely understood immune mediated CNS disorder. There 
is controversy and uncertainty about several aspects of the clinical presentation, 
diagnosis, treatment and prognosis of the different non-infectious inflammatory 
central nervous diseases this disorder covers. In this PhD thesis, several 
aspects concerning the clinical presentation, diagnostic findings, treatment, 
prognosis and outcome were evaluated.  
As a general introduction, a brief overview is given about the current 
literature on the clinical presentation, diagnosis, treatment, outcome and 
prognosis of MUA in dogs. Additionally, points of controversy and suggestions 
for further research are mentioned.  
Part I describes the clinical presentation and diagnostic findings in 
specific groups of dogs with MUA. In Chapter 1, the clinical presentation, 
diagnostic findings and long-term outcome of 28 large dogs (>15kg) diagnosed 
with MUA were assessed. Our study showed that 25% of dogs diagnosed with 
MUA were considered large dogs (28/111 dogs). They significantly more often 
presented with decreased mentation compared to their small counterparts. Age, 
gender, duration of clinical signs prior to diagnosis, presence of seizures or 
cluster seizures, variables on complete blood count and cerebrospinal fluid 
analysis, and all variables on MRI were not significantly different between small 
and large dogs. The MST was 281 and 106 days for the large and small dogs, 
respectively, but no significant difference in survival curves could be detected. 
In Chapter 2, the clinical presentation, MRI findings and long-term outcome in 
21 dogs with MUA only affecting the spinal cord were evaluated. These dogs 
mainly presented with an acute (43%) or chronic (52%) onset ambulatory 
paraparesis (67%) affecting the T3-L3 spinal cord segments, with presence of 
spinal hyperesthesia in 71% of cases. MRI revealed no abnormalities in 10% of 
dogs, and revealed an ill-defined, intramedullary lesion that was hyperintense 
on T2WI and isointense on T1WI with presence of parenchymal and/or 
meningeal enhancement in 86% and 81% of cases, respectively. Regarding 
outcome, 48% of dogs died or was euthanized because of the disease, with an 
overall median survival time of 669 days.  
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Part II describes two possible treatment options for dogs with MUA. In 
Chapter 3, we retrospectively assessed three different sole prednisolone 
treatment schedules (3, 8 and 18-weeks tapering schedule) in 38 dogs with 
MUA. Overall, 37% of dogs died or was euthanized because of MUA, and a 
significant difference in ST  was seen between the three treatment schedules. 
Surprisingly, the highest number of dogs that died because of MUA was seen in 
the 8-week treatment schedule (56%), followed by the 3-week (26%) and 18-
week (0%) treatment schedule. As no dog had deceased in the group receiving 
the most prolonged immunosuppressive schedule (18-weeks tapering 
schedule), it was suggested that dogs might potentially have a better outcome 
using this schedule. 
Chapter 4 prospectively evaluated sole prednisolone therapy and 
combination therapy with ciclosporine in 12 dogs diagnosed with MUA. Two 
clinically useful treatment protocols were described, including the previously 
described 18-week tapering prednisolone treatment protocol and combination 
therapy of the same schedule with 5mg/kg/d ciclosporine. The MST was 87 and 
567.5 days for the sole prednisolone and combination therapy groups, 
respectively, but no difference in survival curves could be detected. None of the 
previously established prognostic factors including clinical and diagnostic 
factors could be confirmed.  
Part III, Chapter 5 evaluated prognostic factors for one-week or short-
term survival in 116 dogs diagnosed with MUA. Overall, 26% of dogs died within 
7 days after diagnosis despite initiation of early and aggressive 
immunosuppressive therapy. Decreased mentation at presentation, presence of 
seizures and increased percentage of neutrophils on cerebrospinal fluid 
analysis were significantly associated with a poor 7-day survival. Unfortunately, 
no clinically useful cut-off value could be identified for the increased percentage 
of neutrophils, limiting the clinically usefulness of this variable.  
In conclusion, the studies presented in this thesis proved new 
information considering clinical presentation, diagnosis, treatment, outcome and 
prognosis in dogs diagnosed with MUA, but further studies are warranted to 
confirm those findings. 
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Meningoencefalomyelitis van onbekende etiologie (MOE) bij de hond is 
een complexe aandoening van het centrale zenuwstelsel. Verschillende 
aspecten van de klinische presentatie, de diagnostische criteria, de behandeling 
en de prognose zijn onderwerp van discussie. In deze doctoraatsthesis hebben 
we verschillende aspecten van de klinische presentatie, de diagnostische 
bevindingen, de behandelingsmogelijkheden, en de lange en korte termijn 
prognose bestudeerd.  
In de algemene introductie werd een kort literatuur overzicht 
gegeven van de huidige details over de klinische presentatie, de diagnostische 
bevindingen, de verschillende behandelingsmogelijkheden en de prognose van 
honden met MOE. Bijkomend zijn ook enkele punten van discussie besproken 
en zijn er mogelijke toekomstige onderzoeksmogelijkheden aangehaald.  
Deel I van deze doctoraatsthesis beschrijft de klinische presentatie en 
de diagnostische bevindingen bij twee specifieke groepen binnen MOE. 
Hoofdstuk 1 bespreekt de klinische presentatie en de diagnostische 
bevindingen, gecombineerd met de lange-termijn prognose bij 28 grote honden 
(> 15kg). Onze studie toonde aan dat 25% van de honden die gediagnosticeerd 
werden met MOE tot deze groep van grote honden behoorden. Bovendien 
werden zij significant vaker aangeboden met klachten van verminderd 
bewustzijn vergeleken met kleine honden (< 15kg). Leeftijd, geslacht, duur van 
de klinische symptomen voor de diagnose gesteld werd, aanwezigheid van 
epileptische aanvallen of cluster epilepsie op het moment van de diagnose, 
variabelen op het algemene bloedonderzoek en op onderzoek van het 
hersenvocht, en alle parameters die werden onderzocht op de MRI beelden, 
waren niet verschillend tussen grote en kleine honden. De mediane 
overlevingstijd van de grote honden was 281 dagen, en deze van de kleine 
honden was 106 dagen. Tussen beide overlevingstijden kon er geen significant 
verschil worden vastgesteld.  
Hoofdstuk 2 bespreekt de klinische presentatie, de MRI bevindingen 
en de prognose van 21 honden met MOE die zich enkel presenteren met 
klachten komende van het ruggenmerg. Deze honden werden meestal 
aangeboden met klachten van een acute (43%) of chronische (52%) 
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ambulatoire paraparese (67%). Meestal werd het letsel gelokaliseerd ter hoogte 
van ruggenmergsegmenten T3-L3, en bij 71% van de honden werd er pijn 
gevonden bij palpatie van de wervelkolom. Een MRI scan van de wervelkolom 
toonde geen afwijkingen bij 10% van de honden. Indien er wel een letsel 
gevisualiseerd werd, dan was dit meestal slecht omschreven, intramedullair, 
hyperintens op T2-gewogen beelden en isointens op T1 gewogen beelden. 
Parenchymale of meningeale contrastcaptatie was aanwezig in respectievelijk 
86% en 81% van de gevallen. Achtenveertig procent van de honden stierf of 
werd geëuthanaseerd ten gevolge van de aandoening, en dit met een mediane 
overlevingstijd van 669 dagen.   
Deel II van de doctoraatsthesis beschrijft twee 
behandelingsmogelijkheden bij honden met MOE. Hoofdstuk 3 evalueert 
retrospectief een behandeling met monotherapie prednisolone bij 38 honden 
met MOE. Hierbij werden 3 verschillende behandelingsschema’s met 
prednisolone met elkaar vergeleken, namelijk een 3-weken, een 8-weken en 
een 18-weken afbouwend prednisolone schema. Er werd een significant 
verschil in overleving gevonden tussen deze drie behandelingsschema’s. De 
meeste honden stierven in de groep die behandeld werd met het 8-weken 
schema (56%), gevolgd door het 3-weken (26%) en het 18-weken (0%) 
schema. Gezien er nog geen honden gestorven waren in de groep die het 18-
weken schema, het meest immunosuppressieve schema, toegediend kregen, 
werd gesuggereerd dat honden met MOE mogelijks een betere overleving 
hebben indien ze een meer immunosuppressief behandelingsschema krijgen.  
Volgend op voorgaande studie, werd een prospectieve studie 
uitgevoerd die beschreven staat in hoofdstuk 4. In deze studie werd het 
verschil in overleving bekeken bij honden met MOE die twee verschillende 
behandelingsschema’s kregen. Een eerste groep honden werd enkel behandeld 
met een schema identiek aan het in het vorige hoofdstuk beschreven 18-weken 
schema prednisolone, en bij een tweede groep honden werd deze behandeling 
gecombineerd met ciclosporine. De mediane overlevingstijd bedroeg 
respectievelijk 87 en 567.5 dagen voor de honden enkel behandeld met 
prednisolone en de honden behandeld met de combinatie prednisolone en 
ciclosporine. Deze mediane overlevingstijden waren niet significant 
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verschillend. Bovendien werden enkele vooraf beschreven prognostische 
factoren geëvalueerd, maar geen enkele factor kon in deze studie bevestigd 
worden.  
Deel III van deze thesis evalueert de prognostische factoren voor de 
kans op overleving binnen de eerste week na diagnose van MOE. De resultaten 
van deze studie staan beschreven in hoofdstuk 5. Een totaal van 116 honden 
werd retrospectief geïncludeerd in deze studie, waarbij 26% stierf binnen de 7 
dagen na diagnose ondanks er een vroegtijdige en agressieve behandeling 
werd ingesteld. Verminderd bewustzijn, aanwezigheid van epileptische 
aanvallen en de aanwezigheid van een verhoogd percentage neutrofielen op 
onderzoek van cerebrospinaal vocht op moment van diagnose, waren 
significant geassocieerd met een slechte kans op het overleven van deze 
eerste 7 dagen na diagnose. Jammer genoeg kon er voor het percentage 
neutrofielen geen cut-of waarde aangeduid worden, en dus is deze factor 
klinisch niet bruikbaar. 
Als conclusie van deze thesis kan er gesteld worden dat er nieuwe 
informatie werd aangebracht inzake de klinische presentatie, de diagnostische 
criteria, de behandelingsmogelijkheden en de prognose van honden met MOE, 
maar verdere studies zijn nodig om onze bevindingen te bevestigen. 
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komt! Wat begon als een idee over stamcelonderzoek enkele jaren geleden, is 
uitgedraaid op een onderzoek over meningoencefalitis. Ik kan me het moment 
van die beslissing niet meer herinneren, maar het is toch een goede gebleken. 
Bedankt om van in het begin van dit verhaal in mij en mijn onderzoek te blijven 
geloven. Het eerste artikel heeft letterlijk bloed, zweet en tranen gekost, maar 
vanaf dan is het toch beter beginnen gaan. Bedankt om een luisterend oor te 
zijn, voor de gedetailleerde correcties en je ongezouten – maar daarom niet 
minder geapprecieerde - mening. Ik wens je alle succes toe met het Epicentrum 
project, en ik ben fier om er deel van te mogen uitmaken!  
 Luc, jouw liefde voor de neurologie werkt inspirerend! Na de 
masterproef en mijn internwerkje met case report hebben we het wat grootser 
aangepakt en dat resultaat ligt er nu. Bedankt om me te steunen in mijn 
onderzoek, mijn residency, mijn jaar naar het buitenland, … Ik mocht  u tijdens 
mijn wachten dag en nacht opbellen, en ik stond er dan vaak van versteld hoe u 
met één blik op een myelogram voldoende had om de lokalisatie te bepalen! 
Die tijden liggen al eventjes achter ons, de myelogram avonturen zijn 
geschiedenis geworden, maar de fijne samenwerking is wel gebleven! Heel erg 
bedankt! 
Ingrid, dankzij u konden we de prospectieve studie doen, en de 
mensen toch overtuigen van het nut om de hersenen van hun hond opnieuw te 
laten scannen. Ook al hebben we geen grote aantallen patiënten verzameld 
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tijd verderzetten! Evelien, ook al zien we elkaar minder, en is afspreken telkens 
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opnieuw een agendagewijze uitdaging, toch geniet ik altijd van de babbels! Ook 
jij staat voor een nieuw hoofdstuk in je leven, geniet er ten volle van! Bieke, wat 
ben ik blij dat jij bij de hondjes terechtgekomen bent! Het is een schip op zich, 
en dat varende houden vereist soms heel wat vaar – en roeikunsten, maar tot 
hiertoe lukt dat altijd wonderwel! Bedankt om naast een goede mama voor al 
die hartendiefjes ook een luisterend oor en superfijne collega te zijn! Geniet nu 
maar van de tijd met de kleine baby (de naam is tot het moment van dit 
schrijven nog altijd een verrassing) en dan beginnen we er nadien samen terug 
vol goede moed aan!  
Almost 2 years ago now, I was working for one year as a neurologist at 
the Queen Mother Hospital for Animals in London. Holger, thank you so much 
for this year as part of your amazing team, and for the support and (statistical) 
help throughout the different studies. Although I always believed only women 
can multitask, you showed me that it is possible for some men as well! Elsa, I 
still miss the morning coffees (or hot chocolates) and the lovely chats. I can only 
wish you a lovely future with lots of diving holidays! I don’t have Instagram, but I 
would otherwise be one of your “followers” for those amazing pictures! Miss you 
loads!! Patrick, Stieven, Joe, Tom, Fran, Abbe, Alex and Danielle, thank you 
all for letting me being part of the neuro – team! Keep up the good job, you are 
all amazing people! Hope we can meet soon! Birgit, life can be hard and very 
unfair, but I admire your strength and optimism! I love the Skype and WhatsApp 
messages from you, including the beautiful pictures (that don’t make me feel 
jealous at all)! What a powerful women you are! I’m really looking forward to 
seeing you in a couple of days!  
Nele en Annelies, ook wij zien elkaar wat minder, maar het stukje 
taart laatst heeft me toch ongelooflijk gesmaakt (en smaakte misschien wel 
naar meer?). Veel succes met jullie praktijk, en alle bewondering voor jullie 
harde werk daar! Gosia, wat een ongelooflijk sterke vrouw ben jij! Drie kindjes 
(ik herinner me nog altijd het moment dat we het sms’je kregen in de aula dat 
Simon geboren was – voor ons toen echt een “ver van mijn bed” show!) en ook 
bijna je doctoraat. Hopelijk tot binnenkort en veel succes op je nieuwe functie. 
Jody, de knapste van ons interngroepje, ook voor jou veel bewondering dat je 
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het leven als mama van Terence en Eloise kan combineren met je eigen 
praktijk. Eten we snel nog eens een broodje samen?  
Koen en Tania, Mark en Lore, Hans en Leen, jullie hebben me er 
gratis en voor niets bijgekregen! Binnenkort zal de vriendengroep uit Leuven 
zowel bestaan uit tieners (pubers?), peuters en baby’tjes, we kijken er al naar 
uit!  
Antita zonder Tony, bedankt voor de fijne babbels en de miljoenen 
kopjes thee en koekjes. Voor de zaterdagse en zondagse bezoekjes aan 
bestaande en onbestaande tweedehands beurzen. Voor de wandelingen met 
de honden en de hulp met dit doctoraat. Antita met Tony voor de discussies 
over bioproducten, dierenwelzijn en politiek. Ik sta nog altijd versteld van je 
enthousiasme soms! En natuurlijk ook een dikke zoen voor kleine Ernest en 
een knuffel voor Caillou (ik stel me nu zijn enthousiaste onthaalgeluiden voor).  
Josine. We hebben samen al heel wat meegemaakt, maar onze 
vriendschap is er alleen maar sterker door geworden, en daar ben ik je oneindig 
dankbaar voor. Ook bij jou heb ik al liters thee gedronken en massa’s koekjes 
gegeten. Het blijft leuk om met je van gedachten te wisselen over onze vele 
gemeenschappelijke interesses (de tuin, je vele dieren, interieurkeuzes, …). 
Bedankt om altijd een luisterend oor te zijn, en hopelijk kan ik dat ook voor jou 
nog heel lang blijven! Dimitri, ook jij heel erg bedankt om er al die jaren 
geweest te zijn! 
Tim en Bram. Volgens mij kennen jullie als enige mijn aanleg voor 
zang en dans, ook al is het repertoire redelijk beperkt. Tim, bedankt voor je 
jarenlange hulp bij de hondjes, en de fijne wandelingen nadien. Het pack van 
toen is behoorlijk geslonken, zorg dus nog maar goed voor het laatste 
gemenerikje. Bedankt voor de vele telefoontjes, en om mijn frustraties en 
gezaag te blijven verdragen. Bram, wat zouden de jetsers (en tezamen hebben 
wij veeeel jetsers) zijn zonder jouw kennis over films, muziek, politiek (of wist jij 
wel wie de president van Oekraïne is?), … Tijdens de zomer – als we nog eens 
gaan zwemmen in de Ster – wil ik ook graag nog eens je beroemde paella 
paella eten!  
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Nele en Jurgen. Nele, bedankt om ondertussen al dik 25 jaar deel uit 
te maken van mijn leven! Om die steunpilaar te zijn in moeilijke en gemakkelijke 
momenten, voor een lach en een traan. Je bent een fantastische mama voor 
jullie drie kindjes, waaronder mijn metekindje Jules! Hopelijk kunnen we elkaar 
in de toekomst terug wat vaker zien, en kunnen we nog vele diner-dates 
houden! Bedankt dat ik doorheen de jaren bij jullie altijd welkom ben geweest! 
Ludo en Tineke, Wim en Leen, Ann en Stef, bedankt om zo een fijne 
schone familie voor mij te zijn! Ook al wonen jullie dan aan de verkeerde kant 
van het water, het is fijn te weten dat we bij jullie altijd welkom zijn! Cleo en 
Lise, jullie worden binnenkort grote zussen van Wout zijn neefje, en ik beloof 
jullie dat jongetjes soms ook heel lief kunnen zijn.  
Bomma’s en bompa, dat ik nog 3 van mijn 4 grootouders heb, is 
bijzonder. Mijn peter zou op een dag als vandaag zeker en vast heel trots 
geweest zijn! We zien elkaar op dit moment niet zo vaak, maar ik koester wel 
heel fijne herinneringen aan de vele leuke momenten met jullie!  
Mama en papa, ook al weet ik nog altijd niet heel goed vanwaar (of 
van wie) ik mijn liefde voor dieren heb, jullie hebben me altijd gesteund in mijn 
droom om dierenarts te worden! Mama, bedankt om er altijd voor ons te zijn, en 
voor de fantastische zorgen! Papa, ook wel daddy perfect (of Daddy P voor de 
vrienden), bedankt om mij gedurende verschillende jaren altijd naar mijn kot te 
brengen op zondag avond (na het nieuws!). Merci dat we altijd welkom zijn, en 
om zo’n toegewijde bomma en bompa te zijn voor Wout, Maarten en Jolien! 
Bart en Annemie, Hans en Dymphna, Erwin, en Gerd en Lore, wat zou mijn 
leven saai zijn zonder jullie (en stil). Gelukkig zien we elkaar nog altijd 
regelmatig aan de brug van den Azijn. Weet dat jullie altijd welkom zijn in Melle! 
Rik, onze liefde is begonnen met Bob’s verlies van zijn staart. Hij is er 
ondertussen niet meer, maar gelukkig is de liefde wel gebleven (mooi 
geformuleerd he!). Ondertussen mag ik je al “husband” noemen en is er zelfs 
een klein rondkruipend hummeltje bijgekomen. Bovendien weet ik nu ook dat 
Freddy Mercury blijkbaar geen deel uitmaakt van de Beatles … Bedankt om er 
altijd voor mij te zijn, om mijn grillen te verdragen (soms toch) en om zo’n 
fantastische papa voor Woutje te zijn! Lieve kleine Wout, mama ziet je zo super 
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graag! Ook al zou ik ’s nachts soms graag willen dat je een “uit” knopje had, als 
je dan naar ons kijkt, lacht en een keer dada doet, dan zijn we het onmiddellijk 
weer vergeten! Hopelijk kan je opgroeien tot een fijn, zelfzeker en gelukkig 
mannetje!  
Naast de mensen zijn er natuurlijk ook al wat diertjes de revue 
gepasseerd ondertussen. In het verleden enkele poezen in Merksem 
(Scaramouche, Antraciet, Sloeber, Vlekje, Minoes, …) maar toch was ik super 
gelukkig toen ik 7 jaar geleden mijn eerste hondje uit het asiel ging halen! Lieve 
Sali, wat heb je soms mijn leven (en interieur) tot een hel gemaakt, maar wat ik 
je altijd ongelooflijk graag gezien! Er komen nog altijd traantjes als ik aan je 
denk, en aan de vreselijke manier waarop ik je verloren ben. Het was 
aandoenlijk om je samen met Wiebe te zien, bij hem had je eindelijk je rust 
gevonden. Jullie zijn nu voor altijd terug samen, en daar kan ik alleen maar 
dankbaar en blij om zijn! Jullie schitteren op de cover van dit doctoraat!! Lizzy, 
een rode cocker, wat een beslissing! Je hebt wat speciale aandacht nodig, 
maar je past perfect in ons gezin! Hopelijk kunnen we van jou nog lange tijd 
genieten! 
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 Last but not least, zijn er nog enkele hondjes die een belangrijk deel 
uitmaken van mijn leven, en waar ik me ook al gedurende verschillende jaren 
tezamen met verschillende mensen voor inzet. Sommigen onder hen zijn 
ondertussen prachtige sterretjes aan de hemel, andere zijn nog bij ons of 
genieten van hun meer dan welverdiende pensioen in een eigen mandje! Eén 
voor één zijn jullie bijzonder, met jullie eigen persoontje en karakter. Ik zal jullie 
alvast nooit vergeten!  
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